id	sid	tid	token	lemma	pos
dpc-3895	1	1	dermatology	dermatology	NOUN
dpc-3895	1	2	:	:	PUNCT
dpc-3895	1	3	practical	practical	ADJ
dpc-3895	1	4	and	and	CCONJ
dpc-3895	1	5	conceptual	conceptual	ADJ
dpc-3895	1	6	original	original	ADJ
dpc-3895	1	7	article	article	NOUN
dpc-3895	1	8	|	|	ADV
dpc-3895	1	9	dermatol	dermatol	ADJ
dpc-3895	1	10	pract	pract	NOUN
dpc-3895	1	11	concept	concept	NOUN
dpc-3895	1	12	.	.	PUNCT
dpc-3895	2	1	2024;14(2):e2024119	2024;14(2):e2024119	NUM
dpc-3895	2	2	1	1	NUM
dpc-3895	2	3	a	a	DET
dpc-3895	2	4	real	real	ADJ
dpc-3895	2	5	-	-	PUNCT
dpc-3895	2	6	life	life	NOUN
dpc-3895	2	7	208	208	NUM
dpc-3895	2	8	week	week	NOUN
dpc-3895	2	9	single	single	ADV
dpc-3895	2	10	-	-	PUNCT
dpc-3895	2	11	centred	centre	VERB
dpc-3895	2	12	,	,	PUNCT
dpc-3895	2	13	registerbased	registerbase	VERB
dpc-3895	2	14	retrospective	retrospective	ADJ
dpc-3895	2	15	study	study	NOUN
dpc-3895	2	16	assessing	assess	VERB
dpc-3895	2	17	secukinumab	secukinumab	NOUN
dpc-3895	2	18	survival	survival	NOUN
dpc-3895	2	19	and	and	CCONJ
dpc-3895	2	20	long	long	ADJ
dpc-3895	2	21	-	-	PUNCT
dpc-3895	2	22	term	term	NOUN
dpc-3895	2	23	efficacy	efficacy	NOUN
dpc-3895	2	24	and	and	CCONJ
dpc-3895	2	25	safety	safety	NOUN
dpc-3895	2	26	among	among	ADP
dpc-3895	2	27	greek	greek	ADJ
dpc-3895	2	28	patients	patient	NOUN
dpc-3895	2	29	with	with	ADP
dpc-3895	2	30	moderate	moderate	ADJ
dpc-3895	2	31	to	to	ADP
dpc-3895	2	32	severe	severe	ADJ
dpc-3895	2	33	plaque	plaque	NOUN
dpc-3895	2	34	psoriasis	psoriasis	NOUN
dpc-3895	2	35	,	,	PUNCT
dpc-3895	2	36	including	include	VERB
dpc-3895	2	37	difficult	difficult	ADJ
dpc-3895	2	38	-	-	PUNCT
dpc-3895	2	39	to	to	ADP
dpc-3895	2	40	-	-	PUNCT
dpc-3895	2	41	treat	treat	VERB
dpc-3895	2	42	manifestations	manifestation	NOUN
dpc-3895	2	43	such	such	ADJ
dpc-3895	2	44	as	as	ADP
dpc-3895	2	45	genitals	genital	NOUN
dpc-3895	2	46	and	and	CCONJ
dpc-3895	2	47	scalp	scalp	NOUN
dpc-3895	2	48	eirini	eirini	PROPN
dpc-3895	2	49	kyrmanidou1	kyrmanidou1	PROPN
dpc-3895	2	50	,	,	PUNCT
dpc-3895	2	51	christina	christina	PROPN
dpc-3895	2	52	kemanetzi1	kemanetzi1	PROPN
dpc-3895	2	53	,	,	PUNCT
dpc-3895	2	54	chatzopoulos	chatzopoulos	PROPN
dpc-3895	2	55	stavros2	stavros2	PROPN
dpc-3895	2	56	,	,	PUNCT
dpc-3895	2	57	myrto	myrto	PROPN
dpc-3895	2	58	-	-	PUNCT
dpc-3895	2	59	georgia	georgia	PROPN
dpc-3895	2	60	 	 	SPACE
dpc-3895	2	61	trakatelli1	trakatelli1	PROPN
dpc-3895	2	62	,	,	PUNCT
dpc-3895	2	63	aikaterini	aikaterini	PROPN
dpc-3895	2	64	patsatsi1	patsatsi1	PROPN
dpc-3895	2	65	,	,	PUNCT
dpc-3895	2	66	xenia	xenia	PROPN
dpc-3895	2	67	madia3	madia3	PROPN
dpc-3895	2	68	,	,	PUNCT
dpc-3895	2	69	dimitra	dimitra	PROPN
dpc-3895	2	70	ignatiadi3	ignatiadi3	PROPN
dpc-3895	2	71	,	,	PUNCT
dpc-3895	2	72	evangelia	evangelia	PROPN
dpc-3895	2	73	 	 	SPACE
dpc-3895	2	74	kalloniati1	kalloniati1	NOUN
dpc-3895	2	75	,	,	PUNCT
dpc-3895	2	76	zoe	zoe	PROPN
dpc-3895	2	77	apalla1	apalla1	PROPN
dpc-3895	2	78	,	,	PUNCT
dpc-3895	2	79	elizabeth	elizabeth	PROPN
dpc-3895	2	80	lazaridou1	lazaridou1	PROPN
dpc-3895	2	81	1	1	NUM
dpc-3895	2	82	second	second	ADJ
dpc-3895	2	83	department	department	NOUN
dpc-3895	2	84	of	of	ADP
dpc-3895	2	85	dermatology	dermatology	NOUN
dpc-3895	2	86	,	,	PUNCT
dpc-3895	2	87	medical	medical	ADJ
dpc-3895	2	88	school	school	NOUN
dpc-3895	2	89	,	,	PUNCT
dpc-3895	2	90	aristotle	aristotle	PROPN
dpc-3895	2	91	university	university	PROPN
dpc-3895	2	92	of	of	ADP
dpc-3895	2	93	thessaloniki	thessaloniki	PROPN
dpc-3895	2	94	,	,	PUNCT
dpc-3895	2	95	thessaloniki	thessaloniki	PROPN
dpc-3895	2	96	,	,	PUNCT
dpc-3895	2	97	greece	greece	PROPN
dpc-3895	2	98	2	2	NUM
dpc-3895	2	99	school	school	NOUN
dpc-3895	2	100	of	of	ADP
dpc-3895	2	101	statistics	statistic	NOUN
dpc-3895	2	102	and	and	CCONJ
dpc-3895	2	103	insurance	insurance	NOUN
dpc-3895	2	104	science	science	NOUN
dpc-3895	2	105	,	,	PUNCT
dpc-3895	2	106	university	university	NOUN
dpc-3895	2	107	of	of	ADP
dpc-3895	2	108	western	western	ADJ
dpc-3895	2	109	macedonia	macedonia	PROPN
dpc-3895	2	110	,	,	PUNCT
dpc-3895	2	111	kozani	kozani	PROPN
dpc-3895	2	112	,	,	PUNCT
dpc-3895	2	113	greece	greece	PROPN
dpc-3895	2	114	3	3	NUM
dpc-3895	2	115	novartis	novartis	PROPN
dpc-3895	2	116	,	,	PUNCT
dpc-3895	2	117	athens	athens	PROPN
dpc-3895	2	118	,	,	PUNCT
dpc-3895	2	119	greece	greece	PROPN
dpc-3895	2	120	key	key	ADJ
dpc-3895	2	121	words	word	NOUN
dpc-3895	2	122	:	:	PUNCT
dpc-3895	2	123	psoriasis	psoriasis	NOUN
dpc-3895	2	124	,	,	PUNCT
dpc-3895	2	125	genital	genital	ADJ
dpc-3895	2	126	psoriasis	psoriasis	NOUN
dpc-3895	2	127	,	,	PUNCT
dpc-3895	2	128	scalp	scalp	NOUN
dpc-3895	2	129	psoriasis	psoriasis	NOUN
dpc-3895	2	130	,	,	PUNCT
dpc-3895	2	131	secukinumab	secukinumab	NOUN
dpc-3895	2	132	,	,	PUNCT
dpc-3895	2	133	greece	greece	PROPN
dpc-3895	2	134	citation	citation	PROPN
dpc-3895	2	135	:	:	PUNCT
dpc-3895	2	136	kyrmanidou	kyrmanidou	PROPN
dpc-3895	2	137	e	e	PROPN
dpc-3895	2	138	,	,	PUNCT
dpc-3895	2	139	kemanetzi	kemanetzi	NOUN
dpc-3895	2	140	c	c	NOUN
dpc-3895	2	141	,	,	PUNCT
dpc-3895	2	142	stavros	stavros	PROPN
dpc-3895	2	143	c	c	AUX
dpc-3895	2	144	,	,	PUNCT
dpc-3895	2	145	et	et	PROPN
dpc-3895	2	146	al	al	PROPN
dpc-3895	2	147	.	.	PUNCT
dpc-3895	3	1	a	a	DET
dpc-3895	3	2	real	real	ADJ
dpc-3895	3	3	-	-	PUNCT
dpc-3895	3	4	life	life	NOUN
dpc-3895	3	5	208	208	NUM
dpc-3895	3	6	week	week	NOUN
dpc-3895	3	7	single	single	ADV
dpc-3895	3	8	-	-	PUNCT
dpc-3895	3	9	centred	centre	VERB
dpc-3895	3	10	,	,	PUNCT
dpc-3895	3	11	register	register	NOUN
dpc-3895	3	12	-	-	PUNCT
dpc-3895	3	13	based	base	VERB
dpc-3895	3	14	retrospective	retrospective	ADJ
dpc-3895	3	15	study	study	NOUN
dpc-3895	3	16	assessing	assess	VERB
dpc-3895	3	17	secukinumab	secukinumab	NOUN
dpc-3895	3	18	survival	survival	NOUN
dpc-3895	3	19	and	and	CCONJ
dpc-3895	3	20	long	long	ADJ
dpc-3895	3	21	-	-	PUNCT
dpc-3895	3	22	term	term	NOUN
dpc-3895	3	23	efficacy	efficacy	NOUN
dpc-3895	3	24	and	and	CCONJ
dpc-3895	3	25	safety	safety	NOUN
dpc-3895	3	26	among	among	ADP
dpc-3895	3	27	greek	greek	ADJ
dpc-3895	3	28	patients	patient	NOUN
dpc-3895	3	29	with	with	ADP
dpc-3895	3	30	moderate	moderate	ADJ
dpc-3895	3	31	to	to	ADP
dpc-3895	3	32	severe	severe	ADJ
dpc-3895	3	33	plaque	plaque	NOUN
dpc-3895	3	34	psoriasis	psoriasis	NOUN
dpc-3895	3	35	,	,	PUNCT
dpc-3895	3	36	including	include	VERB
dpc-3895	3	37	difficult	difficult	ADJ
dpc-3895	3	38	-	-	PUNCT
dpc-3895	3	39	to	to	ADP
dpc-3895	3	40	-	-	PUNCT
dpc-3895	3	41	treat	treat	VERB
dpc-3895	3	42	manifestations	manifestation	NOUN
dpc-3895	3	43	such	such	ADJ
dpc-3895	3	44	as	as	ADP
dpc-3895	3	45	genitals	genital	NOUN
dpc-3895	3	46	and	and	CCONJ
dpc-3895	3	47	scalp	scalp	NOUN
dpc-3895	3	48	.	.	PUNCT
dpc-3895	4	1	dermatol	dermatol	NOUN
dpc-3895	4	2	pract	pract	PROPN
dpc-3895	4	3	concept	concept	NOUN
dpc-3895	4	4	.	.	PUNCT
dpc-3895	5	1	2024;14(2):e2024119	2024;14(2):e2024119	X
dpc-3895	5	2	.	.	X
dpc-3895	5	3	doi	doi	PROPN
dpc-3895	5	4	:	:	PUNCT
dpc-3895	5	5	https://	https://	PROPN
dpc-3895	5	6	doi.org/10.5826/dpc.1402a119	doi.org/10.5826/dpc.1402a119	PROPN
dpc-3895	5	7	accepted	accept	VERB
dpc-3895	5	8	:	:	PUNCT
dpc-3895	5	9	december	december	PROPN
dpc-3895	5	10	14	14	NUM
dpc-3895	5	11	,	,	PUNCT
dpc-3895	5	12	2023	2023	NUM
dpc-3895	5	13	;	;	PUNCT
dpc-3895	5	14	published	publish	VERB
dpc-3895	5	15	:	:	PUNCT
dpc-3895	6	1	april	april	PROPN
dpc-3895	6	2	2024	2024	NUM
dpc-3895	6	3	copyright	copyright	NOUN
dpc-3895	6	4	:	:	PUNCT
dpc-3895	6	5	©	©	PROPN
dpc-3895	6	6	2024	2024	NUM
dpc-3895	6	7	kyrmanidou	kyrmanidou	NOUN
dpc-3895	6	8	et	et	PROPN
dpc-3895	6	9	al	al	PROPN
dpc-3895	6	10	.	.	PUNCT
dpc-3895	7	1	this	this	PRON
dpc-3895	7	2	is	be	AUX
dpc-3895	7	3	an	an	DET
dpc-3895	7	4	open	open	ADJ
dpc-3895	7	5	-	-	PUNCT
dpc-3895	7	6	access	access	NOUN
dpc-3895	7	7	article	article	NOUN
dpc-3895	7	8	distributed	distribute	VERB
dpc-3895	7	9	under	under	ADP
dpc-3895	7	10	the	the	DET
dpc-3895	7	11	terms	term	NOUN
dpc-3895	7	12	of	of	ADP
dpc-3895	7	13	the	the	DET
dpc-3895	7	14	creative	creative	ADJ
dpc-3895	7	15	commons	common	NOUN
dpc-3895	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-3895	7	17	license	license	NOUN
dpc-3895	7	18	(	(	PUNCT
dpc-3895	7	19	by	by	ADP
dpc-3895	7	20	-	-	PUNCT
dpc-3895	7	21	nc-4.0	nc-4.0	NOUN
dpc-3895	7	22	)	)	PUNCT
dpc-3895	7	23	,	,	PUNCT
dpc-3895	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3895	7	25	,	,	PUNCT
dpc-3895	7	26	which	which	PRON
dpc-3895	7	27	permits	permit	VERB
dpc-3895	7	28	unrestricted	unrestricted	ADJ
dpc-3895	7	29	noncommercial	noncommercial	ADJ
dpc-3895	7	30	use	use	NOUN
dpc-3895	7	31	,	,	PUNCT
dpc-3895	7	32	distribution	distribution	NOUN
dpc-3895	7	33	,	,	PUNCT
dpc-3895	7	34	and	and	CCONJ
dpc-3895	7	35	reproduction	reproduction	NOUN
dpc-3895	7	36	in	in	ADP
dpc-3895	7	37	any	any	DET
dpc-3895	7	38	medium	medium	NOUN
dpc-3895	7	39	,	,	PUNCT
dpc-3895	7	40	provided	provide	VERB
dpc-3895	7	41	the	the	DET
dpc-3895	7	42	original	original	ADJ
dpc-3895	7	43	authors	author	NOUN
dpc-3895	7	44	and	and	CCONJ
dpc-3895	7	45	source	source	NOUN
dpc-3895	7	46	are	be	AUX
dpc-3895	7	47	credited	credit	VERB
dpc-3895	7	48	.	.	PUNCT
dpc-3895	8	1	funding	funding	NOUN
dpc-3895	8	2	:	:	PUNCT
dpc-3895	8	3	received	receive	VERB
dpc-3895	8	4	a	a	DET
dpc-3895	8	5	research	research	NOUN
dpc-3895	8	6	fund	fund	NOUN
dpc-3895	8	7	from	from	ADP
dpc-3895	8	8	novartis	novartis	PROPN
dpc-3895	8	9	,	,	PUNCT
dpc-3895	8	10	greece	greece	PROPN
dpc-3895	8	11	.	.	PUNCT
dpc-3895	9	1	competing	compete	VERB
dpc-3895	9	2	interests	interest	NOUN
dpc-3895	9	3	:	:	PUNCT
dpc-3895	9	4	none	none	NOUN
dpc-3895	9	5	.	.	PUNCT
dpc-3895	10	1	authorship	authorship	NOUN
dpc-3895	10	2	:	:	PUNCT
dpc-3895	10	3	all	all	DET
dpc-3895	10	4	authors	author	NOUN
dpc-3895	10	5	have	have	AUX
dpc-3895	10	6	contributed	contribute	VERB
dpc-3895	10	7	significantly	significantly	ADV
dpc-3895	10	8	to	to	ADP
dpc-3895	10	9	this	this	DET
dpc-3895	10	10	publication	publication	NOUN
dpc-3895	10	11	.	.	PUNCT
dpc-3895	11	1	corresponding	correspond	VERB
dpc-3895	11	2	author	author	NOUN
dpc-3895	11	3	:	:	PUNCT
dpc-3895	11	4	kyrmanidou	kyrmanidou	PROPN
dpc-3895	11	5	eirini	eirini	PROPN
dpc-3895	11	6	,	,	PUNCT
dpc-3895	11	7	i.passalidi	i.passalidi	VERB
dpc-3895	11	8	77	77	NUM
dpc-3895	11	9	,	,	PUNCT
dpc-3895	11	10	55132	55132	NUM
dpc-3895	11	11	thessaloniki	thessaloniki	NOUN
dpc-3895	11	12	.	.	PUNCT
dpc-3895	12	1	email	email	NOUN
dpc-3895	12	2	:	:	PUNCT
dpc-3895	13	1	ekyrmanidou@gmail.com	ekyrmanidou@gmail.com	X
dpc-3895	13	2	introduction	introduction	NOUN
dpc-3895	13	3	:	:	PUNCT
dpc-3895	13	4	psoriasis	psoriasis	NOUN
dpc-3895	13	5	is	be	AUX
dpc-3895	13	6	a	a	DET
dpc-3895	13	7	chronic	chronic	ADJ
dpc-3895	13	8	inflammatory	inflammatory	ADJ
dpc-3895	13	9	disease	disease	NOUN
dpc-3895	13	10	with	with	ADP
dpc-3895	13	11	multiple	multiple	ADJ
dpc-3895	13	12	skin	skin	NOUN
dpc-3895	13	13	manifestations	manifestation	NOUN
dpc-3895	13	14	,	,	PUNCT
dpc-3895	13	15	and	and	CCONJ
dpc-3895	13	16	in	in	ADP
dpc-3895	13	17	case	case	NOUN
dpc-3895	13	18	of	of	ADP
dpc-3895	13	19	lesions	lesion	NOUN
dpc-3895	13	20	affecting	affect	VERB
dpc-3895	13	21	the	the	DET
dpc-3895	13	22	genital	genital	ADJ
dpc-3895	13	23	area	area	NOUN
dpc-3895	13	24	,	,	PUNCT
dpc-3895	13	25	sexual	sexual	ADJ
dpc-3895	13	26	health	health	NOUN
dpc-3895	13	27	impairment	impairment	NOUN
dpc-3895	13	28	and	and	CCONJ
dpc-3895	13	29	psychological	psychological	ADJ
dpc-3895	13	30	distress	distress	NOUN
dpc-3895	13	31	can	can	AUX
dpc-3895	13	32	furthermore	furthermore	ADV
dpc-3895	13	33	impair	impair	VERB
dpc-3895	13	34	the	the	DET
dpc-3895	13	35	patients	patient	NOUN
dpc-3895	13	36	quality	quality	NOUN
dpc-3895	13	37	of	of	ADP
dpc-3895	13	38	life	life	NOUN
dpc-3895	13	39	.	.	PUNCT
dpc-3895	14	1	secukinumab	secukinumab	NOUN
dpc-3895	14	2	is	be	AUX
dpc-3895	14	3	a	a	DET
dpc-3895	14	4	fully	fully	ADV
dpc-3895	14	5	humanized	humanize	VERB
dpc-3895	14	6	immunoglobulin	immunoglobulin	NOUN
dpc-3895	14	7	g1	g1	PROPN
dpc-3895	14	8	kappa	kappa	PROPN
dpc-3895	14	9	antagonist	antagonist	NOUN
dpc-3895	14	10	of	of	ADP
dpc-3895	14	11	il-17a	il-17a	PROPN
dpc-3895	14	12	and	and	CCONJ
dpc-3895	14	13	is	be	AUX
dpc-3895	14	14	indicated	indicate	VERB
dpc-3895	14	15	for	for	ADP
dpc-3895	14	16	the	the	DET
dpc-3895	14	17	treatment	treatment	NOUN
dpc-3895	14	18	of	of	ADP
dpc-3895	14	19	moderate	moderate	ADJ
dpc-3895	14	20	-	-	PUNCT
dpc-3895	14	21	to	to	ADP
dpc-3895	14	22	-	-	PUNCT
dpc-3895	14	23	severe	severe	ADJ
dpc-3895	14	24	psoriasis	psoriasis	NOUN
dpc-3895	14	25	,	,	PUNCT
dpc-3895	14	26	since	since	SCONJ
dpc-3895	14	27	it	it	PRON
dpc-3895	14	28	shows	show	VERB
dpc-3895	14	29	a	a	DET
dpc-3895	14	30	significant	significant	ADJ
dpc-3895	14	31	efficacy	efficacy	NOUN
dpc-3895	14	32	in	in	ADP
dpc-3895	14	33	clinical	clinical	ADJ
dpc-3895	14	34	outcomes	outcome	NOUN
dpc-3895	14	35	,	,	PUNCT
dpc-3895	14	36	with	with	ADP
dpc-3895	14	37	rapid	rapid	ADJ
dpc-3895	14	38	onset	onset	NOUN
dpc-3895	14	39	of	of	ADP
dpc-3895	14	40	remission	remission	NOUN
dpc-3895	14	41	,	,	PUNCT
dpc-3895	14	42	prolonged	prolonged	ADJ
dpc-3895	14	43	treatment	treatment	NOUN
dpc-3895	14	44	response	response	NOUN
dpc-3895	14	45	rate	rate	NOUN
dpc-3895	14	46	,	,	PUNCT
dpc-3895	14	47	advantageous	advantageous	ADJ
dpc-3895	14	48	safety	safety	NOUN
dpc-3895	14	49	profile	profile	NOUN
dpc-3895	14	50	and	and	CCONJ
dpc-3895	14	51	a	a	DET
dpc-3895	14	52	valuable	valuable	ADJ
dpc-3895	14	53	improvement	improvement	NOUN
dpc-3895	14	54	of	of	ADP
dpc-3895	14	55	the	the	DET
dpc-3895	14	56	patients	patient	NOUN
dpc-3895	14	57	quality	quality	NOUN
dpc-3895	14	58	of	of	ADP
dpc-3895	14	59	life	life	NOUN
dpc-3895	14	60	.	.	PUNCT
dpc-3895	15	1	objectives	objective	NOUN
dpc-3895	15	2	:	:	PUNCT
dpc-3895	15	3	this	this	DET
dpc-3895	15	4	study	study	NOUN
dpc-3895	15	5	was	be	AUX
dpc-3895	15	6	conducted	conduct	VERB
dpc-3895	15	7	in	in	ADP
dpc-3895	15	8	order	order	NOUN
dpc-3895	15	9	to	to	PART
dpc-3895	15	10	gather	gather	VERB
dpc-3895	15	11	retrospective	retrospective	ADJ
dpc-3895	15	12	real	real	ADJ
dpc-3895	15	13	-	-	PUNCT
dpc-3895	15	14	world	world	NOUN
dpc-3895	15	15	data	datum	NOUN
dpc-3895	15	16	regarding	regard	VERB
dpc-3895	15	17	the	the	DET
dpc-3895	15	18	efficacy	efficacy	NOUN
dpc-3895	15	19	of	of	ADP
dpc-3895	15	20	secukinumab	secukinumab	NOUN
dpc-3895	15	21	in	in	ADP
dpc-3895	15	22	treating	treat	VERB
dpc-3895	15	23	patients	patient	NOUN
dpc-3895	15	24	with	with	ADP
dpc-3895	15	25	moderate	moderate	ADJ
dpc-3895	15	26	-	-	PUNCT
dpc-3895	15	27	to	to	ADP
dpc-3895	15	28	-	-	PUNCT
dpc-3895	15	29	severe	severe	ADJ
dpc-3895	15	30	plaque	plaque	NOUN
dpc-3895	15	31	psoriasis	psoriasis	NOUN
dpc-3895	15	32	in	in	ADP
dpc-3895	15	33	greece	greece	PROPN
dpc-3895	15	34	.	.	PUNCT
dpc-3895	16	1	to	to	PART
dpc-3895	16	2	abstract	abstract	VERB
dpc-3895	16	3	2	2	NUM
dpc-3895	16	4	original	original	ADJ
dpc-3895	16	5	article	article	NOUN
dpc-3895	16	6	|	|	ADV
dpc-3895	16	7	dermatol	dermatol	ADJ
dpc-3895	16	8	pract	pract	NOUN
dpc-3895	16	9	concept	concept	NOUN
dpc-3895	16	10	.	.	PUNCT
dpc-3895	17	1	2024;14(2):e2024119	2024;14(2):e2024119	NUM
dpc-3895	17	2	introduction	introduction	NOUN
dpc-3895	17	3	psoriasis	psoriasis	NOUN
dpc-3895	17	4	is	be	AUX
dpc-3895	17	5	a	a	DET
dpc-3895	17	6	chronic	chronic	ADJ
dpc-3895	17	7	inflammatory	inflammatory	ADJ
dpc-3895	17	8	disease	disease	NOUN
dpc-3895	17	9	with	with	ADP
dpc-3895	17	10	multiple	multiple	ADJ
dpc-3895	17	11	skin	skin	NOUN
dpc-3895	17	12	manifestations	manifestation	NOUN
dpc-3895	17	13	and	and	CCONJ
dpc-3895	17	14	from	from	ADP
dpc-3895	17	15	epidemiological	epidemiological	ADJ
dpc-3895	17	16	studies	study	NOUN
dpc-3895	17	17	in	in	ADP
dpc-3895	17	18	the	the	DET
dpc-3895	17	19	united	united	PROPN
dpc-3895	17	20	states	states	PROPN
dpc-3895	17	21	it	it	PRON
dpc-3895	17	22	is	be	AUX
dpc-3895	17	23	estimated	estimate	VERB
dpc-3895	17	24	that	that	SCONJ
dpc-3895	17	25	3	3	NUM
dpc-3895	17	26	%	%	NOUN
dpc-3895	17	27	of	of	ADP
dpc-3895	17	28	adult	adult	NOUN
dpc-3895	17	29	population	population	NOUN
dpc-3895	17	30	shows	show	VERB
dpc-3895	17	31	signs	sign	NOUN
dpc-3895	17	32	of	of	ADP
dpc-3895	17	33	psoriatic	psoriatic	ADJ
dpc-3895	17	34	disease	disease	NOUN
dpc-3895	17	35	[	[	X
dpc-3895	17	36	1	1	NUM
dpc-3895	17	37	]	]	PUNCT
dpc-3895	17	38	.	.	PUNCT
dpc-3895	18	1	90	90	NUM
dpc-3895	18	2	%	%	NOUN
dpc-3895	18	3	of	of	ADP
dpc-3895	18	4	patients	patient	NOUN
dpc-3895	18	5	with	with	ADP
dpc-3895	18	6	psoriasis	psoriasis	NOUN
dpc-3895	18	7	have	have	VERB
dpc-3895	18	8	chronic	chronic	ADJ
dpc-3895	18	9	plaque	plaque	NOUN
dpc-3895	18	10	psoriasis	psoriasis	NOUN
dpc-3895	18	11	,	,	PUNCT
dpc-3895	18	12	whereas	whereas	SCONJ
dpc-3895	18	13	less	less	ADV
dpc-3895	18	14	common	common	ADJ
dpc-3895	18	15	psoriasis	psoriasis	NOUN
dpc-3895	18	16	can	can	AUX
dpc-3895	18	17	affect	affect	VERB
dpc-3895	18	18	the	the	DET
dpc-3895	18	19	nails	nail	NOUN
dpc-3895	18	20	(	(	PUNCT
dpc-3895	18	21	23%-27	23%-27	NUM
dpc-3895	18	22	%	%	NOUN
dpc-3895	18	23	)	)	PUNCT
dpc-3895	18	24	,	,	PUNCT
dpc-3895	18	25	face	face	NOUN
dpc-3895	18	26	(	(	PUNCT
dpc-3895	18	27	49	49	NUM
dpc-3895	18	28	%	%	NOUN
dpc-3895	18	29	)	)	PUNCT
dpc-3895	18	30	palms	palm	NOUN
dpc-3895	18	31	and	and	CCONJ
dpc-3895	18	32	soles	sol	NOUN
dpc-3895	18	33	(	(	PUNCT
dpc-3895	18	34	12%-16	12%-16	NUM
dpc-3895	18	35	%	%	NOUN
dpc-3895	18	36	)	)	PUNCT
dpc-3895	18	37	,	,	PUNCT
dpc-3895	18	38	or	or	CCONJ
dpc-3895	18	39	intertriginous	intertriginous	ADJ
dpc-3895	18	40	folds	fold	NOUN
dpc-3895	18	41	(	(	PUNCT
dpc-3895	18	42	21%-30	21%-30	NUM
dpc-3895	18	43	%	%	NOUN
dpc-3895	18	44	)	)	PUNCT
dpc-3895	18	45	.	.	PUNCT
dpc-3895	19	1	quality	quality	NOUN
dpc-3895	19	2	of	of	ADP
dpc-3895	19	3	life	life	NOUN
dpc-3895	19	4	is	be	AUX
dpc-3895	19	5	impaired	impair	VERB
dpc-3895	19	6	in	in	ADP
dpc-3895	19	7	patients	patient	NOUN
dpc-3895	19	8	with	with	ADP
dpc-3895	19	9	psoriasis	psoriasis	NOUN
dpc-3895	19	10	,	,	PUNCT
dpc-3895	19	11	especially	especially	ADV
dpc-3895	19	12	when	when	SCONJ
dpc-3895	19	13	sites	site	NOUN
dpc-3895	19	14	of	of	ADP
dpc-3895	19	15	aesthetic	aesthetic	ADJ
dpc-3895	19	16	significance	significance	NOUN
dpc-3895	19	17	are	be	AUX
dpc-3895	19	18	affected	affect	VERB
dpc-3895	19	19	like	like	ADP
dpc-3895	19	20	the	the	DET
dpc-3895	19	21	scalp	scalp	NOUN
dpc-3895	19	22	and	and	CCONJ
dpc-3895	19	23	palms	palm	NOUN
dpc-3895	19	24	[	[	X
dpc-3895	19	25	2	2	NUM
dpc-3895	19	26	]	]	PUNCT
dpc-3895	19	27	.	.	PUNCT
dpc-3895	20	1	moreover	moreover	ADV
dpc-3895	20	2	psoriasis	psoriasis	NOUN
dpc-3895	20	3	affecting	affect	VERB
dpc-3895	20	4	the	the	DET
dpc-3895	20	5	genital	genital	ADJ
dpc-3895	20	6	area	area	NOUN
dpc-3895	20	7	can	can	AUX
dpc-3895	20	8	be	be	AUX
dpc-3895	20	9	the	the	DET
dpc-3895	20	10	cause	cause	NOUN
dpc-3895	20	11	of	of	ADP
dpc-3895	20	12	sexual	sexual	ADJ
dpc-3895	20	13	health	health	NOUN
dpc-3895	20	14	impairment	impairment	NOUN
dpc-3895	20	15	and	and	CCONJ
dpc-3895	20	16	psychological	psychological	ADJ
dpc-3895	20	17	distress	distress	NOUN
dpc-3895	20	18	,	,	PUNCT
dpc-3895	20	19	despite	despite	SCONJ
dpc-3895	20	20	the	the	DET
dpc-3895	20	21	fact	fact	NOUN
dpc-3895	20	22	that	that	SCONJ
dpc-3895	20	23	it	it	PRON
dpc-3895	20	24	only	only	ADV
dpc-3895	20	25	affects	affect	VERB
dpc-3895	20	26	≤	≤	NUM
dpc-3895	20	27	1	1	NUM
dpc-3895	20	28	%	%	NOUN
dpc-3895	20	29	of	of	ADP
dpc-3895	20	30	the	the	DET
dpc-3895	20	31	body	body	NOUN
dpc-3895	20	32	surface	surface	NOUN
dpc-3895	20	33	area	area	NOUN
dpc-3895	20	34	(	(	PUNCT
dpc-3895	20	35	bsa	bsa	PROPN
dpc-3895	20	36	)	)	PUNCT
dpc-3895	21	1	[	[	X
dpc-3895	21	2	3	3	NUM
dpc-3895	21	3	]	]	PUNCT
dpc-3895	21	4	.	.	PUNCT
dpc-3895	22	1	although	although	SCONJ
dpc-3895	22	2	the	the	DET
dpc-3895	22	3	exact	exact	ADJ
dpc-3895	22	4	pathogenetic	pathogenetic	ADJ
dpc-3895	22	5	mechanism	mechanism	NOUN
dpc-3895	22	6	of	of	ADP
dpc-3895	22	7	psoriasis	psoriasis	NOUN
dpc-3895	22	8	has	have	AUX
dpc-3895	22	9	been	be	AUX
dpc-3895	22	10	under	under	ADP
dpc-3895	22	11	investigation	investigation	NOUN
dpc-3895	22	12	until	until	ADP
dpc-3895	22	13	now	now	ADV
dpc-3895	22	14	,	,	PUNCT
dpc-3895	22	15	it	it	PRON
dpc-3895	22	16	seems	seem	VERB
dpc-3895	22	17	that	that	SCONJ
dpc-3895	22	18	both	both	CCONJ
dpc-3895	22	19	genetic	genetic	ADJ
dpc-3895	22	20	and	and	CCONJ
dpc-3895	22	21	environmental	environmental	ADJ
dpc-3895	22	22	factors	factor	NOUN
dpc-3895	22	23	lead	lead	VERB
dpc-3895	22	24	to	to	ADP
dpc-3895	22	25	an	an	DET
dpc-3895	22	26	immune	immune	ADJ
dpc-3895	22	27	mediated	mediate	VERB
dpc-3895	22	28	hyperproliferation	hyperproliferation	NOUN
dpc-3895	22	29	of	of	ADP
dpc-3895	22	30	the	the	DET
dpc-3895	22	31	epidermal	epidermal	ADJ
dpc-3895	22	32	keratinocytes	keratinocyte	NOUN
dpc-3895	22	33	,	,	PUNCT
dpc-3895	22	34	an	an	DET
dpc-3895	22	35	aberrant	aberrant	ADJ
dpc-3895	22	36	inflammatory	inflammatory	ADJ
dpc-3895	22	37	infiltration	infiltration	NOUN
dpc-3895	22	38	of	of	ADP
dpc-3895	22	39	the	the	DET
dpc-3895	22	40	dermis	dermis	NOUN
dpc-3895	22	41	and	and	CCONJ
dpc-3895	22	42	an	an	DET
dpc-3895	22	43	increased	increase	VERB
dpc-3895	22	44	angiogenesis	angiogenesis	NOUN
dpc-3895	22	45	in	in	ADP
dpc-3895	22	46	the	the	DET
dpc-3895	22	47	psoriatic	psoriatic	ADJ
dpc-3895	22	48	lesions	lesion	NOUN
dpc-3895	22	49	.	.	PUNCT
dpc-3895	23	1	recently	recently	ADV
dpc-3895	23	2	,	,	PUNCT
dpc-3895	23	3	the	the	DET
dpc-3895	23	4	interleukin-23	interleukin-23	PROPN
dpc-3895	23	5	/	/	SYM
dpc-3895	23	6	t	t	PROPN
dpc-3895	23	7	helper	helper	NOUN
dpc-3895	23	8	17	17	NUM
dpc-3895	23	9	(	(	PUNCT
dpc-3895	23	10	il-23	il-23	NOUN
dpc-3895	23	11	/	/	SYM
dpc-3895	23	12	th17	th17	NOUN
dpc-3895	23	13	)	)	PUNCT
dpc-3895	23	14	pathway	pathway	NOUN
dpc-3895	23	15	has	have	AUX
dpc-3895	23	16	been	be	AUX
dpc-3895	23	17	recognized	recognize	VERB
dpc-3895	23	18	as	as	ADP
dpc-3895	23	19	a	a	DET
dpc-3895	23	20	key	key	ADJ
dpc-3895	23	21	axis	axis	NOUN
dpc-3895	23	22	in	in	ADP
dpc-3895	23	23	the	the	DET
dpc-3895	23	24	pathogenesis	pathogenesis	NOUN
dpc-3895	23	25	of	of	ADP
dpc-3895	23	26	psoriasis	psoriasis	NOUN
dpc-3895	23	27	,	,	PUNCT
dpc-3895	23	28	which	which	PRON
dpc-3895	23	29	leads	lead	VERB
dpc-3895	23	30	to	to	ADP
dpc-3895	23	31	the	the	DET
dpc-3895	23	32	overexpression	overexpression	NOUN
dpc-3895	23	33	of	of	ADP
dpc-3895	23	34	the	the	DET
dpc-3895	23	35	proinflammatory	proinflammatory	ADJ
dpc-3895	23	36	cytokine	cytokine	NOUN
dpc-3895	23	37	interleukin	interleukin	NOUN
dpc-3895	23	38	17a	17a	X
dpc-3895	23	39	(	(	PUNCT
dpc-3895	23	40	il-17a	il-17a	PROPN
dpc-3895	23	41	)	)	PUNCT
dpc-3895	23	42	.	.	PUNCT
dpc-3895	24	1	secukinumab	secukinumab	NOUN
dpc-3895	24	2	is	be	AUX
dpc-3895	24	3	a	a	DET
dpc-3895	24	4	fully	fully	ADV
dpc-3895	24	5	humanized	humanize	VERB
dpc-3895	24	6	immunoglobulin	immunoglobulin	NOUN
dpc-3895	24	7	g1	g1	PROPN
dpc-3895	24	8	kappa	kappa	PROPN
dpc-3895	24	9	antagonist	antagonist	NOUN
dpc-3895	24	10	of	of	ADP
dpc-3895	24	11	il-17a	il-17a	PROPN
dpc-3895	24	12	and	and	CCONJ
dpc-3895	24	13	is	be	AUX
dpc-3895	24	14	indicated	indicate	VERB
dpc-3895	24	15	for	for	ADP
dpc-3895	24	16	the	the	DET
dpc-3895	24	17	treatment	treatment	NOUN
dpc-3895	24	18	of	of	ADP
dpc-3895	24	19	moderatetosevere	moderatetosevere	ADP
dpc-3895	24	20	psoriasis	psoriasis	NOUN
dpc-3895	24	21	,	,	PUNCT
dpc-3895	24	22	moderate	moderate	ADJ
dpc-3895	24	23	-	-	PUNCT
dpc-3895	24	24	to	to	ADP
dpc-3895	24	25	-	-	PUNCT
dpc-3895	24	26	severe	severe	ADJ
dpc-3895	24	27	paediatric	paediatric	ADJ
dpc-3895	24	28	plaque	plaque	NOUN
dpc-3895	24	29	psoriasis	psoriasis	NOUN
dpc-3895	24	30	,	,	PUNCT
dpc-3895	24	31	psoriatic	psoriatic	ADJ
dpc-3895	24	32	arthritis	arthritis	NOUN
dpc-3895	24	33	(	(	PUNCT
dpc-3895	24	34	psa	psa	NOUN
dpc-3895	24	35	)	)	PUNCT
dpc-3895	24	36	,	,	PUNCT
dpc-3895	24	37	axial	axial	ADJ
dpc-3895	24	38	spondyloarthritis	spondyloarthritis	NOUN
dpc-3895	24	39	,	,	PUNCT
dpc-3895	24	40	juvevile	juvevile	ADJ
dpc-3895	24	41	idiopathic	idiopathic	ADJ
dpc-3895	24	42	arthritis	arthritis	NOUN
dpc-3895	24	43	(	(	PUNCT
dpc-3895	24	44	enthesitis	enthesitis	NOUN
dpc-3895	24	45	-	-	PUNCT
dpc-3895	24	46	related	relate	VERB
dpc-3895	24	47	arthritis	arthritis	NOUN
dpc-3895	24	48	and	and	CCONJ
dpc-3895	24	49	juvenile	juvenile	ADJ
dpc-3895	24	50	psoriatic	psoriatic	ADJ
dpc-3895	24	51	arthritis	arthritis	NOUN
dpc-3895	24	52	)	)	PUNCT
dpc-3895	24	53	and	and	CCONJ
dpc-3895	24	54	hidradenitis	hidradenitis	PROPN
dpc-3895	24	55	suppurativa	suppurativa	NOUN
dpc-3895	24	56	[	[	X
dpc-3895	24	57	1	1	NUM
dpc-3895	24	58	-	-	SYM
dpc-3895	24	59	9	9	NUM
dpc-3895	24	60	]	]	PUNCT
dpc-3895	24	61	.	.	PUNCT
dpc-3895	25	1	namely	namely	ADV
dpc-3895	25	2	for	for	ADP
dpc-3895	25	3	the	the	DET
dpc-3895	25	4	treatment	treatment	NOUN
dpc-3895	25	5	of	of	ADP
dpc-3895	25	6	moderate	moderate	ADJ
dpc-3895	25	7	-	-	PUNCT
dpc-3895	25	8	to	to	ADP
dpc-3895	25	9	-	-	PUNCT
dpc-3895	25	10	severe	severe	ADJ
dpc-3895	25	11	plaque	plaque	NOUN
dpc-3895	25	12	psoriasis	psoriasis	NOUN
dpc-3895	25	13	in	in	ADP
dpc-3895	25	14	adults	adult	NOUN
dpc-3895	25	15	,	,	PUNCT
dpc-3895	25	16	secukinumab	secukinumab	NOUN
dpc-3895	25	17	is	be	AUX
dpc-3895	25	18	indicated	indicate	VERB
dpc-3895	25	19	as	as	ADP
dpc-3895	25	20	first	first	ADJ
dpc-3895	25	21	line	line	NOUN
dpc-3895	25	22	treatment	treatment	NOUN
dpc-3895	25	23	.	.	PUNCT
dpc-3895	26	1	secukinumab	secukinumab	PROPN
dpc-3895	26	2	shows	show	VERB
dpc-3895	26	3	a	a	DET
dpc-3895	26	4	significant	significant	ADJ
dpc-3895	26	5	efficacy	efficacy	NOUN
dpc-3895	26	6	in	in	ADP
dpc-3895	26	7	clinical	clinical	ADJ
dpc-3895	26	8	outcomes	outcome	NOUN
dpc-3895	26	9	,	,	PUNCT
dpc-3895	26	10	with	with	ADP
dpc-3895	26	11	rapid	rapid	ADJ
dpc-3895	26	12	onset	onset	NOUN
dpc-3895	26	13	of	of	ADP
dpc-3895	26	14	remission	remission	NOUN
dpc-3895	26	15	,	,	PUNCT
dpc-3895	26	16	prolonged	prolonged	ADJ
dpc-3895	26	17	treatment	treatment	NOUN
dpc-3895	26	18	response	response	NOUN
dpc-3895	26	19	rate	rate	NOUN
dpc-3895	26	20	,	,	PUNCT
dpc-3895	26	21	advantageous	advantageous	ADJ
dpc-3895	26	22	safety	safety	NOUN
dpc-3895	26	23	profile	profile	NOUN
dpc-3895	26	24	and	and	CCONJ
dpc-3895	26	25	a	a	DET
dpc-3895	26	26	valuable	valuable	ADJ
dpc-3895	26	27	improvement	improvement	NOUN
dpc-3895	26	28	of	of	ADP
dpc-3895	26	29	patients	patient	NOUN
dpc-3895	26	30	quality	quality	NOUN
dpc-3895	26	31	of	of	ADP
dpc-3895	26	32	life	life	NOUN
dpc-3895	26	33	,	,	PUNCT
dpc-3895	26	34	not	not	PART
dpc-3895	26	35	only	only	ADV
dpc-3895	26	36	from	from	ADP
dpc-3895	26	37	phase	phase	NOUN
dpc-3895	26	38	-	-	PUNCT
dpc-3895	26	39	iii	iii	NOUN
dpc-3895	26	40	clinical	clinical	ADJ
dpc-3895	26	41	trials	trial	NOUN
dpc-3895	26	42	but	but	CCONJ
dpc-3895	26	43	from	from	ADP
dpc-3895	26	44	real	real	ADJ
dpc-3895	26	45	-	-	PUNCT
dpc-3895	26	46	life	life	NOUN
dpc-3895	26	47	data	datum	NOUN
dpc-3895	26	48	as	as	ADV
dpc-3895	26	49	well	well	ADV
dpc-3895	26	50	[	[	X
dpc-3895	26	51	4,5	4,5	NUM
dpc-3895	26	52	]	]	PUNCT
dpc-3895	26	53	.	.	PUNCT
dpc-3895	27	1	objectives	objective	NOUN
dpc-3895	27	2	this	this	DET
dpc-3895	27	3	study	study	NOUN
dpc-3895	27	4	was	be	AUX
dpc-3895	27	5	conducted	conduct	VERB
dpc-3895	27	6	in	in	ADP
dpc-3895	27	7	order	order	NOUN
dpc-3895	27	8	to	to	PART
dpc-3895	27	9	gather	gather	VERB
dpc-3895	27	10	retrospective	retrospective	ADJ
dpc-3895	27	11	real	real	ADJ
dpc-3895	27	12	-	-	PUNCT
dpc-3895	27	13	world	world	NOUN
dpc-3895	27	14	data	datum	NOUN
dpc-3895	27	15	regarding	regard	VERB
dpc-3895	27	16	the	the	DET
dpc-3895	27	17	efficacy	efficacy	NOUN
dpc-3895	27	18	of	of	ADP
dpc-3895	27	19	secukinumab	secukinumab	NOUN
dpc-3895	27	20	in	in	ADP
dpc-3895	27	21	treating	treat	VERB
dpc-3895	27	22	patients	patient	NOUN
dpc-3895	27	23	with	with	ADP
dpc-3895	27	24	moderate	moderate	ADJ
dpc-3895	27	25	-	-	PUNCT
dpc-3895	27	26	to	to	ADP
dpc-3895	27	27	-	-	PUNCT
dpc-3895	27	28	severe	severe	ADJ
dpc-3895	27	29	plaque	plaque	NOUN
dpc-3895	27	30	psoriasis	psoriasis	NOUN
dpc-3895	27	31	at	at	ADP
dpc-3895	27	32	the	the	DET
dpc-3895	27	33	psoriasis	psoriasis	NOUN
dpc-3895	27	34	clinic	clinic	NOUN
dpc-3895	27	35	of	of	ADP
dpc-3895	27	36	the	the	DET
dpc-3895	27	37	second	second	ADJ
dpc-3895	27	38	dermatology	dermatology	NOUN
dpc-3895	27	39	department	department	NOUN
dpc-3895	27	40	of	of	ADP
dpc-3895	27	41	the	the	DET
dpc-3895	27	42	aristotle	aristotle	PROPN
dpc-3895	27	43	university	university	PROPN
dpc-3895	27	44	of	of	ADP
dpc-3895	27	45	thessaloniki	thessaloniki	PROPN
dpc-3895	27	46	,	,	PUNCT
dpc-3895	27	47	“	"	PUNCT
dpc-3895	27	48	papageorgiou	papageorgiou	NOUN
dpc-3895	27	49	”	"	PUNCT
dpc-3895	27	50	general	general	ADJ
dpc-3895	27	51	hospital	hospital	NOUN
dpc-3895	27	52	.	.	PUNCT
dpc-3895	28	1	fill	fill	VERB
dpc-3895	28	2	the	the	DET
dpc-3895	28	3	relevant	relevant	ADJ
dpc-3895	28	4	literature	literature	NOUN
dpc-3895	28	5	gap	gap	NOUN
dpc-3895	28	6	,	,	PUNCT
dpc-3895	28	7	we	we	PRON
dpc-3895	28	8	included	include	VERB
dpc-3895	28	9	difficult	difficult	ADJ
dpc-3895	28	10	-	-	PUNCT
dpc-3895	28	11	to	to	ADP
dpc-3895	28	12	-	-	PUNCT
dpc-3895	28	13	treat	treat	VERB
dpc-3895	28	14	manifestations	manifestation	NOUN
dpc-3895	28	15	in	in	ADP
dpc-3895	28	16	our	our	PRON
dpc-3895	28	17	analysis	analysis	NOUN
dpc-3895	28	18	,	,	PUNCT
dpc-3895	28	19	specifically	specifically	ADV
dpc-3895	28	20	regarding	regard	VERB
dpc-3895	28	21	the	the	DET
dpc-3895	28	22	efficacy	efficacy	NOUN
dpc-3895	28	23	in	in	ADP
dpc-3895	28	24	the	the	DET
dpc-3895	28	25	genital	genital	ADJ
dpc-3895	28	26	area	area	NOUN
dpc-3895	28	27	and	and	CCONJ
dpc-3895	28	28	on	on	ADP
dpc-3895	28	29	the	the	DET
dpc-3895	28	30	skin	skin	NOUN
dpc-3895	28	31	folds	fold	NOUN
dpc-3895	28	32	where	where	SCONJ
dpc-3895	28	33	relevant	relevant	ADJ
dpc-3895	28	34	data	datum	NOUN
dpc-3895	28	35	are	be	AUX
dpc-3895	28	36	missing	miss	VERB
dpc-3895	28	37	both	both	CCONJ
dpc-3895	28	38	from	from	ADP
dpc-3895	28	39	the	the	DET
dpc-3895	28	40	drug	drug	NOUN
dpc-3895	28	41	clinical	clinical	ADJ
dpc-3895	28	42	program	program	NOUN
dpc-3895	28	43	as	as	ADV
dpc-3895	28	44	well	well	ADV
dpc-3895	28	45	as	as	ADP
dpc-3895	28	46	from	from	ADP
dpc-3895	28	47	the	the	DET
dpc-3895	28	48	real	real	ADJ
dpc-3895	28	49	-	-	PUNCT
dpc-3895	28	50	world	world	NOUN
dpc-3895	28	51	setting	setting	NOUN
dpc-3895	28	52	.	.	PUNCT
dpc-3895	29	1	methods	method	NOUN
dpc-3895	29	2	:	:	PUNCT
dpc-3895	29	3	all	all	DET
dpc-3895	29	4	adult	adult	NOUN
dpc-3895	29	5	patients	patient	NOUN
dpc-3895	29	6	receiving	receive	VERB
dpc-3895	29	7	300	300	NUM
dpc-3895	29	8	mg	mg	NOUN
dpc-3895	29	9	secukinumab	secukinumab	NOUN
dpc-3895	29	10	and	and	CCONJ
dpc-3895	29	11	attending	attend	VERB
dpc-3895	29	12	follow	follow	NOUN
dpc-3895	29	13	-	-	PUNCT
dpc-3895	29	14	up	up	NOUN
dpc-3895	29	15	visits	visit	NOUN
dpc-3895	29	16	on	on	ADP
dpc-3895	29	17	a	a	DET
dpc-3895	29	18	regular	regular	ADJ
dpc-3895	29	19	basis	basis	NOUN
dpc-3895	29	20	,	,	PUNCT
dpc-3895	29	21	according	accord	VERB
dpc-3895	29	22	to	to	ADP
dpc-3895	29	23	routine	routine	ADJ
dpc-3895	29	24	medical	medical	ADJ
dpc-3895	29	25	practice	practice	NOUN
dpc-3895	29	26	were	be	AUX
dpc-3895	29	27	included	include	VERB
dpc-3895	29	28	.	.	PUNCT
dpc-3895	30	1	the	the	DET
dpc-3895	30	2	timeline	timeline	NOUN
dpc-3895	30	3	of	of	ADP
dpc-3895	30	4	the	the	DET
dpc-3895	30	5	study	study	NOUN
dpc-3895	30	6	was	be	AUX
dpc-3895	30	7	from	from	ADP
dpc-3895	30	8	2015	2015	NUM
dpc-3895	30	9	to	to	ADP
dpc-3895	30	10	2020	2020	NUM
dpc-3895	30	11	.	.	PUNCT
dpc-3895	31	1	primary	primary	ADJ
dpc-3895	31	2	endpoint	endpoint	NOUN
dpc-3895	31	3	of	of	ADP
dpc-3895	31	4	the	the	DET
dpc-3895	31	5	study	study	NOUN
dpc-3895	31	6	was	be	AUX
dpc-3895	31	7	the	the	DET
dpc-3895	31	8	percentage	percentage	NOUN
dpc-3895	31	9	of	of	ADP
dpc-3895	31	10	patients	patient	NOUN
dpc-3895	31	11	who	who	PRON
dpc-3895	31	12	achieved	achieve	VERB
dpc-3895	31	13	a	a	DET
dpc-3895	31	14	psoriasis	psoriasis	NOUN
dpc-3895	31	15	area	area	NOUN
dpc-3895	31	16	and	and	CCONJ
dpc-3895	31	17	severity	severity	NOUN
dpc-3895	31	18	index	index	NOUN
dpc-3895	31	19	(	(	PUNCT
dpc-3895	31	20	pasi	pasi	NOUN
dpc-3895	31	21	)	)	PUNCT
dpc-3895	31	22	75	75	NUM
dpc-3895	31	23	response	response	NOUN
dpc-3895	31	24	rate	rate	NOUN
dpc-3895	31	25	at	at	ADP
dpc-3895	31	26	week	week	NOUN
dpc-3895	31	27	16	16	NUM
dpc-3895	31	28	and	and	CCONJ
dpc-3895	31	29	week	week	NOUN
dpc-3895	31	30	52	52	NUM
dpc-3895	31	31	post	post	NOUN
dpc-3895	31	32	baseline	baseline	NOUN
dpc-3895	31	33	.	.	PUNCT
dpc-3895	32	1	secondary	secondary	ADJ
dpc-3895	32	2	endpoints	endpoint	NOUN
dpc-3895	32	3	were	be	AUX
dpc-3895	32	4	the	the	DET
dpc-3895	32	5	evaluation	evaluation	NOUN
dpc-3895	32	6	at	at	ADP
dpc-3895	32	7	baseline	baseline	PROPN
dpc-3895	32	8	(	(	PUNCT
dpc-3895	32	9	week	week	NOUN
dpc-3895	32	10	0	0	NUM
dpc-3895	32	11	)	)	PUNCT
dpc-3895	32	12	,	,	PUNCT
dpc-3895	32	13	week	week	NOUN
dpc-3895	32	14	4	4	NUM
dpc-3895	32	15	(	(	PUNCT
dpc-3895	32	16	±1	±1	NOUN
dpc-3895	32	17	)	)	PUNCT
dpc-3895	32	18	,	,	PUNCT
dpc-3895	32	19	week	week	NOUN
dpc-3895	32	20	16	16	NUM
dpc-3895	32	21	(	(	PUNCT
dpc-3895	32	22	±1	±1	PROPN
dpc-3895	32	23	)	)	PUNCT
dpc-3895	32	24	,	,	PUNCT
dpc-3895	32	25	week52	week52	NOUN
dpc-3895	32	26	(	(	PUNCT
dpc-3895	32	27	±1	±1	ADJ
dpc-3895	32	28	)	)	PUNCT
dpc-3895	32	29	,	,	PUNCT
dpc-3895	32	30	and	and	CCONJ
dpc-3895	32	31	week	week	NOUN
dpc-3895	32	32	104	104	NUM
dpc-3895	32	33	(	(	PUNCT
dpc-3895	32	34	±1	±1	PROPN
dpc-3895	32	35	)	)	PUNCT
dpc-3895	32	36	,	,	PUNCT
dpc-3895	32	37	week	week	NOUN
dpc-3895	32	38	156	156	NUM
dpc-3895	32	39	(	(	PUNCT
dpc-3895	32	40	±1	±1	ADJ
dpc-3895	32	41	)	)	PUNCT
dpc-3895	32	42	,	,	PUNCT
dpc-3895	32	43	week	week	NOUN
dpc-3895	32	44	208	208	NUM
dpc-3895	32	45	(	(	PUNCT
dpc-3895	32	46	±1	±1	ADJ
dpc-3895	32	47	)	)	PUNCT
dpc-3895	32	48	of	of	ADP
dpc-3895	32	49	clinical	clinical	ADJ
dpc-3895	32	50	outcomes	outcome	NOUN
dpc-3895	32	51	,	,	PUNCT
dpc-3895	32	52	incidence	incidence	NOUN
dpc-3895	32	53	of	of	ADP
dpc-3895	32	54	adverse	adverse	ADJ
dpc-3895	32	55	events	event	NOUN
dpc-3895	32	56	and	and	CCONJ
dpc-3895	32	57	potential	potential	ADJ
dpc-3895	32	58	predictive	predictive	ADJ
dpc-3895	32	59	variables	variable	NOUN
dpc-3895	32	60	influencing	influence	VERB
dpc-3895	32	61	response	response	NOUN
dpc-3895	32	62	rate	rate	NOUN
dpc-3895	32	63	.	.	PUNCT
dpc-3895	33	1	results	result	NOUN
dpc-3895	33	2	:	:	PUNCT
dpc-3895	33	3	ninety	ninety	NUM
dpc-3895	33	4	-	-	PUNCT
dpc-3895	33	5	nine	nine	NUM
dpc-3895	33	6	patients	patient	NOUN
dpc-3895	33	7	were	be	AUX
dpc-3895	33	8	included	include	VERB
dpc-3895	33	9	in	in	ADP
dpc-3895	33	10	the	the	DET
dpc-3895	33	11	study	study	NOUN
dpc-3895	33	12	population	population	NOUN
dpc-3895	33	13	,	,	PUNCT
dpc-3895	33	14	from	from	ADP
dpc-3895	33	15	whom	whom	PRON
dpc-3895	33	16	sixty	sixty	NUM
dpc-3895	33	17	six	six	NUM
dpc-3895	33	18	patients	patient	NOUN
dpc-3895	33	19	(	(	PUNCT
dpc-3895	33	20	66.67	66.67	NUM
dpc-3895	33	21	%	%	NOUN
dpc-3895	33	22	)	)	PUNCT
dpc-3895	33	23	were	be	AUX
dpc-3895	33	24	bio	bio	ADJ
dpc-3895	33	25	-	-	ADJ
dpc-3895	33	26	naive	naive	ADJ
dpc-3895	33	27	,	,	PUNCT
dpc-3895	33	28	whereas	whereas	SCONJ
dpc-3895	33	29	33	33	NUM
dpc-3895	33	30	patients	patient	NOUN
dpc-3895	33	31	had	have	AUX
dpc-3895	33	32	never	never	ADV
dpc-3895	33	33	received	receive	VERB
dpc-3895	33	34	systemic	systemic	ADJ
dpc-3895	33	35	treatment	treatment	NOUN
dpc-3895	33	36	.	.	PUNCT
dpc-3895	34	1	regarding	regard	VERB
dpc-3895	34	2	difficult	difficult	ADJ
dpc-3895	34	3	-	-	PUNCT
dpc-3895	34	4	to	to	ADP
dpc-3895	34	5	-	-	PUNCT
dpc-3895	34	6	treat	treat	NOUN
dpc-3895	34	7	manifestations	manifestation	NOUN
dpc-3895	34	8	,	,	PUNCT
dpc-3895	34	9	we	we	PRON
dpc-3895	34	10	recorded	record	VERB
dpc-3895	34	11	scalp	scalp	NOUN
dpc-3895	34	12	involvement	involvement	NOUN
dpc-3895	34	13	in	in	ADP
dpc-3895	34	14	74.74	74.74	NUM
dpc-3895	34	15	%	%	NOUN
dpc-3895	34	16	(	(	PUNCT
dpc-3895	34	17	74/99	74/99	NUM
dpc-3895	34	18	)	)	PUNCT
dpc-3895	34	19	of	of	ADP
dpc-3895	34	20	our	our	PRON
dpc-3895	34	21	patients	patient	NOUN
dpc-3895	34	22	,	,	PUNCT
dpc-3895	34	23	genital	genital	ADJ
dpc-3895	34	24	psoriasis	psoriasis	NOUN
dpc-3895	34	25	in	in	ADP
dpc-3895	34	26	27.27	27.27	NUM
dpc-3895	34	27	%	%	NOUN
dpc-3895	34	28	(	(	PUNCT
dpc-3895	34	29	27/99	27/99	NUM
dpc-3895	34	30	)	)	PUNCT
dpc-3895	34	31	and	and	CCONJ
dpc-3895	34	32	skin	skin	NOUN
dpc-3895	34	33	folds	fold	NOUN
dpc-3895	34	34	involvement	involvement	NOUN
dpc-3895	34	35	(	(	PUNCT
dpc-3895	34	36	psoriasis	psoriasis	NOUN
dpc-3895	34	37	inversa	inversa	NOUN
dpc-3895	34	38	)	)	PUNCT
dpc-3895	34	39	in	in	ADP
dpc-3895	34	40	17	17	NUM
dpc-3895	34	41	%	%	NOUN
dpc-3895	34	42	(	(	PUNCT
dpc-3895	34	43	17/99	17/99	NUM
dpc-3895	34	44	)	)	PUNCT
dpc-3895	34	45	.	.	PUNCT
dpc-3895	35	1	at	at	ADP
dpc-3895	35	2	week	week	NOUN
dpc-3895	35	3	16	16	NUM
dpc-3895	35	4	,	,	PUNCT
dpc-3895	35	5	pasi75	pasi75	NOUN
dpc-3895	35	6	/	/	SYM
dpc-3895	35	7	pasi90	pasi90	PROPN
dpc-3895	35	8	/	/	SYM
dpc-3895	35	9	pasi100	pasi100	PROPN
dpc-3895	35	10	were	be	AUX
dpc-3895	35	11	observed	observe	VERB
dpc-3895	35	12	in	in	ADP
dpc-3895	35	13	87.5%/69.8%/49	87.5%/69.8%/49	PROPN
dpc-3895	35	14	%	%	NOUN
dpc-3895	35	15	,	,	PUNCT
dpc-3895	35	16	respectively	respectively	ADV
dpc-3895	35	17	.	.	PUNCT
dpc-3895	36	1	at	at	ADP
dpc-3895	36	2	week	week	NOUN
dpc-3895	36	3	4	4	NUM
dpc-3895	36	4	lesions	lesion	NOUN
dpc-3895	36	5	affecting	affect	VERB
dpc-3895	36	6	the	the	DET
dpc-3895	36	7	genital	genital	ADJ
dpc-3895	36	8	area	area	NOUN
dpc-3895	36	9	and	and	CCONJ
dpc-3895	36	10	patients	patient	NOUN
dpc-3895	36	11	with	with	ADP
dpc-3895	36	12	skin	skin	NOUN
dpc-3895	36	13	fold	fold	NOUN
dpc-3895	36	14	involvement	involvement	NOUN
dpc-3895	36	15	experienced	experience	VERB
dpc-3895	36	16	a	a	DET
dpc-3895	36	17	rapid	rapid	ADJ
dpc-3895	36	18	regression	regression	NOUN
dpc-3895	36	19	and	and	CCONJ
dpc-3895	36	20	84.1	84.1	NUM
dpc-3895	36	21	%	%	NOUN
dpc-3895	36	22	of	of	ADP
dpc-3895	36	23	patients	patient	NOUN
dpc-3895	36	24	achieved	achieve	VERB
dpc-3895	36	25	spga	spga	NOUN
dpc-3895	36	26	0/1	0/1	PROPN
dpc-3895	36	27	(	(	PUNCT
dpc-3895	36	28	physician	physician	NOUN
dpc-3895	36	29	global	global	ADJ
dpc-3895	36	30	assessment	assessment	NOUN
dpc-3895	36	31	)	)	PUNCT
dpc-3895	36	32	.	.	PUNCT
dpc-3895	37	1	treatment	treatment	NOUN
dpc-3895	37	2	with	with	ADP
dpc-3895	37	3	secukinumab	secukinumab	NOUN
dpc-3895	37	4	during	during	ADP
dpc-3895	37	5	the	the	DET
dpc-3895	37	6	208	208	NUM
dpc-3895	37	7	weeks	week	NOUN
dpc-3895	37	8	of	of	ADP
dpc-3895	37	9	observation	observation	NOUN
dpc-3895	37	10	did	do	AUX
dpc-3895	37	11	not	not	PART
dpc-3895	37	12	reveal	reveal	VERB
dpc-3895	37	13	any	any	DET
dpc-3895	37	14	major	major	ADJ
dpc-3895	37	15	adverse	adverse	ADJ
dpc-3895	37	16	event	event	NOUN
dpc-3895	37	17	or	or	CCONJ
dpc-3895	37	18	systemic	systemic	ADJ
dpc-3895	37	19	infection	infection	NOUN
dpc-3895	37	20	and	and	CCONJ
dpc-3895	37	21	generally	generally	ADV
dpc-3895	37	22	it	it	PRON
dpc-3895	37	23	was	be	AUX
dpc-3895	37	24	well	well	ADV
dpc-3895	37	25	tolerated	tolerate	VERB
dpc-3895	37	26	.	.	PUNCT
dpc-3895	38	1	conclusions	conclusion	NOUN
dpc-3895	38	2	:	:	PUNCT
dpc-3895	38	3	according	accord	VERB
dpc-3895	38	4	to	to	ADP
dpc-3895	38	5	our	our	PRON
dpc-3895	38	6	outcomes	outcome	NOUN
dpc-3895	38	7	secukinumab	secukinumab	NOUN
dpc-3895	38	8	is	be	AUX
dpc-3895	38	9	an	an	DET
dpc-3895	38	10	effective	effective	ADJ
dpc-3895	38	11	treatment	treatment	NOUN
dpc-3895	38	12	choice	choice	NOUN
dpc-3895	38	13	for	for	ADP
dpc-3895	38	14	treating	treat	VERB
dpc-3895	38	15	chronic	chronic	ADJ
dpc-3895	38	16	plaque	plaque	NOUN
dpc-3895	38	17	psoriasis	psoriasis	NOUN
dpc-3895	38	18	,	,	PUNCT
dpc-3895	38	19	but	but	CCONJ
dpc-3895	38	20	,	,	PUNCT
dpc-3895	38	21	additionally	additionally	ADV
dpc-3895	38	22	,	,	PUNCT
dpc-3895	38	23	it	it	PRON
dpc-3895	38	24	can	can	AUX
dpc-3895	38	25	be	be	AUX
dpc-3895	38	26	efficacious	efficacious	ADJ
dpc-3895	38	27	in	in	ADP
dpc-3895	38	28	the	the	DET
dpc-3895	38	29	subgroups	subgroup	NOUN
dpc-3895	38	30	of	of	ADP
dpc-3895	38	31	patients	patient	NOUN
dpc-3895	38	32	with	with	ADP
dpc-3895	38	33	difficult	difficult	ADJ
dpc-3895	38	34	-	-	PUNCT
dpc-3895	38	35	to	to	ADP
dpc-3895	38	36	-	-	PUNCT
dpc-3895	38	37	treat	treat	NOUN
dpc-3895	38	38	manifestations	manifestation	NOUN
dpc-3895	38	39	,	,	PUNCT
dpc-3895	38	40	as	as	SCONJ
dpc-3895	38	41	our	our	PRON
dpc-3895	38	42	patients	patient	NOUN
dpc-3895	38	43	experienced	experience	VERB
dpc-3895	38	44	great	great	ADJ
dpc-3895	38	45	improvement	improvement	NOUN
dpc-3895	38	46	starting	start	VERB
dpc-3895	38	47	even	even	ADV
dpc-3895	38	48	5	5	NUM
dpc-3895	38	49	weeks	week	NOUN
dpc-3895	38	50	after	after	ADP
dpc-3895	38	51	treatment	treatment	NOUN
dpc-3895	38	52	initiation	initiation	NOUN
dpc-3895	38	53	.	.	PUNCT
dpc-3895	39	1	this	this	DET
dpc-3895	39	2	real	real	ADJ
dpc-3895	39	3	-	-	PUNCT
dpc-3895	39	4	life	life	NOUN
dpc-3895	39	5	study	study	NOUN
dpc-3895	39	6	offers	offer	VERB
dpc-3895	39	7	information	information	NOUN
dpc-3895	39	8	about	about	ADP
dpc-3895	39	9	clinical	clinical	ADJ
dpc-3895	39	10	efficacy	efficacy	NOUN
dpc-3895	39	11	,	,	PUNCT
dpc-3895	39	12	retention	retention	NOUN
dpc-3895	39	13	and	and	CCONJ
dpc-3895	39	14	safety	safety	NOUN
dpc-3895	39	15	profile	profile	NOUN
dpc-3895	39	16	of	of	ADP
dpc-3895	39	17	secukinumab	secukinumab	NOUN
dpc-3895	39	18	in	in	ADP
dpc-3895	39	19	patients	patient	NOUN
dpc-3895	39	20	from	from	ADP
dpc-3895	39	21	everyday	everyday	ADJ
dpc-3895	39	22	clinical	clinical	ADJ
dpc-3895	39	23	practice	practice	NOUN
dpc-3895	39	24	over	over	ADP
dpc-3895	39	25	a	a	DET
dpc-3895	39	26	long	long	ADJ
dpc-3895	39	27	-	-	PUNCT
dpc-3895	39	28	term	term	NOUN
dpc-3895	39	29	,	,	PUNCT
dpc-3895	39	30	4	4	NUM
dpc-3895	39	31	-	-	PUNCT
dpc-3895	39	32	year	year	NOUN
dpc-3895	39	33	,	,	PUNCT
dpc-3895	39	34	follow	follow	VERB
dpc-3895	39	35	-	-	PUNCT
dpc-3895	39	36	up	up	NOUN
dpc-3895	39	37	period	period	NOUN
dpc-3895	39	38	in	in	ADP
dpc-3895	39	39	greece	greece	PROPN
dpc-3895	39	40	.	.	PUNCT
dpc-3895	40	1	original	original	ADJ
dpc-3895	40	2	article	article	NOUN
dpc-3895	40	3	|	|	ADV
dpc-3895	40	4	dermatol	dermatol	ADJ
dpc-3895	40	5	pract	pract	NOUN
dpc-3895	40	6	concept	concept	NOUN
dpc-3895	40	7	.	.	PUNCT
dpc-3895	41	1	2024;14(2):e2024119	2024;14(2):e2024119	NUM
dpc-3895	41	2	3	3	NUM
dpc-3895	41	3	methods	method	NOUN
dpc-3895	41	4	in	in	ADP
dpc-3895	41	5	order	order	NOUN
dpc-3895	41	6	to	to	PART
dpc-3895	41	7	fill	fill	VERB
dpc-3895	41	8	the	the	DET
dpc-3895	41	9	relevant	relevant	ADJ
dpc-3895	41	10	literature	literature	NOUN
dpc-3895	41	11	gap	gap	NOUN
dpc-3895	41	12	,	,	PUNCT
dpc-3895	41	13	we	we	PRON
dpc-3895	41	14	included	include	VERB
dpc-3895	41	15	difficult	difficult	ADJ
dpc-3895	41	16	-	-	PUNCT
dpc-3895	41	17	to	to	ADP
dpc-3895	41	18	-	-	PUNCT
dpc-3895	41	19	treat	treat	VERB
dpc-3895	41	20	manifestations	manifestation	NOUN
dpc-3895	41	21	in	in	ADP
dpc-3895	41	22	our	our	PRON
dpc-3895	41	23	analysis	analysis	NOUN
dpc-3895	41	24	,	,	PUNCT
dpc-3895	41	25	specifically	specifically	ADV
dpc-3895	41	26	regarding	regard	VERB
dpc-3895	41	27	the	the	DET
dpc-3895	41	28	efficacy	efficacy	NOUN
dpc-3895	41	29	in	in	ADP
dpc-3895	41	30	the	the	DET
dpc-3895	41	31	genital	genital	ADJ
dpc-3895	41	32	area	area	NOUN
dpc-3895	41	33	and	and	CCONJ
dpc-3895	41	34	on	on	ADP
dpc-3895	41	35	the	the	DET
dpc-3895	41	36	skin	skin	NOUN
dpc-3895	41	37	folds	fold	NOUN
dpc-3895	41	38	where	where	SCONJ
dpc-3895	41	39	relevant	relevant	ADJ
dpc-3895	41	40	data	datum	NOUN
dpc-3895	41	41	are	be	AUX
dpc-3895	41	42	missing	miss	VERB
dpc-3895	41	43	both	both	CCONJ
dpc-3895	41	44	from	from	ADP
dpc-3895	41	45	the	the	DET
dpc-3895	41	46	drugclinical	drugclinical	ADJ
dpc-3895	41	47	program	program	NOUN
dpc-3895	41	48	as	as	ADV
dpc-3895	41	49	well	well	ADV
dpc-3895	41	50	as	as	ADP
dpc-3895	41	51	from	from	ADP
dpc-3895	41	52	the	the	DET
dpc-3895	41	53	real	real	ADJ
dpc-3895	41	54	-	-	PUNCT
dpc-3895	41	55	world	world	NOUN
dpc-3895	41	56	setting	setting	NOUN
dpc-3895	41	57	.	.	PUNCT
dpc-3895	42	1	frequency	frequency	NOUN
dpc-3895	42	2	of	of	ADP
dpc-3895	42	3	follow	follow	NOUN
dpc-3895	42	4	-	-	PUNCT
dpc-3895	42	5	up	up	ADP
dpc-3895	42	6	visits	visit	NOUN
dpc-3895	42	7	was	be	AUX
dpc-3895	42	8	determined	determine	VERB
dpc-3895	42	9	by	by	ADP
dpc-3895	42	10	attending	attend	VERB
dpc-3895	42	11	physicians	physician	NOUN
dpc-3895	42	12	according	accord	VERB
dpc-3895	42	13	to	to	ADP
dpc-3895	42	14	routine	routine	ADJ
dpc-3895	42	15	medical	medical	ADJ
dpc-3895	42	16	practice	practice	NOUN
dpc-3895	42	17	,	,	PUNCT
dpc-3895	42	18	however	however	SCONJ
dpc-3895	42	19	data	datum	NOUN
dpc-3895	42	20	were	be	AUX
dpc-3895	42	21	collected	collect	VERB
dpc-3895	42	22	at	at	ADP
dpc-3895	42	23	4	4	NUM
dpc-3895	42	24	,	,	PUNCT
dpc-3895	42	25	16	16	NUM
dpc-3895	42	26	,	,	PUNCT
dpc-3895	42	27	52	52	NUM
dpc-3895	42	28	,	,	PUNCT
dpc-3895	42	29	104	104	NUM
dpc-3895	42	30	and	and	CCONJ
dpc-3895	42	31	208	208	NUM
dpc-3895	42	32	weeks	week	NOUN
dpc-3895	42	33	with	with	ADP
dpc-3895	42	34	a	a	DET
dpc-3895	42	35	time	time	NOUN
dpc-3895	42	36	window	window	NOUN
dpc-3895	42	37	(	(	PUNCT
dpc-3895	42	38	±	±	NOUN
dpc-3895	42	39	1	1	NUM
dpc-3895	42	40	week	week	NOUN
dpc-3895	42	41	)	)	PUNCT
dpc-3895	42	42	after	after	ADP
dpc-3895	42	43	secukinumab	secukinumab	NOUN
dpc-3895	42	44	treatment	treatment	NOUN
dpc-3895	42	45	initiation	initiation	NOUN
dpc-3895	42	46	.	.	PUNCT
dpc-3895	43	1	study	study	NOUN
dpc-3895	43	2	design	design	VERB
dpc-3895	43	3	the	the	DET
dpc-3895	43	4	psoriasis	psoriasis	NOUN
dpc-3895	43	5	outpatient	outpatient	NOUN
dpc-3895	43	6	clinic	clinic	NOUN
dpc-3895	43	7	registry	registry	NOUN
dpc-3895	43	8	of	of	ADP
dpc-3895	43	9	our	our	PRON
dpc-3895	43	10	clinic	clinic	NOUN
dpc-3895	43	11	was	be	AUX
dpc-3895	43	12	reviewed	review	VERB
dpc-3895	43	13	and	and	CCONJ
dpc-3895	43	14	all	all	DET
dpc-3895	43	15	adult	adult	NOUN
dpc-3895	43	16	patients	patient	NOUN
dpc-3895	43	17	receiving	receive	VERB
dpc-3895	43	18	300	300	NUM
dpc-3895	43	19	mg	mg	NOUN
dpc-3895	43	20	secukinumab	secukinumab	NOUN
dpc-3895	43	21	and	and	CCONJ
dpc-3895	43	22	attending	attend	VERB
dpc-3895	43	23	follow	follow	NOUN
dpc-3895	43	24	-	-	PUNCT
dpc-3895	43	25	up	up	NOUN
dpc-3895	43	26	visits	visit	NOUN
dpc-3895	43	27	on	on	ADP
dpc-3895	43	28	a	a	DET
dpc-3895	43	29	regular	regular	ADJ
dpc-3895	43	30	basis	basis	NOUN
dpc-3895	43	31	,	,	PUNCT
dpc-3895	43	32	according	accord	VERB
dpc-3895	43	33	to	to	ADP
dpc-3895	43	34	routine	routine	ADJ
dpc-3895	43	35	medical	medical	ADJ
dpc-3895	43	36	practice	practice	NOUN
dpc-3895	43	37	,	,	PUNCT
dpc-3895	43	38	were	be	AUX
dpc-3895	43	39	included	include	VERB
dpc-3895	43	40	.	.	PUNCT
dpc-3895	44	1	the	the	DET
dpc-3895	44	2	timeline	timeline	NOUN
dpc-3895	44	3	of	of	ADP
dpc-3895	44	4	the	the	DET
dpc-3895	44	5	study	study	NOUN
dpc-3895	44	6	was	be	AUX
dpc-3895	44	7	from	from	ADP
dpc-3895	44	8	2015	2015	NUM
dpc-3895	44	9	to	to	ADP
dpc-3895	44	10	2020	2020	NUM
dpc-3895	44	11	.	.	PUNCT
dpc-3895	45	1	written	write	VERB
dpc-3895	45	2	informed	informed	ADJ
dpc-3895	45	3	consent	consent	NOUN
dpc-3895	45	4	was	be	AUX
dpc-3895	45	5	obtained	obtain	VERB
dpc-3895	45	6	from	from	ADP
dpc-3895	45	7	each	each	DET
dpc-3895	45	8	patient	patient	NOUN
dpc-3895	45	9	.	.	PUNCT
dpc-3895	46	1	patients	patient	NOUN
dpc-3895	46	2	,	,	PUNCT
dpc-3895	46	3	aged	aged	ADJ
dpc-3895	46	4	≥18	≥18	NUM
dpc-3895	46	5	years	year	NOUN
dpc-3895	46	6	,	,	PUNCT
dpc-3895	46	7	with	with	ADP
dpc-3895	46	8	a	a	DET
dpc-3895	46	9	clinical	clinical	ADJ
dpc-3895	46	10	diagnosis	diagnosis	NOUN
dpc-3895	46	11	of	of	ADP
dpc-3895	46	12	chronic	chronic	NOUN
dpc-3895	46	13	(	(	PUNCT
dpc-3895	46	14	≥6	≥6	NUM
dpc-3895	46	15	months	month	NOUN
dpc-3895	46	16	)	)	PUNCT
dpc-3895	46	17	moderate	moderate	ADJ
dpc-3895	46	18	-	-	PUNCT
dpc-3895	46	19	to	to	ADP
dpc-3895	46	20	-	-	PUNCT
dpc-3895	46	21	severe	severe	ADJ
dpc-3895	46	22	plaque	plaque	NOUN
dpc-3895	46	23	psoriasis	psoriasis	NOUN
dpc-3895	46	24	,	,	PUNCT
dpc-3895	46	25	and	and	CCONJ
dpc-3895	46	26	candidates	candidate	NOUN
dpc-3895	46	27	for	for	ADP
dpc-3895	46	28	systemic	systemic	ADJ
dpc-3895	46	29	therapy	therapy	NOUN
dpc-3895	46	30	who	who	PRON
dpc-3895	46	31	were	be	AUX
dpc-3895	46	32	receiving	receive	VERB
dpc-3895	46	33	secukinumab	secukinumab	NOUN
dpc-3895	46	34	(	(	PUNCT
dpc-3895	46	35	as	as	ADP
dpc-3895	46	36	per	per	ADP
dpc-3895	46	37	local	local	ADJ
dpc-3895	46	38	label	label	NOUN
dpc-3895	46	39	indication	indication	NOUN
dpc-3895	46	40	and	and	CCONJ
dpc-3895	46	41	according	accord	VERB
dpc-3895	46	42	to	to	ADP
dpc-3895	46	43	routine	routine	ADJ
dpc-3895	46	44	medical	medical	ADJ
dpc-3895	46	45	practice	practice	NOUN
dpc-3895	46	46	)	)	PUNCT
dpc-3895	46	47	for	for	ADP
dpc-3895	46	48	at	at	ADV
dpc-3895	46	49	least	least	ADJ
dpc-3895	46	50	for	for	ADP
dpc-3895	46	51	16	16	NUM
dpc-3895	46	52	weeks	week	NOUN
dpc-3895	46	53	were	be	AUX
dpc-3895	46	54	included	include	VERB
dpc-3895	46	55	.	.	PUNCT
dpc-3895	47	1	patients	patient	NOUN
dpc-3895	47	2	with	with	ADP
dpc-3895	47	3	a	a	DET
dpc-3895	47	4	baseline	baseline	ADJ
dpc-3895	47	5	psoriasis	psoriasis	NOUN
dpc-3895	47	6	area	area	NOUN
dpc-3895	47	7	and	and	CCONJ
dpc-3895	47	8	severity	severity	NOUN
dpc-3895	47	9	index	index	NOUN
dpc-3895	47	10	(	(	PUNCT
dpc-3895	47	11	pasi	pasi	NOUN
dpc-3895	47	12	)	)	PUNCT
dpc-3895	47	13	<	<	X
dpc-3895	47	14	10	10	NUM
dpc-3895	47	15	were	be	AUX
dpc-3895	47	16	also	also	ADV
dpc-3895	47	17	included	include	VERB
dpc-3895	47	18	if	if	SCONJ
dpc-3895	47	19	the	the	DET
dpc-3895	47	20	baseline	baseline	ADJ
dpc-3895	47	21	dermatology	dermatology	NOUN
dpc-3895	47	22	life	life	NOUN
dpc-3895	47	23	quality	quality	NOUN
dpc-3895	47	24	index	index	NOUN
dpc-3895	47	25	(	(	PUNCT
dpc-3895	47	26	dlqi	dlqi	PROPN
dpc-3895	47	27	)	)	PUNCT
dpc-3895	47	28	was	be	AUX
dpc-3895	47	29	≥10	≥10	ADJ
dpc-3895	47	30	or	or	CCONJ
dpc-3895	47	31	if	if	SCONJ
dpc-3895	47	32	there	there	PRON
dpc-3895	47	33	were	be	VERB
dpc-3895	47	34	symptoms	symptom	NOUN
dpc-3895	47	35	in	in	ADP
dpc-3895	47	36	the	the	DET
dpc-3895	47	37	scalp	scalp	NOUN
dpc-3895	47	38	,	,	PUNCT
dpc-3895	47	39	genitals	genital	NOUN
dpc-3895	47	40	,	,	PUNCT
dpc-3895	47	41	palms	palm	NOUN
dpc-3895	47	42	,	,	PUNCT
dpc-3895	47	43	and	and	CCONJ
dpc-3895	47	44	feet	foot	NOUN
dpc-3895	47	45	or	or	CCONJ
dpc-3895	47	46	if	if	SCONJ
dpc-3895	47	47	onycholysis	onycholysis	NOUN
dpc-3895	47	48	of	of	ADP
dpc-3895	47	49	at	at	ADV
dpc-3895	47	50	least	least	ADV
dpc-3895	47	51	3	3	NUM
dpc-3895	47	52	fingernails	fingernail	NOUN
dpc-3895	47	53	was	be	AUX
dpc-3895	47	54	characterized	characterize	VERB
dpc-3895	47	55	as	as	ADP
dpc-3895	47	56	persistent	persistent	ADJ
dpc-3895	47	57	manifestation	manifestation	NOUN
dpc-3895	47	58	according	accord	VERB
dpc-3895	47	59	to	to	ADP
dpc-3895	47	60	local	local	ADJ
dpc-3895	47	61	and	and	CCONJ
dpc-3895	47	62	global	global	ADJ
dpc-3895	47	63	guidelines	guideline	NOUN
dpc-3895	47	64	.	.	PUNCT
dpc-3895	48	1	use	use	NOUN
dpc-3895	48	2	of	of	ADP
dpc-3895	48	3	concomitant	concomitant	ADJ
dpc-3895	48	4	anti	anti	ADJ
dpc-3895	48	5	-	-	ADJ
dpc-3895	48	6	psoriatic	psoriatic	ADJ
dpc-3895	48	7	agents	agent	NOUN
dpc-3895	48	8	(	(	PUNCT
dpc-3895	48	9	systemic	systemic	ADJ
dpc-3895	48	10	or	or	CCONJ
dpc-3895	48	11	topical	topical	ADJ
dpc-3895	48	12	)	)	PUNCT
dpc-3895	48	13	was	be	AUX
dpc-3895	48	14	permitted	permit	VERB
dpc-3895	48	15	as	as	ADP
dpc-3895	48	16	per	per	ADP
dpc-3895	48	17	everyday	everyday	ADJ
dpc-3895	48	18	clinical	clinical	ADJ
dpc-3895	48	19	practice	practice	NOUN
dpc-3895	48	20	.	.	PUNCT
dpc-3895	49	1	patients	patient	NOUN
dpc-3895	49	2	were	be	AUX
dpc-3895	49	3	excluded	exclude	VERB
dpc-3895	49	4	if	if	SCONJ
dpc-3895	49	5	the	the	DET
dpc-3895	49	6	medical	medical	ADJ
dpc-3895	49	7	file	file	NOUN
dpc-3895	49	8	data	datum	NOUN
dpc-3895	49	9	of	of	ADP
dpc-3895	49	10	interest	interest	NOUN
dpc-3895	49	11	was	be	AUX
dpc-3895	49	12	incomplete	incomplete	ADJ
dpc-3895	49	13	for	for	ADP
dpc-3895	49	14	eligibility	eligibility	NOUN
dpc-3895	49	15	evaluation	evaluation	NOUN
dpc-3895	49	16	and	and	CCONJ
dpc-3895	49	17	if	if	SCONJ
dpc-3895	49	18	there	there	PRON
dpc-3895	49	19	were	be	VERB
dpc-3895	49	20	any	any	DET
dpc-3895	49	21	contradictions	contradiction	NOUN
dpc-3895	49	22	to	to	PART
dpc-3895	49	23	il-17	il-17	ADV
dpc-3895	49	24	/	/	SYM
dpc-3895	49	25	secukinumab	secukinumab	NOUN
dpc-3895	49	26	intake	intake	NOUN
dpc-3895	49	27	as	as	ADP
dpc-3895	49	28	per	per	ADP
dpc-3895	49	29	label	label	NOUN
dpc-3895	49	30	.	.	PUNCT
dpc-3895	50	1	primary	primary	ADJ
dpc-3895	50	2	endpoint	endpoint	NOUN
dpc-3895	50	3	of	of	ADP
dpc-3895	50	4	the	the	DET
dpc-3895	50	5	study	study	NOUN
dpc-3895	50	6	was	be	AUX
dpc-3895	50	7	the	the	DET
dpc-3895	50	8	percentage	percentage	NOUN
dpc-3895	50	9	of	of	ADP
dpc-3895	50	10	patients	patient	NOUN
dpc-3895	50	11	who	who	PRON
dpc-3895	50	12	achieved	achieve	VERB
dpc-3895	50	13	a	a	DET
dpc-3895	50	14	pasi75	pasi75	NOUN
dpc-3895	50	15	response	response	NOUN
dpc-3895	50	16	rate	rate	NOUN
dpc-3895	50	17	at	at	ADP
dpc-3895	50	18	week	week	NOUN
dpc-3895	50	19	16	16	NUM
dpc-3895	50	20	and	and	CCONJ
dpc-3895	50	21	week	week	NOUN
dpc-3895	50	22	52	52	NUM
dpc-3895	50	23	post	post	NOUN
dpc-3895	50	24	baseline	baseline	NOUN
dpc-3895	50	25	.	.	PUNCT
dpc-3895	51	1	secondary	secondary	ADJ
dpc-3895	51	2	endpoints	endpoint	NOUN
dpc-3895	51	3	were	be	AUX
dpc-3895	51	4	the	the	DET
dpc-3895	51	5	evaluation	evaluation	NOUN
dpc-3895	51	6	at	at	ADP
dpc-3895	51	7	baseline	baseline	PROPN
dpc-3895	51	8	(	(	PUNCT
dpc-3895	51	9	week	week	NOUN
dpc-3895	51	10	0	0	NUM
dpc-3895	51	11	)	)	PUNCT
dpc-3895	51	12	,	,	PUNCT
dpc-3895	51	13	week	week	NOUN
dpc-3895	51	14	4	4	NUM
dpc-3895	51	15	(	(	PUNCT
dpc-3895	51	16	±1	±1	NOUN
dpc-3895	51	17	)	)	PUNCT
dpc-3895	51	18	,	,	PUNCT
dpc-3895	51	19	week	week	NOUN
dpc-3895	51	20	16	16	NUM
dpc-3895	51	21	(	(	PUNCT
dpc-3895	51	22	±1	±1	PROPN
dpc-3895	51	23	)	)	PUNCT
dpc-3895	51	24	,	,	PUNCT
dpc-3895	51	25	week52	week52	NOUN
dpc-3895	51	26	(	(	PUNCT
dpc-3895	51	27	±1	±1	ADJ
dpc-3895	51	28	)	)	PUNCT
dpc-3895	51	29	,	,	PUNCT
dpc-3895	51	30	and	and	CCONJ
dpc-3895	51	31	week	week	NOUN
dpc-3895	51	32	104	104	NUM
dpc-3895	51	33	(	(	PUNCT
dpc-3895	51	34	±1	±1	PROPN
dpc-3895	51	35	)	)	PUNCT
dpc-3895	51	36	,	,	PUNCT
dpc-3895	51	37	week	week	NOUN
dpc-3895	51	38	156(±1	156(±1	NUM
dpc-3895	51	39	)	)	PUNCT
dpc-3895	51	40	,	,	PUNCT
dpc-3895	51	41	week	week	NOUN
dpc-3895	51	42	208	208	NUM
dpc-3895	51	43	(	(	PUNCT
dpc-3895	51	44	±1	±1	ADJ
dpc-3895	51	45	)	)	PUNCT
dpc-3895	51	46	of	of	ADP
dpc-3895	51	47	:	:	PUNCT
dpc-3895	51	48	a.	a.	NOUN
dpc-3895	51	49	absolute	absolute	PROPN
dpc-3895	51	50	pasi	pasi	NOUN
dpc-3895	51	51	;	;	PUNCT
dpc-3895	51	52	percentage	percentage	NOUN
dpc-3895	51	53	of	of	ADP
dpc-3895	51	54	patients	patient	NOUN
dpc-3895	51	55	who	who	PRON
dpc-3895	51	56	achieved	achieve	VERB
dpc-3895	51	57	pasi75	pasi75	NOUN
dpc-3895	51	58	,	,	PUNCT
dpc-3895	51	59	pasi90	pasi90	NOUN
dpc-3895	51	60	,	,	PUNCT
dpc-3895	51	61	pasi100	pasi100	PROPN
dpc-3895	51	62	response	response	NOUN
dpc-3895	51	63	rates	rate	NOUN
dpc-3895	51	64	,	,	PUNCT
dpc-3895	51	65	b.	b.	PROPN
dpc-3895	51	66	percentage	percentage	NOUN
dpc-3895	51	67	of	of	ADP
dpc-3895	51	68	patients	patient	NOUN
dpc-3895	51	69	achieving	achieve	VERB
dpc-3895	51	70	scalp	scalp	NOUN
dpc-3895	51	71	pga	pga	PROPN
dpc-3895	51	72	0/1	0/1	PROPN
dpc-3895	51	73	(	(	PUNCT
dpc-3895	51	74	spga	spga	NOUN
dpc-3895	51	75	)	)	PUNCT
dpc-3895	51	76	c.	c.	NOUN
dpc-3895	51	77	percentage	percentage	NOUN
dpc-3895	51	78	of	of	ADP
dpc-3895	51	79	patients	patient	NOUN
dpc-3895	51	80	achieving	achieve	VERB
dpc-3895	51	81	full	full	ADJ
dpc-3895	51	82	/	/	SYM
dpc-3895	51	83	almost	almost	ADV
dpc-3895	51	84	full	full	ADJ
dpc-3895	51	85	genitals	genital	NOUN
dpc-3895	51	86	clearing	clearing	NOUN
dpc-3895	51	87	;	;	PUNCT
dpc-3895	51	88	d.	d.	PROPN
dpc-3895	51	89	percentage	percentage	NOUN
dpc-3895	51	90	of	of	ADP
dpc-3895	51	91	patients	patient	NOUN
dpc-3895	51	92	achieving	achieve	VERB
dpc-3895	51	93	full	full	ADJ
dpc-3895	51	94	/	/	SYM
dpc-3895	51	95	almost	almost	ADV
dpc-3895	51	96	full	full	ADJ
dpc-3895	51	97	folds	fold	NOUN
dpc-3895	51	98	clearing	clearing	NOUN
dpc-3895	51	99	;	;	PUNCT
dpc-3895	51	100	e.	e.	PROPN
dpc-3895	51	101	incidence	incidence	NOUN
dpc-3895	51	102	of	of	ADP
dpc-3895	51	103	adverse	adverse	ADJ
dpc-3895	51	104	events	event	NOUN
dpc-3895	51	105	(	(	PUNCT
dpc-3895	51	106	ae	ae	PROPN
dpc-3895	51	107	)	)	PUNCT
dpc-3895	51	108	and	and	CCONJ
dpc-3895	51	109	serious	serious	ADJ
dpc-3895	51	110	adverse	adverse	ADJ
dpc-3895	51	111	events	event	NOUN
dpc-3895	51	112	(	(	PUNCT
dpc-3895	51	113	saes	sae	NOUN
dpc-3895	51	114	)	)	PUNCT
dpc-3895	51	115	and	and	CCONJ
dpc-3895	51	116	identification	identification	NOUN
dpc-3895	51	117	of	of	ADP
dpc-3895	51	118	ae	ae	PROPN
dpc-3895	51	119	leading	lead	VERB
dpc-3895	51	120	to	to	ADP
dpc-3895	51	121	drug	drug	NOUN
dpc-3895	51	122	discontinuation	discontinuation	NOUN
dpc-3895	51	123	;	;	PUNCT
dpc-3895	51	124	f.	f.	PROPN
dpc-3895	51	125	potential	potential	ADJ
dpc-3895	51	126	predictive	predictive	ADJ
dpc-3895	51	127	clinical	clinical	ADJ
dpc-3895	51	128	variables	variable	NOUN
dpc-3895	51	129	influencing	influence	VERB
dpc-3895	51	130	response	response	NOUN
dpc-3895	51	131	at	at	ADP
dpc-3895	51	132	week	week	NOUN
dpc-3895	51	133	52	52	NUM
dpc-3895	51	134	,	,	PUNCT
dpc-3895	51	135	and	and	CCONJ
dpc-3895	51	136	104	104	NUM
dpc-3895	51	137	.	.	PUNCT
dpc-3895	52	1	assessments	assessment	NOUN
dpc-3895	52	2	were	be	AUX
dpc-3895	52	3	collected	collect	VERB
dpc-3895	52	4	only	only	ADV
dpc-3895	52	5	when	when	SCONJ
dpc-3895	52	6	available	available	ADJ
dpc-3895	52	7	in	in	ADP
dpc-3895	52	8	routine	routine	ADJ
dpc-3895	52	9	clinical	clinical	ADJ
dpc-3895	52	10	practice	practice	NOUN
dpc-3895	52	11	,	,	PUNCT
dpc-3895	52	12	and	and	CCONJ
dpc-3895	52	13	they	they	PRON
dpc-3895	52	14	were	be	AUX
dpc-3895	52	15	not	not	PART
dpc-3895	52	16	prerequisites	prerequisite	NOUN
dpc-3895	52	17	for	for	ADP
dpc-3895	52	18	study	study	NOUN
dpc-3895	52	19	participation	participation	NOUN
dpc-3895	52	20	.	.	PUNCT
dpc-3895	53	1	statistical	statistical	ADJ
dpc-3895	53	2	analysis	analysis	NOUN
dpc-3895	53	3	frequencies	frequency	NOUN
dpc-3895	53	4	and	and	CCONJ
dpc-3895	53	5	percentages	percentage	NOUN
dpc-3895	53	6	are	be	AUX
dpc-3895	53	7	given	give	VERB
dpc-3895	53	8	for	for	ADP
dpc-3895	53	9	qualitative	qualitative	ADJ
dpc-3895	53	10	variables	variable	NOUN
dpc-3895	53	11	,	,	PUNCT
dpc-3895	53	12	while	while	SCONJ
dpc-3895	53	13	means	mean	NOUN
dpc-3895	53	14	and	and	CCONJ
dpc-3895	53	15	standard	standard	ADJ
dpc-3895	53	16	deviations	deviation	NOUN
dpc-3895	53	17	,	,	PUNCT
dpc-3895	53	18	as	as	ADV
dpc-3895	53	19	well	well	ADV
dpc-3895	53	20	as	as	ADP
dpc-3895	53	21	medians	median	NOUN
dpc-3895	53	22	and	and	CCONJ
dpc-3895	53	23	interquartile	interquartile	NOUN
dpc-3895	53	24	ranges	range	NOUN
dpc-3895	53	25	,	,	PUNCT
dpc-3895	53	26	are	be	AUX
dpc-3895	53	27	given	give	VERB
dpc-3895	53	28	for	for	ADP
dpc-3895	53	29	quantitative	quantitative	ADJ
dpc-3895	53	30	variables	variable	NOUN
dpc-3895	53	31	.	.	PUNCT
dpc-3895	54	1	since	since	SCONJ
dpc-3895	54	2	there	there	PRON
dpc-3895	54	3	were	be	VERB
dpc-3895	54	4	limited	limited	ADJ
dpc-3895	54	5	cases	case	NOUN
dpc-3895	54	6	of	of	ADP
dpc-3895	54	7	loss	loss	NOUN
dpc-3895	54	8	to	to	PART
dpc-3895	54	9	follow	follow	VERB
dpc-3895	54	10	-	-	PUNCT
dpc-3895	54	11	up	up	NOUN
dpc-3895	54	12	(	(	PUNCT
dpc-3895	54	13	<	<	X
dpc-3895	54	14	5	5	NUM
dpc-3895	54	15	%	%	NOUN
dpc-3895	54	16	of	of	ADP
dpc-3895	54	17	the	the	DET
dpc-3895	54	18	study	study	NOUN
dpc-3895	54	19	sample	sample	NOUN
dpc-3895	54	20	)	)	PUNCT
dpc-3895	54	21	,	,	PUNCT
dpc-3895	54	22	effectiveness	effectiveness	NOUN
dpc-3895	54	23	data	datum	NOUN
dpc-3895	54	24	were	be	AUX
dpc-3895	54	25	analyzed	analyze	VERB
dpc-3895	54	26	using	use	VERB
dpc-3895	54	27	an	an	DET
dpc-3895	54	28	‘	'	PUNCT
dpc-3895	54	29	as	as	ADP
dpc-3895	54	30	observed	observed	ADJ
dpc-3895	54	31	analysis	analysis	NOUN
dpc-3895	54	32	’	'	PUNCT
dpc-3895	54	33	.	.	PUNCT
dpc-3895	55	1	descriptive	descriptive	ADJ
dpc-3895	55	2	statistics	statistic	NOUN
dpc-3895	55	3	were	be	AUX
dpc-3895	55	4	performed	perform	VERB
dpc-3895	55	5	using	use	VERB
dpc-3895	55	6	relevant	relevant	ADJ
dpc-3895	55	7	descriptive	descriptive	ADJ
dpc-3895	55	8	statistics	statistic	NOUN
dpc-3895	55	9	tests	test	NOUN
dpc-3895	55	10	(	(	PUNCT
dpc-3895	55	11	for	for	ADP
dpc-3895	55	12	example	example	NOUN
dpc-3895	55	13	shapiro	shapiro	PROPN
dpc-3895	55	14	–	–	PUNCT
dpc-3895	55	15	wilk	wilk	PROPN
dpc-3895	55	16	/	/	SYM
dpc-3895	55	17	shapiro	shapiro	PROPN
dpc-3895	55	18	–	–	PUNCT
dpc-3895	55	19	francia	francia	PROPN
dpc-3895	55	20	test	test	NOUN
dpc-3895	55	21	)	)	PUNCT
dpc-3895	55	22	.	.	PUNCT
dpc-3895	56	1	for	for	ADP
dpc-3895	56	2	the	the	DET
dpc-3895	56	3	comparison	comparison	NOUN
dpc-3895	56	4	of	of	ADP
dpc-3895	56	5	categorical	categorical	ADJ
dpc-3895	56	6	variables	variable	NOUN
dpc-3895	56	7	,	,	PUNCT
dpc-3895	56	8	chi	chi	NOUN
dpc-3895	56	9	-	-	PUNCT
dpc-3895	56	10	squared	square	VERB
dpc-3895	56	11	and	and	CCONJ
dpc-3895	56	12	fisher	fisher	PROPN
dpc-3895	56	13	exact	exact	ADJ
dpc-3895	56	14	tests	test	NOUN
dpc-3895	56	15	were	be	AUX
dpc-3895	56	16	used	use	VERB
dpc-3895	56	17	,	,	PUNCT
dpc-3895	56	18	while	while	SCONJ
dpc-3895	56	19	,	,	PUNCT
dpc-3895	56	20	depending	depend	VERB
dpc-3895	56	21	on	on	ADP
dpc-3895	56	22	the	the	DET
dpc-3895	56	23	distribution	distribution	NOUN
dpc-3895	56	24	of	of	ADP
dpc-3895	56	25	continuous	continuous	ADJ
dpc-3895	56	26	variables	variable	NOUN
dpc-3895	56	27	,	,	PUNCT
dpc-3895	56	28	unpaired	unpaired	ADJ
dpc-3895	56	29	t	t	NOUN
dpc-3895	56	30	-	-	PUNCT
dpc-3895	56	31	test	test	NOUN
dpc-3895	56	32	and	and	CCONJ
dpc-3895	56	33	mann	mann	PROPN
dpc-3895	56	34	–	–	PUNCT
dpc-3895	56	35	whitney	whitney	PROPN
dpc-3895	56	36	u	u	NOUN
dpc-3895	56	37	-	-	NOUN
dpc-3895	56	38	test	test	NOUN
dpc-3895	56	39	were	be	AUX
dpc-3895	56	40	applied	apply	VERB
dpc-3895	56	41	.	.	PUNCT
dpc-3895	57	1	the	the	DET
dpc-3895	57	2	chi	chi	ADJ
dpc-3895	57	3	-	-	PUNCT
dpc-3895	57	4	square	square	ADJ
dpc-3895	57	5	test	test	NOUN
dpc-3895	57	6	was	be	AUX
dpc-3895	57	7	applied	apply	VERB
dpc-3895	57	8	to	to	PART
dpc-3895	57	9	analyze	analyze	VERB
dpc-3895	57	10	differences	difference	NOUN
dpc-3895	57	11	in	in	ADP
dpc-3895	57	12	pasi	pasi	NOUN
dpc-3895	57	13	scores	score	NOUN
dpc-3895	57	14	between	between	ADP
dpc-3895	57	15	subgroups	subgroup	NOUN
dpc-3895	57	16	of	of	ADP
dpc-3895	57	17	patients	patient	NOUN
dpc-3895	57	18	,	,	PUNCT
dpc-3895	57	19	such	such	ADJ
dpc-3895	57	20	as	as	ADP
dpc-3895	57	21	psa	psa	NOUN
dpc-3895	57	22	and	and	CCONJ
dpc-3895	57	23	bio	bio	ADJ
dpc-3895	57	24	-	-	ADJ
dpc-3895	57	25	naïve	naïve	ADJ
dpc-3895	57	26	patients	patient	NOUN
dpc-3895	57	27	.	.	PUNCT
dpc-3895	58	1	univariable	univariable	ADJ
dpc-3895	58	2	logistic	logistic	ADJ
dpc-3895	58	3	regression	regression	NOUN
dpc-3895	58	4	analysis	analysis	NOUN
dpc-3895	58	5	considering	consider	VERB
dpc-3895	58	6	all	all	DET
dpc-3895	58	7	variables	variable	NOUN
dpc-3895	58	8	collected	collect	VERB
dpc-3895	58	9	was	be	AUX
dpc-3895	58	10	also	also	ADV
dpc-3895	58	11	performed	perform	VERB
dpc-3895	58	12	in	in	ADP
dpc-3895	58	13	order	order	NOUN
dpc-3895	58	14	to	to	PART
dpc-3895	58	15	identify	identify	VERB
dpc-3895	58	16	potential	potential	ADJ
dpc-3895	58	17	links	link	NOUN
dpc-3895	58	18	and	and	CCONJ
dpc-3895	58	19	clinical	clinical	ADJ
dpc-3895	58	20	factors	factor	NOUN
dpc-3895	58	21	of	of	ADP
dpc-3895	58	22	interest	interest	NOUN
dpc-3895	58	23	associated	associate	VERB
dpc-3895	58	24	with	with	ADP
dpc-3895	58	25	the	the	DET
dpc-3895	58	26	efficacy	efficacy	NOUN
dpc-3895	58	27	as	as	ADP
dpc-3895	58	28	per	per	ADP
dpc-3895	58	29	other	other	ADJ
dpc-3895	58	30	similar	similar	ADJ
dpc-3895	58	31	rwe	rwe	PROPN
dpc-3895	58	32	studies	study	NOUN
dpc-3895	58	33	.	.	PUNCT
dpc-3895	59	1	multivariable	multivariable	ADJ
dpc-3895	59	2	analysis	analysis	NOUN
dpc-3895	59	3	could	could	AUX
dpc-3895	59	4	not	not	PART
dpc-3895	59	5	be	be	AUX
dpc-3895	59	6	performed	perform	VERB
dpc-3895	59	7	due	due	ADP
dpc-3895	59	8	to	to	ADP
dpc-3895	59	9	the	the	DET
dpc-3895	59	10	high	high	ADJ
dpc-3895	59	11	number	number	NOUN
dpc-3895	59	12	of	of	ADP
dpc-3895	59	13	independent	independent	ADJ
dpc-3895	59	14	variables	variable	NOUN
dpc-3895	59	15	,	,	PUNCT
dpc-3895	59	16	along	along	ADP
dpc-3895	59	17	with	with	ADP
dpc-3895	59	18	the	the	DET
dpc-3895	59	19	sample	sample	NOUN
dpc-3895	59	20	size	size	NOUN
dpc-3895	59	21	of	of	ADP
dpc-3895	59	22	present	present	ADJ
dpc-3895	59	23	study	study	NOUN
dpc-3895	59	24	.	.	PUNCT
dpc-3895	60	1	all	all	DET
dpc-3895	60	2	statistical	statistical	ADJ
dpc-3895	60	3	analyses	analysis	NOUN
dpc-3895	60	4	were	be	AUX
dpc-3895	60	5	done	do	VERB
dpc-3895	60	6	with	with	ADP
dpc-3895	60	7	ibm	ibm	PROPN
dpc-3895	60	8	spss	spss	PROPN
dpc-3895	60	9	27.0	27.0	NUM
dpc-3895	60	10	(	(	PUNCT
dpc-3895	60	11	ibm	ibm	PROPN
dpc-3895	60	12	)	)	PUNCT
dpc-3895	60	13	.	.	PUNCT
dpc-3895	60	14	  	  	SPACE
dpc-3895	61	1	alpha	alpha	ADJ
dpc-3895	61	2	level	level	NOUN
dpc-3895	61	3	of	of	ADP
dpc-3895	61	4	significance	significance	NOUN
dpc-3895	61	5	was	be	AUX
dpc-3895	61	6	set	set	VERB
dpc-3895	61	7	at	at	ADP
dpc-3895	61	8	0.05	0.05	NUM
dpc-3895	61	9	.	.	PUNCT
dpc-3895	62	1	results	result	VERB
dpc-3895	62	2	ninety	ninety	NUM
dpc-3895	62	3	-	-	PUNCT
dpc-3895	62	4	nine	nine	NUM
dpc-3895	62	5	patients	patient	NOUN
dpc-3895	62	6	were	be	AUX
dpc-3895	62	7	included	include	VERB
dpc-3895	62	8	in	in	ADP
dpc-3895	62	9	the	the	DET
dpc-3895	62	10	study	study	NOUN
dpc-3895	62	11	population	population	NOUN
dpc-3895	62	12	and	and	CCONJ
dpc-3895	62	13	their	their	PRON
dpc-3895	62	14	demographic	demographic	ADJ
dpc-3895	62	15	and	and	CCONJ
dpc-3895	62	16	baseline	baseline	ADJ
dpc-3895	62	17	characteristics	characteristic	NOUN
dpc-3895	62	18	are	be	AUX
dpc-3895	62	19	summarized	summarize	VERB
dpc-3895	62	20	in	in	ADP
dpc-3895	62	21	table	table	NOUN
dpc-3895	62	22	1	1	NUM
dpc-3895	62	23	.	.	PUNCT
dpc-3895	62	24	more	more	ADV
dpc-3895	62	25	precisely	precisely	ADV
dpc-3895	62	26	,	,	PUNCT
dpc-3895	62	27	74	74	NUM
dpc-3895	62	28	(	(	PUNCT
dpc-3895	62	29	74.75	74.75	NUM
dpc-3895	62	30	%	%	NOUN
dpc-3895	62	31	)	)	PUNCT
dpc-3895	62	32	patients	patient	NOUN
dpc-3895	62	33	had	have	VERB
dpc-3895	62	34	scalp	scalp	NOUN
dpc-3895	62	35	involvement	involvement	NOUN
dpc-3895	62	36	,	,	PUNCT
dpc-3895	62	37	genitals	genital	NOUN
dpc-3895	62	38	and	and	CCONJ
dpc-3895	62	39	skin	skin	NOUN
dpc-3895	62	40	folds	fold	NOUN
dpc-3895	62	41	were	be	AUX
dpc-3895	62	42	affected	affect	VERB
dpc-3895	62	43	in	in	ADP
dpc-3895	62	44	27	27	NUM
dpc-3895	62	45	(	(	PUNCT
dpc-3895	62	46	27.27	27.27	NUM
dpc-3895	62	47	%	%	NOUN
dpc-3895	62	48	)	)	PUNCT
dpc-3895	62	49	and	and	CCONJ
dpc-3895	62	50	17	17	NUM
dpc-3895	62	51	(	(	PUNCT
dpc-3895	62	52	17.17	17.17	NUM
dpc-3895	62	53	%	%	NOUN
dpc-3895	62	54	)	)	PUNCT
dpc-3895	62	55	respectively	respectively	ADV
dpc-3895	62	56	,	,	PUNCT
dpc-3895	62	57	and	and	CCONJ
dpc-3895	62	58	32	32	NUM
dpc-3895	62	59	(	(	PUNCT
dpc-3895	62	60	32.32	32.32	NUM
dpc-3895	62	61	%	%	NOUN
dpc-3895	62	62	)	)	PUNCT
dpc-3895	62	63	of	of	ADP
dpc-3895	62	64	the	the	DET
dpc-3895	62	65	studied	study	VERB
dpc-3895	62	66	population	population	NOUN
dpc-3895	62	67	had	have	VERB
dpc-3895	62	68	psoriatic	psoriatic	ADJ
dpc-3895	62	69	arthritis	arthritis	NOUN
dpc-3895	62	70	.	.	PUNCT
dpc-3895	63	1	sixty	sixty	NUM
dpc-3895	63	2	-	-	PUNCT
dpc-3895	63	3	six	six	NUM
dpc-3895	63	4	patients	patient	NOUN
dpc-3895	63	5	(	(	PUNCT
dpc-3895	63	6	66.67	66.67	NUM
dpc-3895	63	7	%	%	NOUN
dpc-3895	63	8	)	)	PUNCT
dpc-3895	63	9	were	be	AUX
dpc-3895	63	10	bio	bio	ADJ
dpc-3895	63	11	-	-	ADJ
dpc-3895	63	12	naive	naive	ADJ
dpc-3895	63	13	,	,	PUNCT
dpc-3895	63	14	whereas	whereas	SCONJ
dpc-3895	63	15	33	33	NUM
dpc-3895	63	16	patients	patient	NOUN
dpc-3895	63	17	had	have	AUX
dpc-3895	63	18	never	never	ADV
dpc-3895	63	19	received	receive	VERB
dpc-3895	63	20	systemic	systemic	ADJ
dpc-3895	63	21	treatment	treatment	NOUN
dpc-3895	63	22	.	.	PUNCT
dpc-3895	64	1	in	in	ADP
dpc-3895	64	2	the	the	DET
dpc-3895	64	3	bio	bio	ADJ
dpc-3895	64	4	-	-	PUNCT
dpc-3895	64	5	experienced	experienced	ADJ
dpc-3895	64	6	group	group	NOUN
dpc-3895	64	7	,	,	PUNCT
dpc-3895	64	8	12	12	NUM
dpc-3895	64	9	patients	patient	NOUN
dpc-3895	64	10	had	have	AUX
dpc-3895	64	11	received	receive	VERB
dpc-3895	64	12	one	one	NUM
dpc-3895	64	13	biologic	biologic	NOUN
dpc-3895	64	14	agent	agent	NOUN
dpc-3895	64	15	,	,	PUNCT
dpc-3895	64	16	12	12	NUM
dpc-3895	64	17	patients	patient	NOUN
dpc-3895	64	18	had	have	AUX
dpc-3895	64	19	received	receive	VERB
dpc-3895	64	20	two	two	NUM
dpc-3895	64	21	biologic	biologic	NOUN
dpc-3895	64	22	agents	agent	NOUN
dpc-3895	64	23	and	and	CCONJ
dpc-3895	64	24	5	5	NUM
dpc-3895	64	25	patients	patient	NOUN
dpc-3895	64	26	had	have	AUX
dpc-3895	64	27	experienced	experience	VERB
dpc-3895	64	28	treatment	treatment	NOUN
dpc-3895	64	29	failure	failure	NOUN
dpc-3895	64	30	of	of	ADP
dpc-3895	64	31	any	any	DET
dpc-3895	64	32	reason	reason	NOUN
dpc-3895	64	33	in	in	ADP
dpc-3895	64	34	3	3	NUM
dpc-3895	64	35	or	or	CCONJ
dpc-3895	64	36	more	more	ADJ
dpc-3895	64	37	biologic	biologic	ADJ
dpc-3895	64	38	agents	agent	NOUN
dpc-3895	64	39	.	.	PUNCT
dpc-3895	65	1	moreover	moreover	ADV
dpc-3895	65	2	out	out	ADP
dpc-3895	65	3	of	of	ADP
dpc-3895	65	4	all	all	DET
dpc-3895	65	5	the	the	DET
dpc-3895	65	6	studied	studied	ADJ
dpc-3895	65	7	population	population	NOUN
dpc-3895	65	8	17.17	17.17	NUM
dpc-3895	65	9	%	%	NOUN
dpc-3895	65	10	(	(	PUNCT
dpc-3895	65	11	17/99	17/99	NUM
dpc-3895	65	12	)	)	PUNCT
dpc-3895	65	13	,	,	PUNCT
dpc-3895	65	14	11.11	11.11	NUM
dpc-3895	65	15	%	%	NOUN
dpc-3895	65	16	(	(	PUNCT
dpc-3895	65	17	11/99	11/99	NUM
dpc-3895	65	18	)	)	PUNCT
dpc-3895	65	19	,	,	PUNCT
dpc-3895	65	20	12	12	NUM
dpc-3895	65	21	(	(	PUNCT
dpc-3895	65	22	12/99	12/99	NUM
dpc-3895	65	23	)	)	PUNCT
dpc-3895	65	24	,	,	PUNCT
dpc-3895	65	25	10.10	10.10	NUM
dpc-3895	65	26	%	%	NOUN
dpc-3895	65	27	(	(	PUNCT
dpc-3895	65	28	10/99	10/99	NUM
dpc-3895	65	29	)	)	PUNCT
dpc-3895	65	30	,	,	PUNCT
dpc-3895	65	31	2.02	2.02	NUM
dpc-3895	65	32	%	%	NOUN
dpc-3895	65	33	(	(	PUNCT
dpc-3895	65	34	2/99	2/99	NUM
dpc-3895	65	35	)	)	PUNCT
dpc-3895	65	36	had	have	AUX
dpc-3895	65	37	received	receive	VERB
dpc-3895	65	38	adalimumab	adalimumab	NOUN
dpc-3895	65	39	,	,	PUNCT
dpc-3895	65	40	etanercept	etanercept	NOUN
dpc-3895	65	41	,	,	PUNCT
dpc-3895	65	42	infliximab	infliximab	NOUN
dpc-3895	65	43	,	,	PUNCT
dpc-3895	65	44	ustekinumab	ustekinumab	NOUN
dpc-3895	65	45	and	and	CCONJ
dpc-3895	65	46	golimumab	golimumab	NOUN
dpc-3895	65	47	respectively	respectively	ADV
dpc-3895	65	48	.	.	PUNCT
dpc-3895	66	1	pde4	pde4	NOUN
dpc-3895	66	2	inhibitors	inhibitor	NOUN
dpc-3895	66	3	had	have	AUX
dpc-3895	66	4	been	be	AUX
dpc-3895	66	5	prescribed	prescribe	VERB
dpc-3895	66	6	in	in	ADP
dpc-3895	66	7	14.14	14.14	NUM
dpc-3895	66	8	%	%	NOUN
dpc-3895	66	9	(	(	PUNCT
dpc-3895	66	10	14/99	14/99	NUM
dpc-3895	66	11	)	)	PUNCT
dpc-3895	66	12	of	of	ADP
dpc-3895	66	13	them	they	PRON
dpc-3895	66	14	.	.	PUNCT
dpc-3895	67	1	mean	mean	VERB
dpc-3895	67	2	bmi	bmi	PROPN
dpc-3895	67	3	index	index	NOUN
dpc-3895	67	4	in	in	ADP
dpc-3895	67	5	our	our	PRON
dpc-3895	67	6	study	study	NOUN
dpc-3895	67	7	population	population	NOUN
dpc-3895	67	8	was	be	AUX
dpc-3895	67	9	29.3	29.3	NUM
dpc-3895	67	10	.	.	PUNCT
dpc-3895	68	1	regarding	regard	VERB
dpc-3895	68	2	comorbidities	comorbiditie	NOUN
dpc-3895	68	3	15	15	NUM
dpc-3895	68	4	patients	patient	NOUN
dpc-3895	68	5	(	(	PUNCT
dpc-3895	68	6	15.15	15.15	NUM
dpc-3895	68	7	%	%	NOUN
dpc-3895	68	8	)	)	PUNCT
dpc-3895	68	9	were	be	AUX
dpc-3895	68	10	obese	obese	ADJ
dpc-3895	68	11	(	(	PUNCT
dpc-3895	68	12	bmi>30	bmi>30	PROPN
dpc-3895	68	13	)	)	PUNCT
dpc-3895	68	14	,	,	PUNCT
dpc-3895	68	15	42	42	NUM
dpc-3895	68	16	patients	patient	NOUN
dpc-3895	68	17	(	(	PUNCT
dpc-3895	68	18	42.42	42.42	NUM
dpc-3895	68	19	%	%	NOUN
dpc-3895	68	20	)	)	PUNCT
dpc-3895	68	21	had	have	VERB
dpc-3895	68	22	hashimoto	hashimoto	NOUN
dpc-3895	68	23	disease	disease	NOUN
dpc-3895	68	24	,	,	PUNCT
dpc-3895	68	25	19	19	NUM
dpc-3895	68	26	patients	patient	NOUN
dpc-3895	68	27	(	(	PUNCT
dpc-3895	68	28	19.19	19.19	NUM
dpc-3895	68	29	%	%	NOUN
dpc-3895	68	30	)	)	PUNCT
dpc-3895	68	31	were	be	AUX
dpc-3895	68	32	diagnosed	diagnose	VERB
dpc-3895	68	33	with	with	ADP
dpc-3895	68	34	depression	depression	NOUN
dpc-3895	68	35	or	or	CCONJ
dpc-3895	68	36	anxiety	anxiety	NOUN
dpc-3895	68	37	disorder	disorder	NOUN
dpc-3895	68	38	and	and	CCONJ
dpc-3895	68	39	8	8	NUM
dpc-3895	68	40	patients	patient	NOUN
dpc-3895	68	41	(	(	PUNCT
dpc-3895	68	42	8.08	8.08	NUM
dpc-3895	68	43	%	%	NOUN
dpc-3895	68	44	)	)	PUNCT
dpc-3895	68	45	had	have	VERB
dpc-3895	68	46	diabetes	diabetes	NOUN
dpc-3895	68	47	mellitus	mellitus	NOUN
dpc-3895	68	48	.	.	PUNCT
dpc-3895	69	1	overall	overall	ADJ
dpc-3895	69	2	53	53	NUM
dpc-3895	69	3	patients	patient	NOUN
dpc-3895	69	4	(	(	PUNCT
dpc-3895	69	5	53.54	53.54	NUM
dpc-3895	69	6	%	%	NOUN
dpc-3895	69	7	)	)	PUNCT
dpc-3895	69	8	had	have	VERB
dpc-3895	69	9	no	no	DET
dpc-3895	69	10	comorbidities	comorbiditie	NOUN
dpc-3895	69	11	,	,	PUNCT
dpc-3895	69	12	4	4	NUM
dpc-3895	69	13	original	original	ADJ
dpc-3895	69	14	article	article	NOUN
dpc-3895	69	15	|	|	ADV
dpc-3895	69	16	dermatol	dermatol	ADJ
dpc-3895	69	17	pract	pract	NOUN
dpc-3895	69	18	concept	concept	NOUN
dpc-3895	69	19	.	.	PUNCT
dpc-3895	70	1	2024;14(2):e2024119	2024;14(2):e2024119	NUM
dpc-3895	70	2	efficacy	efficacy	NOUN
dpc-3895	70	3	of	of	ADP
dpc-3895	70	4	secukinumab	secukinumab	NOUN
dpc-3895	70	5	at	at	ADP
dpc-3895	70	6	week	week	NOUN
dpc-3895	70	7	16	16	NUM
dpc-3895	70	8	,	,	PUNCT
dpc-3895	70	9	pasi75	pasi75	NOUN
dpc-3895	70	10	was	be	AUX
dpc-3895	70	11	achieved	achieve	VERB
dpc-3895	70	12	by	by	ADP
dpc-3895	70	13	84/96	84/96	NUM
dpc-3895	70	14	(	(	PUNCT
dpc-3895	70	15	87.5	87.5	NUM
dpc-3895	70	16	%	%	NOUN
dpc-3895	70	17	)	)	PUNCT
dpc-3895	70	18	patients	patient	NOUN
dpc-3895	70	19	,	,	PUNCT
dpc-3895	70	20	pasi90	pasi90	NOUN
dpc-3895	70	21	by	by	ADP
dpc-3895	70	22	67/96	67/96	NUM
dpc-3895	70	23	(	(	PUNCT
dpc-3895	70	24	69.8	69.8	NUM
dpc-3895	70	25	%	%	NOUN
dpc-3895	70	26	)	)	PUNCT
dpc-3895	70	27	and	and	CCONJ
dpc-3895	70	28	pasi100	pasi100	PROPN
dpc-3895	70	29	by	by	ADP
dpc-3895	70	30	47/96	47/96	NUM
dpc-3895	70	31	(	(	PUNCT
dpc-3895	70	32	49	49	NUM
dpc-3895	70	33	%	%	NOUN
dpc-3895	70	34	)	)	PUNCT
dpc-3895	70	35	(	(	PUNCT
dpc-3895	70	36	table2	table2	NOUN
dpc-3895	70	37	)	)	PUNCT
dpc-3895	70	38	.	.	PUNCT
dpc-3895	71	1	by	by	ADP
dpc-3895	71	2	week	week	NOUN
dpc-3895	71	3	52	52	NUM
dpc-3895	71	4	pasi75/	pasi75/	NOUN
dpc-3895	71	5	pasi90	pasi90	NOUN
dpc-3895	71	6	/	/	SYM
dpc-3895	71	7	pasi100	pasi100	PROPN
dpc-3895	71	8	was	be	AUX
dpc-3895	71	9	achieved	achieve	VERB
dpc-3895	71	10	by	by	ADP
dpc-3895	71	11	86.4%/77.8%/43.2	86.4%/77.8%/43.2	NUM
dpc-3895	71	12	%	%	NOUN
dpc-3895	71	13	,	,	PUNCT
dpc-3895	71	14	by	by	ADP
dpc-3895	71	15	week	week	NOUN
dpc-3895	71	16	104	104	NUM
dpc-3895	71	17	pasi75	pasi75	NOUN
dpc-3895	71	18	/	/	SYM
dpc-3895	71	19	pasi90	pasi90	PROPN
dpc-3895	71	20	/	/	SYM
dpc-3895	72	1	pasi100	pasi100	PROPN
dpc-3895	72	2	was	be	AUX
dpc-3895	72	3	achieved	achieve	VERB
dpc-3895	72	4	by	by	ADP
dpc-3895	72	5	94.5%/78.2%/47.3	94.5%/78.2%/47.3	NUM
dpc-3895	72	6	%	%	NOUN
dpc-3895	72	7	and	and	CCONJ
dpc-3895	72	8	in	in	ADP
dpc-3895	72	9	9	9	NUM
dpc-3895	72	10	patients	patient	NOUN
dpc-3895	72	11	having	having	AUX
dpc-3895	72	12	completed	complete	VERB
dpc-3895	72	13	208	208	NUM
dpc-3895	72	14	weeks	week	NOUN
dpc-3895	72	15	of	of	ADP
dpc-3895	72	16	therapy	therapy	NOUN
dpc-3895	72	17	pasi100	pasi100	PROPN
dpc-3895	72	18	/	/	SYM
dpc-3895	72	19	pasi90	pasi90	NOUN
dpc-3895	72	20	was	be	AUX
dpc-3895	72	21	achieved	achieve	VERB
dpc-3895	72	22	in	in	ADP
dpc-3895	72	23	a	a	DET
dpc-3895	72	24	percentage	percentage	NOUN
dpc-3895	72	25	of	of	ADP
dpc-3895	72	26	88.9%/100	88.9%/100	NUM
dpc-3895	72	27	%	%	NOUN
dpc-3895	72	28	respectively	respectively	ADV
dpc-3895	72	29	(	(	PUNCT
dpc-3895	72	30	table	table	NOUN
dpc-3895	72	31	2	2	NUM
dpc-3895	72	32	)	)	PUNCT
dpc-3895	72	33	.	.	PUNCT
dpc-3895	73	1	aiming	aim	VERB
dpc-3895	73	2	to	to	PART
dpc-3895	73	3	identify	identify	VERB
dpc-3895	73	4	potential	potential	ADJ
dpc-3895	73	5	predictive	predictive	ADJ
dpc-3895	73	6	factors	factor	NOUN
dpc-3895	73	7	influencing	influence	VERB
dpc-3895	73	8	response	response	NOUN
dpc-3895	73	9	,	,	PUNCT
dpc-3895	73	10	univariable	univariable	ADJ
dpc-3895	73	11	analyses	analysis	NOUN
dpc-3895	73	12	were	be	AUX
dpc-3895	73	13	performed	perform	VERB
dpc-3895	73	14	at	at	ADP
dpc-3895	73	15	weeks	week	NOUN
dpc-3895	73	16	52	52	NUM
dpc-3895	73	17	and	and	CCONJ
dpc-3895	73	18	104	104	NUM
dpc-3895	73	19	taking	take	VERB
dpc-3895	73	20	into	into	ADP
dpc-3895	73	21	consideration	consideration	NOUN
dpc-3895	73	22	various	various	ADJ
dpc-3895	73	23	parameters	parameter	NOUN
dpc-3895	73	24	,	,	PUNCT
dpc-3895	73	25	namely	namely	ADV
dpc-3895	73	26	age	age	NOUN
dpc-3895	73	27	,	,	PUNCT
dpc-3895	73	28	height	height	NOUN
dpc-3895	73	29	,	,	PUNCT
dpc-3895	73	30	weight	weight	NOUN
dpc-3895	73	31	,	,	PUNCT
dpc-3895	73	32	bmi	bmi	PROPN
dpc-3895	73	33	,	,	PUNCT
dpc-3895	73	34	bsa	bsa	PROPN
dpc-3895	73	35	,	,	PUNCT
dpc-3895	73	36	disease	disease	NOUN
dpc-3895	73	37	/	/	SYM
dpc-3895	73	38	therapy	therapy	NOUN
dpc-3895	73	39	duration	duration	NOUN
dpc-3895	73	40	,	,	PUNCT
dpc-3895	73	41	previous	previous	ADJ
dpc-3895	73	42	treatments	treatment	NOUN
dpc-3895	73	43	(	(	PUNCT
dpc-3895	73	44	conventional/	conventional/	NUM
dpc-3895	73	45	biologic	biologic	NOUN
dpc-3895	73	46	)	)	PUNCT
dpc-3895	73	47	,	,	PUNCT
dpc-3895	73	48	special	special	ADJ
dpc-3895	73	49	manifestations	manifestation	NOUN
dpc-3895	73	50	of	of	ADP
dpc-3895	73	51	psoriasis	psoriasis	NOUN
dpc-3895	73	52	(	(	PUNCT
dpc-3895	73	53	scalp	scalp	NOUN
dpc-3895	73	54	,	,	PUNCT
dpc-3895	73	55	nails	nail	NOUN
dpc-3895	73	56	,	,	PUNCT
dpc-3895	73	57	genitals	genital	NOUN
dpc-3895	73	58	,	,	PUNCT
dpc-3895	73	59	folds	fold	NOUN
dpc-3895	73	60	)	)	PUNCT
dpc-3895	73	61	and	and	CCONJ
dpc-3895	73	62	comorbidities	comorbiditie	NOUN
dpc-3895	73	63	(	(	PUNCT
dpc-3895	73	64	psa	psa	NOUN
dpc-3895	73	65	,	,	PUNCT
dpc-3895	73	66	obesity	obesity	NOUN
dpc-3895	73	67	,	,	PUNCT
dpc-3895	73	68	coronary	coronary	ADJ
dpc-3895	73	69	disease	disease	NOUN
dpc-3895	73	70	,	,	PUNCT
dpc-3895	73	71	depression	depression	NOUN
dpc-3895	73	72	,	,	PUNCT
dpc-3895	73	73	5	5	NUM
dpc-3895	73	74	patients	patient	NOUN
dpc-3895	73	75	(	(	PUNCT
dpc-3895	73	76	5.05	5.05	NUM
dpc-3895	73	77	%	%	NOUN
dpc-3895	73	78	)	)	PUNCT
dpc-3895	73	79	had	have	VERB
dpc-3895	73	80	one	one	NUM
dpc-3895	73	81	comorbidity	comorbidity	NOUN
dpc-3895	73	82	,	,	PUNCT
dpc-3895	73	83	30	30	NUM
dpc-3895	73	84	patients	patient	NOUN
dpc-3895	73	85	(	(	PUNCT
dpc-3895	73	86	30.30	30.30	NUM
dpc-3895	73	87	%	%	NOUN
dpc-3895	73	88	)	)	PUNCT
dpc-3895	73	89	had	have	VERB
dpc-3895	73	90	two	two	NUM
dpc-3895	73	91	comorbidities	comorbiditie	NOUN
dpc-3895	73	92	and	and	CCONJ
dpc-3895	73	93	11	11	NUM
dpc-3895	73	94	(	(	PUNCT
dpc-3895	73	95	11.11	11.11	NUM
dpc-3895	73	96	%	%	NOUN
dpc-3895	73	97	)	)	PUNCT
dpc-3895	73	98	patients	patient	NOUN
dpc-3895	73	99	had	have	VERB
dpc-3895	73	100	3	3	NUM
dpc-3895	73	101	or	or	CCONJ
dpc-3895	73	102	more	more	ADJ
dpc-3895	73	103	comorbidities	comorbiditie	NOUN
dpc-3895	73	104	.	.	PUNCT
dpc-3895	74	1	17.17	17.17	NUM
dpc-3895	74	2	%	%	NOUN
dpc-3895	74	3	of	of	ADP
dpc-3895	74	4	the	the	DET
dpc-3895	74	5	patients	patient	NOUN
dpc-3895	74	6	were	be	AUX
dpc-3895	74	7	active	active	ADJ
dpc-3895	74	8	smokers	smoker	NOUN
dpc-3895	74	9	(	(	PUNCT
dpc-3895	74	10	>	>	X
dpc-3895	74	11	10	10	NUM
dpc-3895	74	12	cigarettes	cigarette	NOUN
dpc-3895	74	13	/	/	SYM
dpc-3895	74	14	day	day	NOUN
dpc-3895	74	15	)	)	PUNCT
dpc-3895	74	16	.	.	PUNCT
dpc-3895	75	1	all	all	DET
dpc-3895	75	2	patients	patient	NOUN
dpc-3895	75	3	started	start	VERB
dpc-3895	75	4	receiving	receive	VERB
dpc-3895	75	5	secukinumab	secukinumab	NOUN
dpc-3895	75	6	as	as	ADP
dpc-3895	75	7	monotherapy	monotherapy	NOUN
dpc-3895	75	8	together	together	ADV
dpc-3895	75	9	with	with	ADP
dpc-3895	75	10	topical	topical	ADJ
dpc-3895	75	11	steroids	steroid	NOUN
dpc-3895	75	12	and	and	CCONJ
dpc-3895	75	13	vitamin	vitamin	NOUN
dpc-3895	75	14	d	d	NOUN
dpc-3895	75	15	analogues	analogue	NOUN
dpc-3895	75	16	.	.	PUNCT
dpc-3895	76	1	topical	topical	ADJ
dpc-3895	76	2	treatment	treatment	NOUN
dpc-3895	76	3	was	be	AUX
dpc-3895	76	4	discontinued	discontinue	VERB
dpc-3895	76	5	by	by	ADP
dpc-3895	76	6	almost	almost	ADV
dpc-3895	76	7	all	all	PRON
dpc-3895	76	8	patients	patient	NOUN
dpc-3895	76	9	(	(	PUNCT
dpc-3895	76	10	92/99	92/99	NUM
dpc-3895	76	11	,	,	PUNCT
dpc-3895	76	12	93	93	NUM
dpc-3895	76	13	%	%	NOUN
dpc-3895	76	14	)	)	PUNCT
dpc-3895	76	15	by	by	ADP
dpc-3895	76	16	the	the	DET
dpc-3895	76	17	first	first	ADJ
dpc-3895	76	18	follow	follow	VERB
dpc-3895	76	19	up	up	ADP
dpc-3895	76	20	visit	visit	NOUN
dpc-3895	76	21	at	at	ADP
dpc-3895	76	22	week	week	NOUN
dpc-3895	76	23	4	4	NUM
dpc-3895	76	24	.	.	PUNCT
dpc-3895	77	1	cyclosporine	cyclosporine	PROPN
dpc-3895	77	2	was	be	AUX
dpc-3895	77	3	added	add	VERB
dpc-3895	77	4	as	as	ADP
dpc-3895	77	5	additional	additional	ADJ
dpc-3895	77	6	therapy	therapy	NOUN
dpc-3895	77	7	for	for	ADP
dpc-3895	77	8	two	two	NUM
dpc-3895	77	9	patients	patient	NOUN
dpc-3895	77	10	,	,	PUNCT
dpc-3895	77	11	for	for	ADP
dpc-3895	77	12	12	12	NUM
dpc-3895	77	13	weeks	week	NOUN
dpc-3895	77	14	(	(	PUNCT
dpc-3895	77	15	week	week	NOUN
dpc-3895	77	16	4	4	NUM
dpc-3895	77	17	-	-	PUNCT
dpc-3895	77	18	week	week	NOUN
dpc-3895	77	19	16	16	NUM
dpc-3895	77	20	)	)	PUNCT
dpc-3895	77	21	and	and	CCONJ
dpc-3895	77	22	for	for	ADP
dpc-3895	77	23	24	24	NUM
dpc-3895	77	24	weeks	week	NOUN
dpc-3895	77	25	(	(	PUNCT
dpc-3895	77	26	week	week	NOUN
dpc-3895	77	27	60	60	NUM
dpc-3895	77	28	-	-	PUNCT
dpc-3895	77	29	week	week	NOUN
dpc-3895	77	30	84	84	NUM
dpc-3895	77	31	)	)	PUNCT
dpc-3895	77	32	respectively	respectively	ADV
dpc-3895	77	33	.	.	PUNCT
dpc-3895	78	1	four	four	NUM
dpc-3895	78	2	patients	patient	NOUN
dpc-3895	78	3	received	receive	VERB
dpc-3895	78	4	methotrexate	methotrexate	NOUN
dpc-3895	78	5	additionally	additionally	ADV
dpc-3895	78	6	,	,	PUNCT
dpc-3895	78	7	two	two	NUM
dpc-3895	78	8	at	at	ADP
dpc-3895	78	9	week	week	NOUN
dpc-3895	78	10	8	8	NUM
dpc-3895	78	11	,	,	PUNCT
dpc-3895	78	12	one	one	NUM
dpc-3895	78	13	at	at	ADP
dpc-3895	78	14	week	week	NOUN
dpc-3895	78	15	84	84	NUM
dpc-3895	78	16	and	and	CCONJ
dpc-3895	78	17	one	one	NUM
dpc-3895	78	18	at	at	ADP
dpc-3895	78	19	week	week	NOUN
dpc-3895	78	20	116	116	NUM
dpc-3895	78	21	 	 	SPACE
dpc-3895	78	22	respectively	respectively	ADV
dpc-3895	78	23	.	.	PUNCT
dpc-3895	79	1	baseline	baseline	PROPN
dpc-3895	79	2	mean	mean	PROPN
dpc-3895	79	3	pasi	pasi	PROPN
dpc-3895	79	4	,	,	PUNCT
dpc-3895	79	5	bsa	bsa	PROPN
dpc-3895	79	6	,	,	PUNCT
dpc-3895	79	7	spga	spga	NOUN
dpc-3895	79	8	and	and	CCONJ
dpc-3895	79	9	dlqi	dlqi	ADJ
dpc-3895	79	10	scores	score	NOUN
dpc-3895	79	11	are	be	AUX
dpc-3895	79	12	12.7	12.7	NUM
dpc-3895	79	13	,	,	PUNCT
dpc-3895	79	14	27.14	27.14	NUM
dpc-3895	79	15	,	,	PUNCT
dpc-3895	79	16	2.2	2.2	NUM
dpc-3895	79	17	and	and	CCONJ
dpc-3895	79	18	11.68	11.68	NUM
dpc-3895	79	19	respectively	respectively	ADV
dpc-3895	79	20	.	.	PUNCT
dpc-3895	80	1	addressing	address	VERB
dpc-3895	80	2	the	the	DET
dpc-3895	80	3	table	table	NOUN
dpc-3895	80	4	1	1	NUM
dpc-3895	80	5	.	.	PUNCT
dpc-3895	80	6	epidemiological	epidemiological	ADJ
dpc-3895	80	7	and	and	CCONJ
dpc-3895	80	8	clinical	clinical	ADJ
dpc-3895	80	9	characteristics	characteristic	NOUN
dpc-3895	80	10	at	at	ADP
dpc-3895	80	11	baseline	baseline	PROPN
dpc-3895	80	12	(	(	PUNCT
dpc-3895	80	13	n	n	NOUN
dpc-3895	80	14	=	=	SYM
dpc-3895	80	15	99	99	NUM
dpc-3895	80	16	)	)	PUNCT
dpc-3895	80	17	.	.	PUNCT
dpc-3895	81	1	characteristics	characteristic	NOUN
dpc-3895	81	2	n	n	CCONJ
dpc-3895	81	3	n	n	PRON
dpc-3895	81	4	%	%	NOUN
dpc-3895	81	5	age	age	NOUN
dpc-3895	81	6	(	(	PUNCT
dpc-3895	81	7	yr	yr	NOUN
dpc-3895	81	8	,	,	PUNCT
dpc-3895	81	9	median	median	ADJ
dpc-3895	81	10	,	,	PUNCT
dpc-3895	81	11	range	range	NOUN
dpc-3895	81	12	)	)	PUNCT
dpc-3895	81	13	99	99	NUM
dpc-3895	81	14	50	50	NUM
dpc-3895	81	15	(	(	PUNCT
dpc-3895	81	16	23	23	NUM
dpc-3895	81	17	-	-	SYM
dpc-3895	81	18	76	76	NUM
dpc-3895	81	19	)	)	PUNCT
dpc-3895	81	20	sex	sex	NOUN
dpc-3895	81	21	male	male	NOUN
dpc-3895	81	22	99	99	NUM
dpc-3895	81	23	53	53	NUM
dpc-3895	81	24	53.5	53.5	NUM
dpc-3895	81	25	weight	weight	NOUN
dpc-3895	81	26	(	(	PUNCT
dpc-3895	81	27	kg	kg	X
dpc-3895	81	28	,	,	PUNCT
dpc-3895	81	29	mean	mean	VERB
dpc-3895	82	1	[	[	X
dpc-3895	82	2	sd	sd	X
dpc-3895	82	3	]	]	X
dpc-3895	82	4	)	)	PUNCT
dpc-3895	82	5	99	99	NUM
dpc-3895	83	1	87.78	87.78	NUM
dpc-3895	83	2	[	[	X
dpc-3895	83	3	17.98	17.98	NUM
dpc-3895	83	4	]	]	X
dpc-3895	83	5	bmi	bmi	NOUN
dpc-3895	83	6	(	(	PUNCT
dpc-3895	83	7	mean	mean	VERB
dpc-3895	83	8	,	,	PUNCT
dpc-3895	84	1	[	[	X
dpc-3895	84	2	sd	sd	X
dpc-3895	84	3	]	]	PUNCT
dpc-3895	84	4	)	)	PUNCT
dpc-3895	84	5	99	99	NUM
dpc-3895	85	1	29.3	29.3	NUM
dpc-3895	85	2	[	[	SYM
dpc-3895	85	3	4.88	4.88	NUM
dpc-3895	85	4	]	]	PUNCT
dpc-3895	85	5	bsa	bsa	NOUN
dpc-3895	85	6	(	(	PUNCT
dpc-3895	85	7	mean	mean	VERB
dpc-3895	85	8	[	[	X
dpc-3895	85	9	sd	sd	X
dpc-3895	85	10	]	]	X
dpc-3895	85	11	)	)	PUNCT
dpc-3895	85	12	99	99	NUM
dpc-3895	85	13	27.14	27.14	NUM
dpc-3895	85	14	[	[	X
dpc-3895	85	15	12.01	12.01	NUM
dpc-3895	85	16	]	]	PUNCT
dpc-3895	85	17	pasi	pasi	X
dpc-3895	85	18	baseline	baseline	PROPN
dpc-3895	85	19	(	(	PUNCT
dpc-3895	85	20	mean	mean	VERB
dpc-3895	85	21	[	[	X
dpc-3895	85	22	sd	sd	X
dpc-3895	85	23	]	]	X
dpc-3895	85	24	)	)	PUNCT
dpc-3895	85	25	99	99	NUM
dpc-3895	85	26	12.7	12.7	NUM
dpc-3895	86	1	[	[	X
dpc-3895	86	2	3.94	3.94	NUM
dpc-3895	86	3	]	]	PUNCT
dpc-3895	86	4	dlqi	dlqi	PROPN
dpc-3895	86	5	baseline	baseline	PROPN
dpc-3895	86	6	(	(	PUNCT
dpc-3895	86	7	mean	mean	VERB
dpc-3895	86	8	[	[	X
dpc-3895	86	9	sd	sd	X
dpc-3895	86	10	]	]	X
dpc-3895	86	11	)	)	PUNCT
dpc-3895	86	12	99	99	NUM
dpc-3895	86	13	11.68	11.68	NUM
dpc-3895	87	1	[	[	X
dpc-3895	87	2	2.95	2.95	NUM
dpc-3895	87	3	]	]	PUNCT
dpc-3895	87	4	psoriatic	psoriatic	ADJ
dpc-3895	87	5	arthritis	arthritis	NOUN
dpc-3895	87	6	(	(	PUNCT
dpc-3895	87	7	n	n	CCONJ
dpc-3895	87	8	,	,	PUNCT
dpc-3895	87	9	%	%	INTJ
dpc-3895	87	10	)	)	PUNCT
dpc-3895	87	11	99	99	NUM
dpc-3895	87	12	32	32	NUM
dpc-3895	87	13	32.32	32.32	NUM
dpc-3895	87	14	previous	previous	ADJ
dpc-3895	87	15	systemic	systemic	ADJ
dpc-3895	87	16	treatment	treatment	NOUN
dpc-3895	87	17	99	99	NUM
dpc-3895	87	18	66	66	NUM
dpc-3895	87	19	66.67	66.67	NUM
dpc-3895	87	20	conventional	conventional	ADJ
dpc-3895	87	21	treatment	treatment	NOUN
dpc-3895	87	22	61/99	61/99	NUM
dpc-3895	87	23	61	61	NUM
dpc-3895	87	24	61.61	61.61	NUM
dpc-3895	87	25	previous	previous	ADJ
dpc-3895	87	26	biological	biological	ADJ
dpc-3895	87	27	therapy	therapy	NOUN
dpc-3895	87	28	33	33	NUM
dpc-3895	87	29	biologic	biologic	NOUN
dpc-3895	87	30	naive	naive	ADJ
dpc-3895	87	31	99	99	NUM
dpc-3895	87	32	66	66	NUM
dpc-3895	87	33	66.67	66.67	NUM
dpc-3895	87	34	psoriasis	psoriasis	NOUN
dpc-3895	87	35	genital	genital	ADJ
dpc-3895	87	36	involvement	involvement	NOUN
dpc-3895	87	37	99	99	NUM
dpc-3895	87	38	27	27	NUM
dpc-3895	87	39	27.27	27.27	NUM
dpc-3895	87	40	psoriasis	psoriasis	NOUN
dpc-3895	87	41	scalp	scalp	NOUN
dpc-3895	87	42	99	99	NUM
dpc-3895	87	43	74	74	NUM
dpc-3895	87	44	74.74	74.74	NUM
dpc-3895	87	45	psoriasis	psoriasis	NOUN
dpc-3895	87	46	involving	involve	VERB
dpc-3895	87	47	folds	fold	NOUN
dpc-3895	87	48	99	99	NUM
dpc-3895	87	49	17	17	NUM
dpc-3895	87	50	17.17	17.17	NUM
dpc-3895	87	51	psoriasis	psoriasis	NOUN
dpc-3895	87	52	nails	nail	VERB
dpc-3895	87	53	99	99	NUM
dpc-3895	87	54	49	49	NUM
dpc-3895	87	55	49.49	49.49	NUM
dpc-3895	87	56	comorbidity	comorbidity	NOUN
dpc-3895	87	57	n	n	CCONJ
dpc-3895	87	58	n	n	NUM
dpc-3895	87	59	%	%	NOUN
dpc-3895	87	60	hashimoto	hashimoto	NOUN
dpc-3895	87	61	disease	disease	NOUN
dpc-3895	87	62	99	99	NUM
dpc-3895	87	63	42	42	NUM
dpc-3895	87	64	42.42	42.42	NUM
dpc-3895	87	65	obesity	obesity	NOUN
dpc-3895	87	66	(	(	PUNCT
dpc-3895	87	67	bmi>30	bmi>30	PROPN
dpc-3895	87	68	)	)	PUNCT
dpc-3895	87	69	99	99	NUM
dpc-3895	87	70	15	15	NUM
dpc-3895	87	71	15.15	15.15	NUM
dpc-3895	87	72	depression	depression	NOUN
dpc-3895	87	73	99	99	NUM
dpc-3895	87	74	12	12	NUM
dpc-3895	87	75	12.12	12.12	NUM
dpc-3895	87	76	diabetes	diabetes	NOUN
dpc-3895	87	77	mellitus	mellitus	NOUN
dpc-3895	87	78	99	99	NUM
dpc-3895	87	79	8	8	NUM
dpc-3895	87	80	8.08	8.08	NUM
dpc-3895	87	81	anxiety	anxiety	NOUN
dpc-3895	87	82	disorder	disorder	NOUN
dpc-3895	87	83	99	99	NUM
dpc-3895	87	84	7	7	NUM
dpc-3895	87	85	7.07	7.07	NUM
dpc-3895	87	86	hypertension	hypertension	NOUN
dpc-3895	87	87	99	99	NUM
dpc-3895	87	88	6	6	NUM
dpc-3895	87	89	6.06	6.06	NUM
dpc-3895	87	90	coronary	coronary	ADJ
dpc-3895	87	91	disease	disease	NOUN
dpc-3895	87	92	99	99	NUM
dpc-3895	87	93	3	3	NUM
dpc-3895	87	94	3.03	3.03	NUM
dpc-3895	87	95	dyslipidemia	dyslipidemia	NOUN
dpc-3895	87	96	99	99	NUM
dpc-3895	87	97	3	3	NUM
dpc-3895	87	98	3.03	3.03	NUM
dpc-3895	87	99	smoking	smoking	NOUN
dpc-3895	87	100	99	99	NUM
dpc-3895	87	101	17	17	NUM
dpc-3895	87	102	17.17	17.17	NUM
dpc-3895	87	103	patients	patient	NOUN
dpc-3895	87	104	comorbidities	comorbiditie	VERB
dpc-3895	87	105	none	none	NOUN
dpc-3895	87	106	99	99	NUM
dpc-3895	88	1	53	53	NUM
dpc-3895	88	2	53.53	53.53	NUM
dpc-3895	88	3	1	1	NUM
dpc-3895	88	4	-	-	SYM
dpc-3895	88	5	2	2	NUM
dpc-3895	88	6	99	99	NUM
dpc-3895	88	7	35	35	NUM
dpc-3895	88	8	35.05	35.05	NUM
dpc-3895	88	9	>	>	SYM
dpc-3895	88	10	3	3	NUM
dpc-3895	88	11	99	99	NUM
dpc-3895	88	12	11	11	NUM
dpc-3895	88	13	11.11	11.11	NUM
dpc-3895	88	14	bmi	bmi	NOUN
dpc-3895	88	15	=	=	SYM
dpc-3895	88	16	body	body	NOUN
dpc-3895	88	17	mass	mass	PROPN
dpc-3895	88	18	index	index	NOUN
dpc-3895	88	19	;	;	PUNCT
dpc-3895	88	20	bsa	bsa	PROPN
dpc-3895	88	21	=	=	PROPN
dpc-3895	88	22	body	body	PROPN
dpc-3895	88	23	surface	surface	NOUN
dpc-3895	88	24	area	area	NOUN
dpc-3895	88	25	;	;	PUNCT
dpc-3895	88	26	dlqi	dlqi	ADJ
dpc-3895	88	27	=	=	PUNCT
dpc-3895	88	28	dermatology	dermatology	NOUN
dpc-3895	88	29	quality	quality	NOUN
dpc-3895	88	30	of	of	ADP
dpc-3895	88	31	life	life	NOUN
dpc-3895	88	32	index	index	NOUN
dpc-3895	88	33	;	;	PUNCT
dpc-3895	88	34	sd	sd	NOUN
dpc-3895	88	35	=	=	SYM
dpc-3895	88	36	standard	standard	ADJ
dpc-3895	88	37	deviation	deviation	NOUN
dpc-3895	88	38	.	.	PUNCT
dpc-3895	89	1	original	original	ADJ
dpc-3895	89	2	article	article	NOUN
dpc-3895	89	3	|	|	ADV
dpc-3895	89	4	dermatol	dermatol	ADJ
dpc-3895	89	5	pract	pract	NOUN
dpc-3895	89	6	concept	concept	NOUN
dpc-3895	89	7	.	.	PUNCT
dpc-3895	90	1	2024;14(2):e2024119	2024;14(2):e2024119	NUM
dpc-3895	90	2	5	5	NUM
dpc-3895	90	3	16	16	NUM
dpc-3895	90	4	due	due	ADP
dpc-3895	90	5	to	to	ADP
dpc-3895	90	6	lack	lack	NOUN
dpc-3895	90	7	of	of	ADP
dpc-3895	90	8	efficacy	efficacy	NOUN
dpc-3895	90	9	.	.	PUNCT
dpc-3895	91	1	lastly	lastly	ADV
dpc-3895	91	2	,	,	PUNCT
dpc-3895	91	3	one	one	NUM
dpc-3895	91	4	patient	patient	NOUN
dpc-3895	91	5	was	be	AUX
dpc-3895	91	6	diagnosed	diagnose	VERB
dpc-3895	91	7	with	with	ADP
dpc-3895	91	8	ulcerative	ulcerative	ADJ
dpc-3895	91	9	colitis	colitis	NOUN
dpc-3895	91	10	at	at	ADP
dpc-3895	91	11	week	week	NOUN
dpc-3895	91	12	108	108	NUM
dpc-3895	91	13	and	and	CCONJ
dpc-3895	91	14	the	the	DET
dpc-3895	91	15	treatment	treatment	NOUN
dpc-3895	91	16	was	be	AUX
dpc-3895	91	17	discontinued	discontinue	VERB
dpc-3895	91	18	.	.	PUNCT
dpc-3895	92	1	up	up	ADV
dpc-3895	92	2	until	until	ADP
dpc-3895	92	3	the	the	DET
dpc-3895	92	4	208	208	NUM
dpc-3895	92	5	weeks	week	NOUN
dpc-3895	92	6	of	of	ADP
dpc-3895	92	7	the	the	DET
dpc-3895	92	8	observation	observation	NOUN
dpc-3895	92	9	period	period	NOUN
dpc-3895	92	10	no	no	DET
dpc-3895	92	11	major	major	ADJ
dpc-3895	92	12	adverse	adverse	ADJ
dpc-3895	92	13	events	event	NOUN
dpc-3895	92	14	were	be	AUX
dpc-3895	92	15	recorded	record	VERB
dpc-3895	92	16	.	.	PUNCT
dpc-3895	93	1	during	during	ADP
dpc-3895	93	2	the	the	DET
dpc-3895	93	3	observation	observation	NOUN
dpc-3895	93	4	period	period	NOUN
dpc-3895	93	5	after	after	ADP
dpc-3895	93	6	week	week	NOUN
dpc-3895	93	7	16	16	NUM
dpc-3895	93	8	and	and	CCONJ
dpc-3895	93	9	up	up	ADV
dpc-3895	93	10	until	until	ADP
dpc-3895	93	11	week	week	NOUN
dpc-3895	93	12	208	208	NUM
dpc-3895	93	13	,	,	PUNCT
dpc-3895	93	14	11	11	NUM
dpc-3895	93	15	patients	patient	NOUN
dpc-3895	93	16	discontinued	discontinue	VERB
dpc-3895	93	17	the	the	DET
dpc-3895	93	18	treatment	treatment	NOUN
dpc-3895	93	19	due	due	ADP
dpc-3895	93	20	to	to	ADP
dpc-3895	93	21	lack	lack	NOUN
dpc-3895	93	22	of	of	ADP
dpc-3895	93	23	efficacy	efficacy	NOUN
dpc-3895	93	24	and	and	CCONJ
dpc-3895	93	25	this	this	PRON
dpc-3895	93	26	was	be	AUX
dpc-3895	93	27	observed	observe	VERB
dpc-3895	93	28	mainly	mainly	ADV
dpc-3895	93	29	after	after	ADP
dpc-3895	93	30	104	104	NUM
dpc-3895	93	31	weeks	week	NOUN
dpc-3895	93	32	of	of	ADP
dpc-3895	93	33	therapy	therapy	NOUN
dpc-3895	93	34	,	,	PUNCT
dpc-3895	93	35	in	in	ADP
dpc-3895	93	36	bio	bio	ADJ
dpc-3895	93	37	-	-	ADJ
dpc-3895	93	38	experienced	experienced	ADJ
dpc-3895	93	39	patients	patient	NOUN
dpc-3895	93	40	and	and	CCONJ
dpc-3895	93	41	patients	patient	NOUN
dpc-3895	93	42	with	with	ADP
dpc-3895	93	43	multiple	multiple	ADJ
dpc-3895	93	44	comorbidities	comorbiditie	NOUN
dpc-3895	93	45	(	(	PUNCT
dpc-3895	93	46	table	table	NOUN
dpc-3895	93	47	3	3	NUM
dpc-3895	93	48	)	)	PUNCT
dpc-3895	93	49	.	.	PUNCT
dpc-3895	94	1	in	in	ADP
dpc-3895	94	2	three	three	NUM
dpc-3895	94	3	patients	patient	NOUN
dpc-3895	94	4	a	a	DET
dpc-3895	94	5	quantiferon	quantiferon	PROPN
dpc-3895	94	6	tuberculosis	tuberculosis	NOUN
dpc-3895	94	7	conversion	conversion	NOUN
dpc-3895	94	8	was	be	AUX
dpc-3895	94	9	recorded	record	VERB
dpc-3895	94	10	,	,	PUNCT
dpc-3895	94	11	but	but	CCONJ
dpc-3895	94	12	a	a	DET
dpc-3895	94	13	systematic	systematic	ADJ
dpc-3895	94	14	infection	infection	NOUN
dpc-3895	94	15	was	be	AUX
dpc-3895	94	16	not	not	PART
dpc-3895	94	17	confirmed	confirm	VERB
dpc-3895	94	18	.	.	PUNCT
dpc-3895	95	1	for	for	ADP
dpc-3895	95	2	safety	safety	NOUN
dpc-3895	95	3	reasons	reason	NOUN
dpc-3895	95	4	those	those	DET
dpc-3895	95	5	patients	patient	NOUN
dpc-3895	95	6	underwent	undergo	VERB
dpc-3895	95	7	prophylactic	prophylactic	ADJ
dpc-3895	95	8	antibiotic	antibiotic	ADJ
dpc-3895	95	9	therapy	therapy	NOUN
dpc-3895	95	10	.	.	PUNCT
dpc-3895	96	1	conclusions	conclusion	NOUN
dpc-3895	96	2	our	our	PRON
dpc-3895	96	3	study	study	NOUN
dpc-3895	96	4	provides	provide	VERB
dpc-3895	96	5	retrospective	retrospective	ADJ
dpc-3895	96	6	data	datum	NOUN
dpc-3895	96	7	of	of	ADP
dpc-3895	96	8	patients	patient	NOUN
dpc-3895	96	9	with	with	ADP
dpc-3895	96	10	chronic	chronic	ADJ
dpc-3895	96	11	plaque	plaque	NOUN
dpc-3895	96	12	psoriasis	psoriasis	NOUN
dpc-3895	96	13	and	and	CCONJ
dpc-3895	96	14	their	their	PRON
dpc-3895	96	15	treatment	treatment	NOUN
dpc-3895	96	16	outcomes	outcome	NOUN
dpc-3895	96	17	after	after	ADP
dpc-3895	96	18	receiving	receive	VERB
dpc-3895	96	19	secukinumab	secukinumab	NOUN
dpc-3895	96	20	in	in	ADP
dpc-3895	96	21	real	real	ADJ
dpc-3895	96	22	-	-	PUNCT
dpc-3895	96	23	life	life	NOUN
dpc-3895	96	24	clinical	clinical	ADJ
dpc-3895	96	25	practice	practice	NOUN
dpc-3895	96	26	in	in	ADP
dpc-3895	96	27	greece	greece	PROPN
dpc-3895	96	28	.	.	PUNCT
dpc-3895	97	1	additionally	additionally	ADV
dpc-3895	97	2	,	,	PUNCT
dpc-3895	97	3	we	we	PRON
dpc-3895	97	4	focused	focus	VERB
dpc-3895	97	5	on	on	ADP
dpc-3895	97	6	difficult	difficult	ADJ
dpc-3895	97	7	-	-	PUNCT
dpc-3895	97	8	to	to	ADP
dpc-3895	97	9	-	-	PUNCT
dpc-3895	97	10	treat	treat	NOUN
dpc-3895	97	11	areas	area	NOUN
dpc-3895	97	12	,	,	PUNCT
dpc-3895	97	13	namely	namely	ADV
dpc-3895	97	14	psoriasis	psoriasis	NOUN
dpc-3895	97	15	affecting	affect	VERB
dpc-3895	97	16	the	the	DET
dpc-3895	97	17	skin	skin	NOUN
dpc-3895	97	18	folds	fold	NOUN
dpc-3895	97	19	and	and	CCONJ
dpc-3895	97	20	the	the	DET
dpc-3895	97	21	genital	genital	ADJ
dpc-3895	97	22	area	area	NOUN
dpc-3895	97	23	,	,	PUNCT
dpc-3895	97	24	mainly	mainly	ADV
dpc-3895	97	25	because	because	SCONJ
dpc-3895	97	26	data	datum	NOUN
dpc-3895	97	27	of	of	ADP
dpc-3895	97	28	the	the	DET
dpc-3895	97	29	effect	effect	NOUN
dpc-3895	97	30	of	of	ADP
dpc-3895	97	31	secukinumab	secukinumab	NOUN
dpc-3895	97	32	on	on	ADP
dpc-3895	97	33	these	these	DET
dpc-3895	97	34	manifestations	manifestation	NOUN
dpc-3895	97	35	are	be	AUX
dpc-3895	97	36	limited	limited	ADJ
dpc-3895	97	37	.	.	PUNCT
dpc-3895	98	1	the	the	DET
dpc-3895	98	2	studied	studied	ADJ
dpc-3895	98	3	population	population	NOUN
dpc-3895	98	4	that	that	PRON
dpc-3895	98	5	was	be	AUX
dpc-3895	98	6	selected	select	VERB
dpc-3895	98	7	were	be	AUX
dpc-3895	98	8	patients	patient	NOUN
dpc-3895	98	9	with	with	ADP
dpc-3895	98	10	moderate	moderate	ADJ
dpc-3895	98	11	to	to	ADP
dpc-3895	98	12	severe	severe	ADJ
dpc-3895	98	13	chronic	chronic	ADJ
dpc-3895	98	14	plaque	plaque	NOUN
dpc-3895	98	15	psoriasis	psoriasis	NOUN
dpc-3895	98	16	that	that	PRON
dpc-3895	98	17	were	be	AUX
dpc-3895	98	18	treated	treat	VERB
dpc-3895	98	19	with	with	ADP
dpc-3895	98	20	secukinumab	secukinumab	NOUN
dpc-3895	98	21	at	at	ADP
dpc-3895	98	22	the	the	DET
dpc-3895	98	23	recommended	recommend	VERB
dpc-3895	98	24	dose	dose	PROPN
dpc-3895	98	25	.	.	PUNCT
dpc-3895	98	26	bio	bio	PROPN
dpc-3895	98	27	-	-	PROPN
dpc-3895	98	28	naïve	naïve	ADJ
dpc-3895	98	29	,	,	PUNCT
dpc-3895	98	30	as	as	ADV
dpc-3895	98	31	well	well	ADV
dpc-3895	98	32	as	as	ADP
dpc-3895	98	33	bio	bio	ADJ
dpc-3895	98	34	-	-	ADJ
dpc-3895	98	35	experienced	experienced	ADJ
dpc-3895	98	36	patients	patient	NOUN
dpc-3895	98	37	were	be	AUX
dpc-3895	98	38	included	include	VERB
dpc-3895	98	39	.	.	PUNCT
dpc-3895	99	1	increased	increase	VERB
dpc-3895	99	2	rates	rate	NOUN
dpc-3895	99	3	of	of	ADP
dpc-3895	99	4	comorbidities	comorbiditie	NOUN
dpc-3895	99	5	were	be	AUX
dpc-3895	99	6	recorded	record	VERB
dpc-3895	99	7	,	,	PUNCT
dpc-3895	99	8	with	with	ADP
dpc-3895	99	9	almost	almost	ADV
dpc-3895	99	10	half	half	NOUN
dpc-3895	99	11	of	of	ADP
dpc-3895	99	12	the	the	DET
dpc-3895	99	13	patients	patient	NOUN
dpc-3895	99	14	reporting	report	VERB
dpc-3895	99	15	at	at	ADP
dpc-3895	99	16	least	least	ADJ
dpc-3895	99	17	one	one	NUM
dpc-3895	99	18	;	;	PUNCT
dpc-3895	99	19	a	a	DET
dpc-3895	99	20	factor	factor	NOUN
dpc-3895	99	21	that	that	PRON
dpc-3895	99	22	generally	generally	ADV
dpc-3895	99	23	levels	level	VERB
dpc-3895	99	24	up	up	ADP
dpc-3895	99	25	the	the	DET
dpc-3895	99	26	difficulty	difficulty	NOUN
dpc-3895	99	27	in	in	ADP
dpc-3895	99	28	managing	manage	VERB
dpc-3895	99	29	the	the	DET
dpc-3895	99	30	disease	disease	NOUN
dpc-3895	99	31	.	.	PUNCT
dpc-3895	100	1	secukinumab	secukinumab	PROPN
dpc-3895	100	2	accomplished	accomplish	VERB
dpc-3895	100	3	to	to	PART
dpc-3895	100	4	improve	improve	VERB
dpc-3895	100	5	the	the	DET
dpc-3895	100	6	disease	disease	NOUN
dpc-3895	100	7	burden	burden	NOUN
dpc-3895	100	8	in	in	ADP
dpc-3895	100	9	an	an	DET
dpc-3895	100	10	impressively	impressively	ADV
dpc-3895	100	11	fast	fast	ADJ
dpc-3895	100	12	manner	manner	NOUN
dpc-3895	100	13	,	,	PUNCT
dpc-3895	100	14	with	with	ADP
dpc-3895	100	15	over	over	ADP
dpc-3895	100	16	half	half	NOUN
dpc-3895	100	17	of	of	ADP
dpc-3895	100	18	the	the	DET
dpc-3895	100	19	patients	patient	NOUN
dpc-3895	100	20	(	(	PUNCT
dpc-3895	100	21	55.6	55.6	NUM
dpc-3895	100	22	%	%	NOUN
dpc-3895	100	23	)	)	PUNCT
dpc-3895	100	24	achieving	achieve	VERB
dpc-3895	100	25	pasi75	pasi75	NOUN
dpc-3895	100	26	and	and	CCONJ
dpc-3895	100	27	one	one	NUM
dpc-3895	100	28	out	out	ADP
dpc-3895	100	29	of	of	ADP
dpc-3895	100	30	four	four	NUM
dpc-3895	100	31	patients	patient	NOUN
dpc-3895	100	32	(	(	PUNCT
dpc-3895	100	33	25.3	25.3	NUM
dpc-3895	100	34	%	%	NOUN
dpc-3895	100	35	)	)	PUNCT
dpc-3895	100	36	achieving	achieve	VERB
dpc-3895	100	37	pasi90	pasi90	NOUN
dpc-3895	100	38	at	at	ADP
dpc-3895	100	39	week	week	NOUN
dpc-3895	100	40	4	4	NUM
dpc-3895	100	41	.	.	PUNCT
dpc-3895	101	1	this	this	DET
dpc-3895	101	2	improvement	improvement	NOUN
dpc-3895	101	3	continued	continue	VERB
dpc-3895	101	4	to	to	PART
dpc-3895	101	5	increase	increase	VERB
dpc-3895	101	6	to	to	PART
dpc-3895	101	7	reach	reach	VERB
dpc-3895	101	8	at	at	ADP
dpc-3895	101	9	week	week	NOUN
dpc-3895	101	10	16	16	NUM
dpc-3895	101	11	pasi75/	pasi75/	NOUN
dpc-3895	101	12	pasi90	pasi90	NOUN
dpc-3895	101	13	/	/	SYM
dpc-3895	101	14	pasi100	pasi100	PROPN
dpc-3895	101	15	in	in	ADP
dpc-3895	101	16	87.5%/69.8%/49	87.5%/69.8%/49	NOUN
dpc-3895	101	17	%	%	NOUN
dpc-3895	101	18	respectively	respectively	ADV
dpc-3895	101	19	.	.	PUNCT
dpc-3895	102	1	in	in	ADP
dpc-3895	102	2	accordance	accordance	NOUN
dpc-3895	102	3	with	with	ADP
dpc-3895	102	4	the	the	DET
dpc-3895	102	5	treatment	treatment	NOUN
dpc-3895	102	6	outcomes	outcome	NOUN
dpc-3895	102	7	of	of	ADP
dpc-3895	102	8	this	this	DET
dpc-3895	102	9	study	study	NOUN
dpc-3895	102	10	,	,	PUNCT
dpc-3895	102	11	secukinumab	secukinumab	NOUN
dpc-3895	102	12	has	have	AUX
dpc-3895	102	13	shown	show	VERB
dpc-3895	102	14	high	high	ADJ
dpc-3895	102	15	efficacy	efficacy	NOUN
dpc-3895	102	16	in	in	ADP
dpc-3895	102	17	managing	manage	VERB
dpc-3895	102	18	psoriasis	psoriasis	NOUN
dpc-3895	102	19	quickly	quickly	ADV
dpc-3895	102	20	.	.	PUNCT
dpc-3895	103	1	in	in	ADP
dpc-3895	103	2	fact	fact	NOUN
dpc-3895	103	3	in	in	ADP
dpc-3895	103	4	erasure	erasure	NOUN
dpc-3895	103	5	,	,	PUNCT
dpc-3895	103	6	feature	feature	NOUN
dpc-3895	103	7	and	and	CCONJ
dpc-3895	103	8	juncture	juncture	ADJ
dpc-3895	103	9	clinical	clinical	ADJ
dpc-3895	103	10	trials	trial	NOUN
dpc-3895	103	11	there	there	PRON
dpc-3895	103	12	was	be	VERB
dpc-3895	103	13	a	a	DET
dpc-3895	103	14	pasi75	pasi75	NOUN
dpc-3895	103	15	/	/	SYM
dpc-3895	103	16	pasi90	pasi90	PROPN
dpc-3895	103	17	/	/	SYM
dpc-3895	103	18	pasi100	pasi100	PROPN
dpc-3895	103	19	reduction	reduction	NOUN
dpc-3895	103	20	rate	rate	NOUN
dpc-3895	103	21	at	at	ADP
dpc-3895	103	22	week	week	NOUN
dpc-3895	103	23	16	16	NUM
dpc-3895	103	24	in	in	ADP
dpc-3895	103	25	86.1%/69.8%/41.6	86.1%/69.8%/41.6	NUM
dpc-3895	103	26	%	%	NOUN
dpc-3895	103	27	[	[	X
dpc-3895	103	28	5	5	NUM
dpc-3895	103	29	]	]	PUNCT
dpc-3895	103	30	.	.	PUNCT
dpc-3895	104	1	similar	similar	ADJ
dpc-3895	104	2	were	be	AUX
dpc-3895	104	3	the	the	DET
dpc-3895	104	4	results	result	NOUN
dpc-3895	104	5	from	from	ADP
dpc-3895	104	6	rompoti	rompoti	PROPN
dpc-3895	104	7	et	et	PROPN
dpc-3895	104	8	al	al	PROPN
dpc-3895	104	9	in	in	ADP
dpc-3895	104	10	greece	greece	PROPN
dpc-3895	104	11	where	where	SCONJ
dpc-3895	104	12	,	,	PUNCT
dpc-3895	104	13	at	at	ADP
dpc-3895	104	14	week	week	NOUN
dpc-3895	104	15	16	16	NUM
dpc-3895	104	16	,	,	PUNCT
dpc-3895	104	17	a	a	DET
dpc-3895	104	18	pasi75	pasi75	NOUN
dpc-3895	104	19	/	/	SYM
dpc-3895	104	20	pasi90	pasi90	PROPN
dpc-3895	104	21	/	/	SYM
dpc-3895	104	22	pasi100	pasi100	PROPN
dpc-3895	104	23	reduction	reduction	NOUN
dpc-3895	104	24	rate	rate	NOUN
dpc-3895	104	25	in	in	ADP
dpc-3895	104	26	83.3%/70%/46.3	83.3%/70%/46.3	NUM
dpc-3895	104	27	%	%	NOUN
dpc-3895	104	28	of	of	ADP
dpc-3895	104	29	the	the	DET
dpc-3895	104	30	patients	patient	NOUN
dpc-3895	104	31	was	be	AUX
dpc-3895	104	32	recorded	record	VERB
dpc-3895	104	33	[	[	X
dpc-3895	104	34	6	6	NUM
dpc-3895	104	35	]	]	PUNCT
dpc-3895	104	36	.	.	PUNCT
dpc-3895	105	1	our	our	PRON
dpc-3895	105	2	study	study	NOUN
dpc-3895	105	3	population	population	NOUN
dpc-3895	105	4	shares	share	VERB
dpc-3895	105	5	some	some	DET
dpc-3895	105	6	characteristics	characteristic	NOUN
dpc-3895	105	7	with	with	ADP
dpc-3895	105	8	the	the	DET
dpc-3895	105	9	abovementioned	abovementione	VERB
dpc-3895	105	10	study	study	NOUN
dpc-3895	105	11	in	in	ADP
dpc-3895	105	12	greece	greece	PROPN
dpc-3895	105	13	.	.	PUNCT
dpc-3895	106	1	namely	namely	ADV
dpc-3895	106	2	both	both	PRON
dpc-3895	106	3	include	include	VERB
dpc-3895	106	4	overweight	overweight	ADJ
dpc-3895	106	5	patients	patient	NOUN
dpc-3895	106	6	(	(	PUNCT
dpc-3895	106	7	mean	mean	INTJ
dpc-3895	106	8	bmi	bmi	PROPN
dpc-3895	106	9	:	:	PUNCT
dpc-3895	106	10	29.3	29.3	NUM
dpc-3895	106	11	;	;	PUNCT
dpc-3895	106	12	range	range	NOUN
dpc-3895	106	13	:	:	PUNCT
dpc-3895	106	14	18.4	18.4	NUM
dpc-3895	106	15	-	-	SYM
dpc-3895	106	16	45.2	45.2	NUM
dpc-3895	106	17	versus	versus	ADP
dpc-3895	106	18	29.1	29.1	NUM
dpc-3895	106	19	;	;	PUNCT
dpc-3895	106	20	range	range	NOUN
dpc-3895	106	21	:	:	PUNCT
dpc-3895	106	22	17.3	17.3	NUM
dpc-3895	106	23	-	-	SYM
dpc-3895	106	24	50.2	50.2	NUM
dpc-3895	106	25	)	)	PUNCT
dpc-3895	106	26	and	and	CCONJ
dpc-3895	106	27	almost	almost	ADV
dpc-3895	106	28	half	half	NOUN
dpc-3895	106	29	of	of	ADP
dpc-3895	106	30	the	the	DET
dpc-3895	106	31	studied	studied	ADJ
dpc-3895	106	32	population	population	NOUN
dpc-3895	106	33	in	in	ADP
dpc-3895	106	34	both	both	DET
dpc-3895	106	35	trials	trial	NOUN
dpc-3895	106	36	have	have	VERB
dpc-3895	106	37	at	at	ADV
dpc-3895	106	38	least	least	ADV
dpc-3895	106	39	one	one	NUM
dpc-3895	106	40	comorbidity	comorbidity	NOUN
dpc-3895	106	41	(	(	PUNCT
dpc-3895	106	42	46	46	NUM
dpc-3895	106	43	%	%	NOUN
dpc-3895	106	44	versus	versus	ADP
dpc-3895	106	45	49.4	49.4	NUM
dpc-3895	106	46	%	%	NOUN
dpc-3895	106	47	)	)	PUNCT
dpc-3895	106	48	.	.	PUNCT
dpc-3895	107	1	we	we	PRON
dpc-3895	107	2	report	report	VERB
dpc-3895	107	3	32.3	32.3	NUM
dpc-3895	107	4	%	%	NOUN
dpc-3895	107	5	patients	patient	NOUN
dpc-3895	107	6	with	with	ADP
dpc-3895	107	7	psa	psa	NOUN
dpc-3895	107	8	whereas	whereas	SCONJ
dpc-3895	107	9	rompoti	rompoti	PROPN
dpc-3895	107	10	et	et	PROPN
dpc-3895	107	11	al	al	PROPN
dpc-3895	107	12	report	report	PROPN
dpc-3895	107	13	43.2	43.2	NUM
dpc-3895	107	14	%	%	NOUN
dpc-3895	107	15	(	(	PUNCT
dpc-3895	107	16	versus	versus	ADP
dpc-3895	107	17	20	20	NUM
dpc-3895	107	18	%	%	NOUN
dpc-3895	107	19	in	in	ADP
dpc-3895	107	20	clinical	clinical	ADJ
dpc-3895	107	21	trials	trial	NOUN
dpc-3895	107	22	)	)	PUNCT
dpc-3895	107	23	.	.	PUNCT
dpc-3895	108	1	bai	bai	PROPN
dpc-3895	108	2	et	et	PROPN
dpc-3895	108	3	al	al	PROPN
dpc-3895	108	4	conducted	conduct	VERB
dpc-3895	108	5	a	a	DET
dpc-3895	108	6	systematic	systematic	ADJ
dpc-3895	108	7	review	review	NOUN
dpc-3895	108	8	with	with	ADP
dpc-3895	108	9	a	a	DET
dpc-3895	108	10	network	network	NOUN
dpc-3895	108	11	meta	meta	NOUN
dpc-3895	108	12	analysis	analysis	NOUN
dpc-3895	108	13	(	(	PUNCT
dpc-3895	108	14	nma	nma	PROPN
dpc-3895	108	15	)	)	PUNCT
dpc-3895	108	16	of	of	ADP
dpc-3895	108	17	all	all	DET
dpc-3895	108	18	randomized	randomized	ADJ
dpc-3895	108	19	trials	trial	NOUN
dpc-3895	108	20	in	in	ADP
dpc-3895	108	21	order	order	NOUN
dpc-3895	108	22	to	to	PART
dpc-3895	108	23	determine	determine	VERB
dpc-3895	108	24	the	the	DET
dpc-3895	108	25	differences	difference	NOUN
dpc-3895	108	26	in	in	ADP
dpc-3895	108	27	efficacy	efficacy	NOUN
dpc-3895	108	28	and	and	CCONJ
dpc-3895	108	29	safety	safety	NOUN
dpc-3895	108	30	profiles	profile	NOUN
dpc-3895	108	31	of	of	ADP
dpc-3895	108	32	il-17	il-17	NOUN
dpc-3895	108	33	,	,	PUNCT
dpc-3895	108	34	diabetes	diabetes	NOUN
dpc-3895	108	35	mellitus	mellitus	NOUN
dpc-3895	108	36	,	,	PUNCT
dpc-3895	108	37	dyslipidemia	dyslipidemia	NOUN
dpc-3895	108	38	,	,	PUNCT
dpc-3895	108	39	hypertension	hypertension	NOUN
dpc-3895	108	40	,	,	PUNCT
dpc-3895	108	41	hashimoto	hashimoto	NOUN
dpc-3895	108	42	disease	disease	NOUN
dpc-3895	108	43	,	,	PUNCT
dpc-3895	108	44	anxiety	anxiety	NOUN
dpc-3895	108	45	disorder	disorder	NOUN
dpc-3895	108	46	,	,	PUNCT
dpc-3895	108	47	smoking	smoking	NOUN
dpc-3895	108	48	)	)	PUNCT
dpc-3895	108	49	.	.	PUNCT
dpc-3895	109	1	in	in	ADP
dpc-3895	109	2	a	a	DET
dpc-3895	109	3	univariate	univariate	ADJ
dpc-3895	109	4	analysis	analysis	NOUN
dpc-3895	109	5	,	,	PUNCT
dpc-3895	109	6	no	no	DET
dpc-3895	109	7	medical	medical	ADJ
dpc-3895	109	8	,	,	PUNCT
dpc-3895	109	9	sociodemographic	sociodemographic	ADJ
dpc-3895	109	10	and	and	CCONJ
dpc-3895	109	11	 	 	SPACE
dpc-3895	109	12	the	the	DET
dpc-3895	109	13	assessed	assess	VERB
dpc-3895	109	14	clinical	clinical	ADJ
dpc-3895	109	15	biomarker	biomarker	NOUN
dpc-3895	109	16	was	be	AUX
dpc-3895	109	17	significantly	significantly	ADV
dpc-3895	109	18	associated	associate	VERB
dpc-3895	109	19	with	with	ADP
dpc-3895	109	20	pasi	pasi	NOUN
dpc-3895	109	21	responses	response	NOUN
dpc-3895	109	22	.	.	PUNCT
dpc-3895	110	1	regarding	regard	VERB
dpc-3895	110	2	difficult	difficult	ADJ
dpc-3895	110	3	-	-	PUNCT
dpc-3895	110	4	to	to	ADP
dpc-3895	110	5	-	-	PUNCT
dpc-3895	110	6	treat	treat	NOUN
dpc-3895	110	7	manifestations	manifestation	NOUN
dpc-3895	110	8	,	,	PUNCT
dpc-3895	110	9	we	we	PRON
dpc-3895	110	10	recorded	record	VERB
dpc-3895	110	11	scalp	scalp	NOUN
dpc-3895	110	12	involvement	involvement	NOUN
dpc-3895	110	13	in	in	ADP
dpc-3895	110	14	74.74	74.74	NUM
dpc-3895	110	15	%	%	NOUN
dpc-3895	110	16	(	(	PUNCT
dpc-3895	110	17	74/99	74/99	NUM
dpc-3895	110	18	)	)	PUNCT
dpc-3895	110	19	of	of	ADP
dpc-3895	110	20	our	our	PRON
dpc-3895	110	21	patients	patient	NOUN
dpc-3895	110	22	,	,	PUNCT
dpc-3895	110	23	genital	genital	ADJ
dpc-3895	110	24	psoriasis	psoriasis	NOUN
dpc-3895	110	25	in	in	ADP
dpc-3895	110	26	27.27	27.27	NUM
dpc-3895	110	27	%	%	NOUN
dpc-3895	110	28	(	(	PUNCT
dpc-3895	110	29	27/99	27/99	NUM
dpc-3895	110	30	)	)	PUNCT
dpc-3895	110	31	and	and	CCONJ
dpc-3895	110	32	skin	skin	NOUN
dpc-3895	110	33	folds	fold	NOUN
dpc-3895	110	34	involvement	involvement	NOUN
dpc-3895	110	35	(	(	PUNCT
dpc-3895	110	36	psoriasis	psoriasis	NOUN
dpc-3895	110	37	inversa	inversa	NOUN
dpc-3895	110	38	)	)	PUNCT
dpc-3895	110	39	in	in	ADP
dpc-3895	110	40	17	17	NUM
dpc-3895	110	41	%	%	NOUN
dpc-3895	110	42	(	(	PUNCT
dpc-3895	110	43	17/99	17/99	NUM
dpc-3895	110	44	)	)	PUNCT
dpc-3895	110	45	.	.	PUNCT
dpc-3895	111	1	after	after	ADP
dpc-3895	111	2	secukinumab	secukinumab	NOUN
dpc-3895	111	3	initiation	initiation	NOUN
dpc-3895	111	4	(	(	PUNCT
dpc-3895	111	5	week	week	NOUN
dpc-3895	111	6	4	4	NUM
dpc-3895	111	7	)	)	PUNCT
dpc-3895	111	8	lesions	lesion	NOUN
dpc-3895	111	9	in	in	ADP
dpc-3895	111	10	the	the	DET
dpc-3895	111	11	genital	genital	ADJ
dpc-3895	111	12	area	area	NOUN
dpc-3895	111	13	and	and	CCONJ
dpc-3895	111	14	patients	patient	NOUN
dpc-3895	111	15	with	with	ADP
dpc-3895	111	16	skin	skin	NOUN
dpc-3895	111	17	fold	fold	NOUN
dpc-3895	111	18	involvement	involvement	NOUN
dpc-3895	111	19	experienced	experience	VERB
dpc-3895	111	20	a	a	DET
dpc-3895	111	21	rapid	rapid	ADJ
dpc-3895	111	22	regression	regression	NOUN
dpc-3895	111	23	which	which	PRON
dpc-3895	111	24	was	be	AUX
dpc-3895	111	25	evident	evident	ADJ
dpc-3895	111	26	in	in	ADP
dpc-3895	111	27	37/44	37/44	NUM
dpc-3895	111	28	(	(	PUNCT
dpc-3895	111	29	84.1	84.1	NUM
dpc-3895	111	30	%	%	NOUN
dpc-3895	111	31	)	)	PUNCT
dpc-3895	111	32	of	of	ADP
dpc-3895	111	33	patients	patient	NOUN
dpc-3895	111	34	.	.	PUNCT
dpc-3895	112	1	skin	skin	NOUN
dpc-3895	112	2	folds	fold	NOUN
dpc-3895	112	3	and	and	CCONJ
dpc-3895	112	4	genitals	genital	NOUN
dpc-3895	112	5	were	be	AUX
dpc-3895	112	6	remarkably	remarkably	ADV
dpc-3895	112	7	cleared	clear	VERB
dpc-3895	112	8	at	at	ADP
dpc-3895	112	9	week	week	NOUN
dpc-3895	112	10	5	5	NUM
dpc-3895	112	11	(	(	PUNCT
dpc-3895	112	12	mean	mean	ADJ
dpc-3895	112	13	week	week	NOUN
dpc-3895	112	14	of	of	ADP
dpc-3895	112	15	clearing	clear	VERB
dpc-3895	112	16	5.29	5.29	NUM
dpc-3895	113	1	[	[	NOUN
dpc-3895	113	2	sd	sd	ADP
dpc-3895	113	3	1.49	1.49	NUM
dpc-3895	113	4	]	]	PUNCT
dpc-3895	113	5	,	,	PUNCT
dpc-3895	113	6	median	median	ADJ
dpc-3895	113	7	week	week	NOUN
dpc-3895	113	8	of	of	ADP
dpc-3895	113	9	clearing	clearing	NOUN
dpc-3895	113	10	:	:	PUNCT
dpc-3895	113	11	5	5	NUM
dpc-3895	113	12	,	,	PUNCT
dpc-3895	113	13	[	[	X
dpc-3895	113	14	iqr:2	iqr:2	NOUN
dpc-3895	113	15	]	]	PUNCT
dpc-3895	113	16	)	)	PUNCT
dpc-3895	113	17	,	,	PUNCT
dpc-3895	113	18	and	and	CCONJ
dpc-3895	113	19	spga	spga	NOUN
dpc-3895	113	20	0/1	0/1	NUM
dpc-3895	113	21	at	at	ADP
dpc-3895	113	22	week	week	NOUN
dpc-3895	113	23	4	4	NUM
dpc-3895	113	24	.	.	PUNCT
dpc-3895	113	25	regarding	regard	VERB
dpc-3895	113	26	drug	drug	NOUN
dpc-3895	113	27	retention	retention	NOUN
dpc-3895	113	28	,	,	PUNCT
dpc-3895	113	29	we	we	PRON
dpc-3895	113	30	report	report	VERB
dpc-3895	113	31	11	11	NUM
dpc-3895	113	32	patients	patient	NOUN
dpc-3895	113	33	that	that	PRON
dpc-3895	113	34	had	have	VERB
dpc-3895	113	35	to	to	PART
dpc-3895	113	36	discontinue	discontinue	VERB
dpc-3895	113	37	treatment	treatment	NOUN
dpc-3895	113	38	throughout	throughout	ADP
dpc-3895	113	39	the	the	DET
dpc-3895	113	40	observation	observation	NOUN
dpc-3895	113	41	period	period	NOUN
dpc-3895	113	42	.	.	PUNCT
dpc-3895	114	1	7	7	NUM
dpc-3895	114	2	patients	patient	NOUN
dpc-3895	114	3	lost	lose	VERB
dpc-3895	114	4	pasi75	pasi75	NOUN
dpc-3895	114	5	within	within	ADP
dpc-3895	114	6	more	more	ADJ
dpc-3895	114	7	than	than	ADP
dpc-3895	114	8	2	2	NUM
dpc-3895	114	9	years	year	NOUN
dpc-3895	114	10	of	of	ADP
dpc-3895	114	11	the	the	DET
dpc-3895	114	12	treatment	treatment	NOUN
dpc-3895	114	13	and	and	CCONJ
dpc-3895	114	14	lost	lose	VERB
dpc-3895	114	15	its	its	PRON
dpc-3895	114	16	effectiveness	effectiveness	NOUN
dpc-3895	114	17	.	.	PUNCT
dpc-3895	115	1	3	3	NUM
dpc-3895	115	2	patients	patient	NOUN
dpc-3895	115	3	had	have	VERB
dpc-3895	115	4	to	to	PART
dpc-3895	115	5	switch	switch	VERB
dpc-3895	115	6	to	to	ADP
dpc-3895	115	7	other	other	ADJ
dpc-3895	115	8	therapies	therapy	NOUN
dpc-3895	115	9	because	because	SCONJ
dpc-3895	115	10	they	they	PRON
dpc-3895	115	11	did	do	AUX
dpc-3895	115	12	not	not	PART
dpc-3895	115	13	respond	respond	VERB
dpc-3895	115	14	to	to	ADP
dpc-3895	115	15	the	the	DET
dpc-3895	115	16	drug	drug	NOUN
dpc-3895	115	17	by	by	ADP
dpc-3895	115	18	week	week	NOUN
dpc-3895	115	19	16	16	NUM
dpc-3895	115	20	(	(	PUNCT
dpc-3895	115	21	table	table	NOUN
dpc-3895	115	22	3	3	NUM
dpc-3895	115	23	)	)	PUNCT
dpc-3895	115	24	.	.	PUNCT
dpc-3895	116	1	safety	safety	NOUN
dpc-3895	116	2	most	most	ADJ
dpc-3895	116	3	of	of	ADP
dpc-3895	116	4	the	the	DET
dpc-3895	116	5	adverse	adverse	ADJ
dpc-3895	116	6	events	event	NOUN
dpc-3895	116	7	(	(	PUNCT
dpc-3895	116	8	ae	ae	PROPN
dpc-3895	116	9	)	)	PUNCT
dpc-3895	116	10	recorded	record	VERB
dpc-3895	116	11	was	be	AUX
dpc-3895	116	12	characterized	characterize	VERB
dpc-3895	116	13	as	as	ADP
dpc-3895	116	14	low	low	ADJ
dpc-3895	116	15	grade	grade	NOUN
dpc-3895	116	16	and	and	CCONJ
dpc-3895	116	17	did	do	AUX
dpc-3895	116	18	not	not	PART
dpc-3895	116	19	require	require	VERB
dpc-3895	116	20	a	a	DET
dpc-3895	116	21	treatment	treatment	NOUN
dpc-3895	116	22	discontinuation	discontinuation	NOUN
dpc-3895	116	23	.	.	PUNCT
dpc-3895	117	1	actually	actually	ADV
dpc-3895	117	2	3	3	NUM
dpc-3895	117	3	patients	patient	NOUN
dpc-3895	117	4	reported	report	VERB
dpc-3895	117	5	ae	ae	PROPN
dpc-3895	117	6	:	:	PUNCT
dpc-3895	117	7	two	two	NUM
dpc-3895	117	8	patients	patient	NOUN
dpc-3895	117	9	reported	report	VERB
dpc-3895	117	10	fatigue	fatigue	NOUN
dpc-3895	117	11	grade	grade	NOUN
dpc-3895	117	12	1	1	NUM
dpc-3895	117	13	ctcae	ctcae	NOUN
dpc-3895	117	14	possibly	possibly	ADV
dpc-3895	117	15	drug	drug	NOUN
dpc-3895	117	16	-	-	PUNCT
dpc-3895	117	17	related	relate	VERB
dpc-3895	117	18	and	and	CCONJ
dpc-3895	117	19	one	one	NUM
dpc-3895	117	20	reported	report	VERB
dpc-3895	117	21	headache	headache	NOUN
dpc-3895	117	22	grade	grade	NOUN
dpc-3895	117	23	1	1	NUM
dpc-3895	117	24	ctcae	ctcae	NOUN
dpc-3895	117	25	probably	probably	ADV
dpc-3895	117	26	not	not	PART
dpc-3895	117	27	-	-	PUNCT
dpc-3895	117	28	drug	drug	NOUN
dpc-3895	117	29	related	relate	VERB
dpc-3895	117	30	.	.	PUNCT
dpc-3895	118	1	four	four	NUM
dpc-3895	118	2	patients	patient	NOUN
dpc-3895	118	3	had	have	VERB
dpc-3895	118	4	to	to	PART
dpc-3895	118	5	discontinue	discontinue	VERB
dpc-3895	118	6	the	the	DET
dpc-3895	118	7	treatment	treatment	NOUN
dpc-3895	118	8	up	up	ADP
dpc-3895	118	9	until	until	ADP
dpc-3895	118	10	week	week	NOUN
dpc-3895	118	11	table	table	NOUN
dpc-3895	118	12	2	2	NUM
dpc-3895	118	13	.	.	PUNCT
dpc-3895	118	14	clinical	clinical	ADJ
dpc-3895	118	15	efficacy	efficacy	NOUN
dpc-3895	118	16	of	of	ADP
dpc-3895	118	17	secukinumab	secukinumab	NOUN
dpc-3895	118	18	.	.	PUNCT
dpc-3895	119	1	pasi	pasi	NOUN
dpc-3895	119	2	outcomes	outcome	NOUN
dpc-3895	119	3	as	as	ADP
dpc-3895	119	4	observed	observed	ADJ
dpc-3895	119	5	week	week	NOUN
dpc-3895	119	6	n	n	CCONJ
dpc-3895	119	7	n	n	PROPN
dpc-3895	119	8	(	(	PUNCT
dpc-3895	119	9	%	%	INTJ
dpc-3895	119	10	)	)	PUNCT
dpc-3895	119	11	pasi	pasi	NOUN
dpc-3895	119	12	75	75	NUM
dpc-3895	119	13	4	4	NUM
dpc-3895	119	14	99	99	NUM
dpc-3895	119	15	55/99	55/99	NUM
dpc-3895	119	16	(	(	PUNCT
dpc-3895	119	17	55.6	55.6	NUM
dpc-3895	119	18	%	%	NOUN
dpc-3895	119	19	)	)	PUNCT
dpc-3895	119	20	16	16	NUM
dpc-3895	119	21	96	96	NUM
dpc-3895	119	22	84/96	84/96	NUM
dpc-3895	119	23	(	(	PUNCT
dpc-3895	119	24	87.5	87.5	NUM
dpc-3895	119	25	%	%	NOUN
dpc-3895	119	26	)	)	PUNCT
dpc-3895	119	27	52	52	NUM
dpc-3895	119	28	81	81	NUM
dpc-3895	119	29	70/81	70/81	NUM
dpc-3895	119	30	(	(	PUNCT
dpc-3895	119	31	86.4	86.4	NUM
dpc-3895	119	32	%	%	NOUN
dpc-3895	119	33	)	)	PUNCT
dpc-3895	119	34	104	104	NUM
dpc-3895	119	35	55	55	NUM
dpc-3895	119	36	52/55	52/55	NUM
dpc-3895	119	37	(	(	PUNCT
dpc-3895	119	38	94.5	94.5	NUM
dpc-3895	119	39	%	%	NOUN
dpc-3895	119	40	)	)	PUNCT
dpc-3895	119	41	156	156	NUM
dpc-3895	119	42	30	30	NUM
dpc-3895	119	43	29/30	29/30	NUM
dpc-3895	119	44	(	(	PUNCT
dpc-3895	119	45	96.7	96.7	NUM
dpc-3895	119	46	%	%	NOUN
dpc-3895	119	47	)	)	PUNCT
dpc-3895	119	48	208	208	NUM
dpc-3895	119	49	9	9	NUM
dpc-3895	119	50	9/9	9/9	NUM
dpc-3895	119	51	(	(	PUNCT
dpc-3895	119	52	100	100	NUM
dpc-3895	119	53	%	%	NOUN
dpc-3895	119	54	)	)	PUNCT
dpc-3895	119	55	pasi	pasi	NOUN
dpc-3895	119	56	90	90	NUM
dpc-3895	119	57	4	4	NUM
dpc-3895	119	58	99	99	NUM
dpc-3895	119	59	25/99	25/99	NUM
dpc-3895	119	60	(	(	PUNCT
dpc-3895	119	61	25.3	25.3	NUM
dpc-3895	119	62	%	%	NOUN
dpc-3895	119	63	)	)	PUNCT
dpc-3895	119	64	16	16	NUM
dpc-3895	119	65	96	96	NUM
dpc-3895	119	66	67/96	67/96	NUM
dpc-3895	119	67	(	(	PUNCT
dpc-3895	119	68	69.8	69.8	NUM
dpc-3895	119	69	%	%	NOUN
dpc-3895	119	70	)	)	PUNCT
dpc-3895	120	1	52	52	NUM
dpc-3895	120	2	81	81	NUM
dpc-3895	120	3	70/81	70/81	NUM
dpc-3895	120	4	(	(	PUNCT
dpc-3895	120	5	77.8	77.8	NUM
dpc-3895	120	6	%	%	NOUN
dpc-3895	120	7	)	)	PUNCT
dpc-3895	120	8	104	104	NUM
dpc-3895	120	9	55	55	NUM
dpc-3895	120	10	43/55	43/55	NUM
dpc-3895	120	11	(	(	PUNCT
dpc-3895	120	12	78.2	78.2	NUM
dpc-3895	120	13	%	%	NOUN
dpc-3895	120	14	)	)	PUNCT
dpc-3895	120	15	156	156	NUM
dpc-3895	120	16	30	30	NUM
dpc-3895	120	17	24/30	24/30	NUM
dpc-3895	120	18	(	(	PUNCT
dpc-3895	120	19	80.0	80.0	NUM
dpc-3895	120	20	%	%	NOUN
dpc-3895	120	21	)	)	PUNCT
dpc-3895	120	22	208	208	NUM
dpc-3895	120	23	9	9	NUM
dpc-3895	120	24	9/9	9/9	NUM
dpc-3895	120	25	(	(	PUNCT
dpc-3895	120	26	100	100	NUM
dpc-3895	120	27	%	%	NOUN
dpc-3895	120	28	)	)	PUNCT
dpc-3895	120	29	pasi	pasi	NOUN
dpc-3895	120	30	100	100	NUM
dpc-3895	120	31	4	4	NUM
dpc-3895	120	32	99	99	NUM
dpc-3895	120	33	14/99	14/99	NUM
dpc-3895	120	34	(	(	PUNCT
dpc-3895	120	35	14.1	14.1	NUM
dpc-3895	120	36	%	%	NOUN
dpc-3895	120	37	)	)	PUNCT
dpc-3895	120	38	16	16	NUM
dpc-3895	120	39	96	96	NUM
dpc-3895	120	40	47/96	47/96	NUM
dpc-3895	120	41	(	(	PUNCT
dpc-3895	120	42	49.0	49.0	NUM
dpc-3895	120	43	%	%	NOUN
dpc-3895	120	44	)	)	PUNCT
dpc-3895	120	45	52	52	NUM
dpc-3895	120	46	81	81	NUM
dpc-3895	120	47	35/81	35/81	NUM
dpc-3895	120	48	(	(	PUNCT
dpc-3895	120	49	43.2	43.2	NUM
dpc-3895	120	50	%	%	NOUN
dpc-3895	120	51	)	)	PUNCT
dpc-3895	120	52	104	104	NUM
dpc-3895	120	53	55	55	NUM
dpc-3895	120	54	26/55	26/55	NUM
dpc-3895	120	55	(	(	PUNCT
dpc-3895	120	56	47.3	47.3	NUM
dpc-3895	120	57	%	%	NOUN
dpc-3895	120	58	)	)	PUNCT
dpc-3895	120	59	156	156	NUM
dpc-3895	120	60	30	30	NUM
dpc-3895	120	61	15/30	15/30	NUM
dpc-3895	120	62	(	(	PUNCT
dpc-3895	120	63	50.0	50.0	NUM
dpc-3895	120	64	%	%	NOUN
dpc-3895	120	65	)	)	PUNCT
dpc-3895	120	66	208	208	NUM
dpc-3895	120	67	9	9	NUM
dpc-3895	120	68	8/9	8/9	NUM
dpc-3895	120	69	(	(	PUNCT
dpc-3895	120	70	88.9	88.9	NUM
dpc-3895	120	71	%	%	NOUN
dpc-3895	120	72	)	)	PUNCT
dpc-3895	120	73	pasi	pasi	NOUN
dpc-3895	120	74	=	=	SYM
dpc-3895	120	75	psoriasis	psoriasis	NOUN
dpc-3895	120	76	area	area	NOUN
dpc-3895	120	77	and	and	CCONJ
dpc-3895	120	78	severity	severity	NOUN
dpc-3895	120	79	index	index	NOUN
dpc-3895	120	80	.	.	PUNCT
dpc-3895	121	1	6	6	NUM
dpc-3895	121	2	original	original	ADJ
dpc-3895	121	3	article	article	NOUN
dpc-3895	121	4	|	|	ADV
dpc-3895	121	5	dermatol	dermatol	ADJ
dpc-3895	121	6	pract	pract	NOUN
dpc-3895	121	7	concept	concept	NOUN
dpc-3895	121	8	.	.	PUNCT
dpc-3895	122	1	2024;14(2):e2024119	2024;14(2):e2024119	NUM
dpc-3895	122	2	sustained	sustain	VERB
dpc-3895	122	3	until	until	ADP
dpc-3895	122	4	the	the	DET
dpc-3895	122	5	end	end	NOUN
dpc-3895	122	6	of	of	ADP
dpc-3895	122	7	the	the	DET
dpc-3895	122	8	observation	observation	NOUN
dpc-3895	122	9	period	period	NOUN
dpc-3895	122	10	(	(	PUNCT
dpc-3895	122	11	week	week	NOUN
dpc-3895	122	12	208	208	NUM
dpc-3895	122	13	)	)	PUNCT
dpc-3895	122	14	.	.	PUNCT
dpc-3895	123	1	these	these	DET
dpc-3895	123	2	findings	finding	NOUN
dpc-3895	123	3	are	be	AUX
dpc-3895	123	4	in	in	ADP
dpc-3895	123	5	agreement	agreement	NOUN
dpc-3895	123	6	with	with	ADP
dpc-3895	123	7	clinical	clinical	ADJ
dpc-3895	123	8	trials	trial	NOUN
dpc-3895	123	9	reporting	report	VERB
dpc-3895	123	10	5	5	NUM
dpc-3895	123	11	-	-	PUNCT
dpc-3895	123	12	year	year	NOUN
dpc-3895	123	13	data	datum	NOUN
dpc-3895	123	14	,	,	PUNCT
dpc-3895	123	15	as	as	ADV
dpc-3895	123	16	well	well	ADV
dpc-3895	123	17	as	as	ADP
dpc-3895	123	18	other	other	ADJ
dpc-3895	123	19	long	long	ADJ
dpc-3895	123	20	-	-	PUNCT
dpc-3895	123	21	term	term	NOUN
dpc-3895	123	22	real	real	ADJ
dpc-3895	123	23	-	-	PUNCT
dpc-3895	123	24	life	life	NOUN
dpc-3895	123	25	studies	study	NOUN
dpc-3895	123	26	for	for	ADP
dpc-3895	123	27	secukinumab	secukinumab	NOUN
dpc-3895	123	28	[	[	X
dpc-3895	123	29	8	8	NUM
dpc-3895	123	30	-	-	SYM
dpc-3895	123	31	10	10	NUM
dpc-3895	123	32	]	]	PUNCT
dpc-3895	123	33	.	.	PUNCT
dpc-3895	124	1	addressing	address	VERB
dpc-3895	124	2	the	the	DET
dpc-3895	124	3	difficult	difficult	ADJ
dpc-3895	124	4	-	-	PUNCT
dpc-3895	124	5	to	to	AUX
dpc-3895	124	6	-	-	PUNCT
dpc-3895	124	7	treat	treat	VERB
dpc-3895	124	8	psoriatic	psoriatic	ADJ
dpc-3895	124	9	manifestations	manifestation	NOUN
dpc-3895	124	10	,	,	PUNCT
dpc-3895	124	11	in	in	ADP
dpc-3895	124	12	particular	particular	ADJ
dpc-3895	124	13	scalp	scalp	NOUN
dpc-3895	124	14	psoriasis	psoriasis	NOUN
dpc-3895	124	15	,	,	PUNCT
dpc-3895	124	16	nail	nail	NOUN
dpc-3895	124	17	psoriasis	psoriasis	NOUN
dpc-3895	124	18	and	and	CCONJ
dpc-3895	124	19	palmoplantar	palmoplantar	NOUN
dpc-3895	124	20	psoriasis	psoriasis	NOUN
dpc-3895	124	21	,	,	PUNCT
dpc-3895	124	22	secukinumab	secukinumab	NOUN
dpc-3895	124	23	has	have	AUX
dpc-3895	124	24	shown	show	VERB
dpc-3895	124	25	a	a	DET
dpc-3895	124	26	rapid	rapid	ADJ
dpc-3895	124	27	and	and	CCONJ
dpc-3895	124	28	sustained	sustained	ADJ
dpc-3895	124	29	response	response	NOUN
dpc-3895	124	30	in	in	ADP
dpc-3895	124	31	improving	improve	VERB
dpc-3895	124	32	psoriatic	psoriatic	ADJ
dpc-3895	124	33	lesions	lesion	NOUN
dpc-3895	124	34	and	and	CCONJ
dpc-3895	124	35	associated	associated	ADJ
dpc-3895	124	36	symptoms	symptom	NOUN
dpc-3895	124	37	[	[	X
dpc-3895	124	38	11	11	NUM
dpc-3895	124	39	-	-	SYM
dpc-3895	124	40	15	15	NUM
dpc-3895	124	41	]	]	PUNCT
dpc-3895	124	42	.	.	PUNCT
dpc-3895	125	1	likewise	likewise	ADV
dpc-3895	125	2	treatment	treatment	NOUN
dpc-3895	125	3	response	response	NOUN
dpc-3895	125	4	in	in	ADP
dpc-3895	125	5	our	our	PRON
dpc-3895	125	6	studied	study	VERB
dpc-3895	125	7	population	population	NOUN
dpc-3895	125	8	showed	show	VERB
dpc-3895	125	9	significant	significant	ADJ
dpc-3895	125	10	improvement	improvement	NOUN
dpc-3895	125	11	in	in	ADP
dpc-3895	125	12	difficult	difficult	ADJ
dpc-3895	125	13	-	-	PUNCT
dpc-3895	125	14	to	to	PART
dpc-3895	125	15	-	-	PUNCT
dpc-3895	125	16	treat	treat	VERB
dpc-3895	125	17	specific	specific	ADJ
dpc-3895	125	18	locations	location	NOUN
dpc-3895	125	19	.	.	PUNCT
dpc-3895	126	1	we	we	PRON
dpc-3895	126	2	recorded	record	VERB
dpc-3895	126	3	scalp	scalp	NOUN
dpc-3895	126	4	involvement	involvement	NOUN
dpc-3895	126	5	in	in	ADP
dpc-3895	126	6	74,74	74,74	NUM
dpc-3895	126	7	%	%	NOUN
dpc-3895	126	8	(	(	PUNCT
dpc-3895	126	9	74/99	74/99	NUM
dpc-3895	126	10	)	)	PUNCT
dpc-3895	126	11	of	of	ADP
dpc-3895	126	12	our	our	PRON
dpc-3895	126	13	patients	patient	NOUN
dpc-3895	126	14	,	,	PUNCT
dpc-3895	126	15	genital	genital	ADJ
dpc-3895	126	16	psoriasis	psoriasis	NOUN
dpc-3895	126	17	in	in	ADP
dpc-3895	126	18	27.27	27.27	NUM
dpc-3895	126	19	%	%	NOUN
dpc-3895	126	20	(	(	PUNCT
dpc-3895	126	21	27/99	27/99	NUM
dpc-3895	126	22	)	)	PUNCT
dpc-3895	126	23	and	and	CCONJ
dpc-3895	126	24	skin	skin	NOUN
dpc-3895	126	25	folds	fold	NOUN
dpc-3895	126	26	involvement	involvement	NOUN
dpc-3895	126	27	(	(	PUNCT
dpc-3895	126	28	psoriasis	psoriasis	NOUN
dpc-3895	126	29	inversa	inversa	NOUN
dpc-3895	126	30	)	)	PUNCT
dpc-3895	126	31	in	in	ADP
dpc-3895	126	32	17	17	NUM
dpc-3895	126	33	%	%	NOUN
dpc-3895	126	34	(	(	PUNCT
dpc-3895	126	35	17/99	17/99	NUM
dpc-3895	126	36	)	)	PUNCT
dpc-3895	126	37	.	.	PUNCT
dpc-3895	127	1	after	after	ADP
dpc-3895	127	2	secukinumab	secukinumab	NOUN
dpc-3895	127	3	initiation	initiation	NOUN
dpc-3895	127	4	lesions	lesion	NOUN
dpc-3895	127	5	in	in	ADP
dpc-3895	127	6	the	the	DET
dpc-3895	127	7	genital	genital	ADJ
dpc-3895	127	8	area	area	NOUN
dpc-3895	127	9	and	and	CCONJ
dpc-3895	127	10	patients	patient	NOUN
dpc-3895	127	11	with	with	ADP
dpc-3895	127	12	skin	skin	NOUN
dpc-3895	127	13	fold	fold	NOUN
dpc-3895	127	14	involvement	involvement	NOUN
dpc-3895	127	15	experienced	experience	VERB
dpc-3895	127	16	a	a	DET
dpc-3895	127	17	rapid	rapid	ADJ
dpc-3895	127	18	regression	regression	NOUN
dpc-3895	127	19	which	which	PRON
dpc-3895	127	20	was	be	AUX
dpc-3895	127	21	evident	evident	ADJ
dpc-3895	127	22	in	in	ADP
dpc-3895	127	23	37/44	37/44	NUM
dpc-3895	127	24	(	(	PUNCT
dpc-3895	127	25	84.1	84.1	NUM
dpc-3895	127	26	%	%	NOUN
dpc-3895	127	27	)	)	PUNCT
dpc-3895	127	28	of	of	ADP
dpc-3895	127	29	patients	patient	NOUN
dpc-3895	127	30	.	.	PUNCT
dpc-3895	128	1	skin	skin	NOUN
dpc-3895	128	2	folds	fold	NOUN
dpc-3895	128	3	and	and	CCONJ
dpc-3895	128	4	genitals	genital	NOUN
dpc-3895	128	5	were	be	AUX
dpc-3895	128	6	remarkably	remarkably	ADV
dpc-3895	128	7	cleared	clear	VERB
dpc-3895	128	8	at	at	ADP
dpc-3895	128	9	week	week	NOUN
dpc-3895	128	10	5	5	NUM
dpc-3895	128	11	(	(	PUNCT
dpc-3895	128	12	mean	mean	PROPN
dpc-3895	128	13	5.29	5.29	NUM
dpc-3895	129	1	[	[	X
dpc-3895	129	2	sd	sd	ADP
dpc-3895	129	3	1.49	1.49	NUM
dpc-3895	129	4	]	]	PUNCT
dpc-3895	129	5	,	,	PUNCT
dpc-3895	129	6	median	median	NOUN
dpc-3895	129	7	:	:	PUNCT
dpc-3895	129	8	5	5	NUM
dpc-3895	129	9	,	,	PUNCT
dpc-3895	129	10	[	[	X
dpc-3895	129	11	iqr:2	iqr:2	NOUN
dpc-3895	129	12	]	]	PUNCT
dpc-3895	129	13	)	)	PUNCT
dpc-3895	129	14	,	,	PUNCT
dpc-3895	129	15	and	and	CCONJ
dpc-3895	129	16	spga	spga	NOUN
dpc-3895	129	17	0/1	0/1	NUM
dpc-3895	129	18	at	at	ADP
dpc-3895	129	19	week	week	NOUN
dpc-3895	129	20	4	4	NUM
dpc-3895	129	21	.	.	PUNCT
dpc-3895	130	1	data	datum	NOUN
dpc-3895	130	2	regarding	regard	VERB
dpc-3895	130	3	secukinumab	secukinumab	NOUN
dpc-3895	130	4	efficacy	efficacy	NOUN
dpc-3895	130	5	on	on	ADP
dpc-3895	130	6	areas	area	NOUN
dpc-3895	130	7	with	with	ADP
dpc-3895	130	8	fold	fold	ADJ
dpc-3895	130	9	involvement	involvement	NOUN
dpc-3895	130	10	as	as	ADV
dpc-3895	130	11	well	well	ADV
dpc-3895	130	12	as	as	ADP
dpc-3895	130	13	genital	genital	ADJ
dpc-3895	130	14	psoriasis	psoriasis	NOUN
dpc-3895	130	15	are	be	AUX
dpc-3895	130	16	lacking	lack	VERB
dpc-3895	130	17	from	from	ADP
dpc-3895	130	18	the	the	DET
dpc-3895	130	19	drug	drug	NOUN
dpc-3895	130	20	clinical	clinical	ADJ
dpc-3895	130	21	program	program	NOUN
dpc-3895	130	22	,	,	PUNCT
dpc-3895	130	23	as	as	ADV
dpc-3895	130	24	well	well	ADV
dpc-3895	130	25	as	as	ADP
dpc-3895	130	26	the	the	DET
dpc-3895	130	27	real	real	ADJ
dpc-3895	130	28	-	-	PUNCT
dpc-3895	130	29	world	world	NOUN
dpc-3895	130	30	setting	setting	NOUN
dpc-3895	130	31	.	.	PUNCT
dpc-3895	131	1	to	to	ADP
dpc-3895	131	2	our	our	PRON
dpc-3895	131	3	knowledge	knowledge	NOUN
dpc-3895	131	4	this	this	PRON
dpc-3895	131	5	is	be	AUX
dpc-3895	131	6	the	the	DET
dpc-3895	131	7	first	first	ADJ
dpc-3895	131	8	study	study	NOUN
dpc-3895	131	9	that	that	PRON
dpc-3895	131	10	included	include	VERB
dpc-3895	131	11	skin	skin	NOUN
dpc-3895	131	12	fold	fold	NOUN
dpc-3895	131	13	improvement	improvement	NOUN
dpc-3895	131	14	as	as	ADP
dpc-3895	131	15	a	a	DET
dpc-3895	131	16	treatment	treatment	NOUN
dpc-3895	131	17	endpoint	endpoint	NOUN
dpc-3895	131	18	for	for	ADP
dpc-3895	131	19	investigating	investigate	VERB
dpc-3895	131	20	the	the	DET
dpc-3895	131	21	treatment	treatment	NOUN
dpc-3895	131	22	efficacy	efficacy	NOUN
dpc-3895	131	23	of	of	ADP
dpc-3895	131	24	secukinumab	secukinumab	NOUN
dpc-3895	131	25	in	in	ADP
dpc-3895	131	26	this	this	DET
dpc-3895	131	27	difficult	difficult	ADJ
dpc-3895	131	28	-	-	PUNCT
dpc-3895	131	29	to	to	ADP
dpc-3895	131	30	-	-	PUNCT
dpc-3895	131	31	treat	treat	NOUN
dpc-3895	131	32	area	area	NOUN
dpc-3895	131	33	.	.	PUNCT
dpc-3895	132	1	however	however	ADV
dpc-3895	132	2	,	,	PUNCT
dpc-3895	132	3	patients	patient	NOUN
dpc-3895	132	4	of	of	ADP
dpc-3895	132	5	this	this	DET
dpc-3895	132	6	study	study	NOUN
dpc-3895	132	7	who	who	PRON
dpc-3895	132	8	had	have	VERB
dpc-3895	132	9	chronic	chronic	ADJ
dpc-3895	132	10	plaque	plaque	NOUN
dpc-3895	132	11	psoriasis	psoriasis	NOUN
dpc-3895	132	12	and	and	CCONJ
dpc-3895	132	13	lesions	lesion	NOUN
dpc-3895	132	14	affecting	affect	VERB
dpc-3895	132	15	the	the	DET
dpc-3895	132	16	skin	skin	NOUN
dpc-3895	132	17	folds	fold	NOUN
dpc-3895	132	18	and	and	CCONJ
dpc-3895	132	19	the	the	DET
dpc-3895	132	20	genital	genital	ADJ
dpc-3895	132	21	area	area	NOUN
dpc-3895	132	22	could	could	AUX
dpc-3895	132	23	be	be	AUX
dpc-3895	132	24	characterized	characterize	VERB
dpc-3895	132	25	as	as	ADP
dpc-3895	132	26	il12/23	il12/23	NOUN
dpc-3895	132	27	and	and	CCONJ
dpc-3895	132	28	il23	il23	PROPN
dpc-3895	132	29	inhibitors	inhibitor	NOUN
dpc-3895	132	30	used	use	VERB
dpc-3895	132	31	in	in	ADP
dpc-3895	132	32	treating	treat	VERB
dpc-3895	132	33	moderate	moderate	ADJ
dpc-3895	132	34	to	to	ADP
dpc-3895	132	35	severe	severe	ADJ
dpc-3895	132	36	plaque	plaque	NOUN
dpc-3895	132	37	psoriasis	psoriasis	NOUN
dpc-3895	132	38	.	.	PUNCT
dpc-3895	133	1	regarding	regard	VERB
dpc-3895	133	2	the	the	DET
dpc-3895	133	3	short	short	ADJ
dpc-3895	133	4	-	-	PUNCT
dpc-3895	133	5	term	term	NOUN
dpc-3895	133	6	achievements	achievement	NOUN
dpc-3895	133	7	amongst	amongst	ADP
dpc-3895	133	8	19840	19840	NUM
dpc-3895	133	9	patients	patient	NOUN
dpc-3895	133	10	from	from	ADP
dpc-3895	133	11	28	28	NUM
dpc-3895	133	12	trials	trial	NOUN
dpc-3895	133	13	secukinumab	secukinumab	NOUN
dpc-3895	133	14	ranked	rank	VERB
dpc-3895	133	15	first	first	ADV
dpc-3895	133	16	in	in	ADP
dpc-3895	133	17	achieving	achieve	VERB
dpc-3895	133	18	spga	spga	NOUN
dpc-3895	133	19	0/1	0/1	PROPN
dpc-3895	133	20	or	or	CCONJ
dpc-3895	133	21	iga	iga	PROPN
dpc-3895	133	22	0/1	0/1	PROPN
dpc-3895	133	23	or	or	CCONJ
dpc-3895	133	24	pga	pga	NOUN
dpc-3895	133	25	0/1	0/1	NUM
dpc-3895	133	26	,	,	PUNCT
dpc-3895	133	27	and	and	CCONJ
dpc-3895	133	28	second	second	ADV
dpc-3895	133	29	in	in	ADP
dpc-3895	133	30	achieving	achieve	VERB
dpc-3895	133	31	pasi75	pasi75	NOUN
dpc-3895	133	32	at	at	ADP
dpc-3895	133	33	week	week	NOUN
dpc-3895	133	34	12	12	NUM
dpc-3895	133	35	or	or	CCONJ
dpc-3895	133	36	16	16	NUM
dpc-3895	134	1	[	[	X
dpc-3895	134	2	7	7	NUM
dpc-3895	134	3	]	]	PUNCT
dpc-3895	134	4	.	.	PUNCT
dpc-3895	135	1	in	in	ADP
dpc-3895	135	2	agreement	agreement	NOUN
dpc-3895	135	3	with	with	ADP
dpc-3895	135	4	that	that	PRON
dpc-3895	135	5	,	,	PUNCT
dpc-3895	135	6	and	and	CCONJ
dpc-3895	135	7	according	accord	VERB
dpc-3895	135	8	to	to	ADP
dpc-3895	135	9	the	the	DET
dpc-3895	135	10	results	result	NOUN
dpc-3895	135	11	of	of	ADP
dpc-3895	135	12	our	our	PRON
dpc-3895	135	13	study	study	NOUN
dpc-3895	135	14	,	,	PUNCT
dpc-3895	135	15	secukinumab	secukinumab	NOUN
dpc-3895	135	16	is	be	AUX
dpc-3895	135	17	highly	highly	ADV
dpc-3895	135	18	efficacious	efficacious	ADJ
dpc-3895	135	19	in	in	ADP
dpc-3895	135	20	managing	manage	VERB
dpc-3895	135	21	the	the	DET
dpc-3895	135	22	disease	disease	NOUN
dpc-3895	135	23	burden	burden	NOUN
dpc-3895	135	24	of	of	ADP
dpc-3895	135	25	chronic	chronic	ADJ
dpc-3895	135	26	plaque	plaque	NOUN
dpc-3895	135	27	psoriasis	psoriasis	NOUN
dpc-3895	135	28	in	in	ADP
dpc-3895	135	29	a	a	DET
dpc-3895	135	30	fast	fast	ADJ
dpc-3895	135	31	manner	manner	NOUN
dpc-3895	135	32	in	in	ADP
dpc-3895	135	33	real	real	ADJ
dpc-3895	135	34	life	life	NOUN
dpc-3895	135	35	clinical	clinical	ADJ
dpc-3895	135	36	practice	practice	NOUN
dpc-3895	135	37	too	too	ADV
dpc-3895	135	38	.	.	PUNCT
dpc-3895	136	1	in	in	ADP
dpc-3895	136	2	phase	phase	NOUN
dpc-3895	136	3	ii	ii	PROPN
dpc-3895	136	4	/	/	SYM
dpc-3895	136	5	iii	iii	PROPN
dpc-3895	136	6	,	,	PUNCT
dpc-3895	136	7	clinical	clinical	ADJ
dpc-3895	136	8	trials	trial	NOUN
dpc-3895	136	9	patients	patient	NOUN
dpc-3895	136	10	are	be	AUX
dpc-3895	136	11	selected	select	VERB
dpc-3895	136	12	according	accord	VERB
dpc-3895	136	13	to	to	ADP
dpc-3895	136	14	specific	specific	ADJ
dpc-3895	136	15	inclusion	inclusion	NOUN
dpc-3895	136	16	criteria	criterion	NOUN
dpc-3895	136	17	.	.	PUNCT
dpc-3895	137	1	it	it	PRON
dpc-3895	137	2	is	be	AUX
dpc-3895	137	3	reasonable	reasonable	ADJ
dpc-3895	137	4	to	to	PART
dpc-3895	137	5	hypothesize	hypothesize	VERB
dpc-3895	137	6	that	that	SCONJ
dpc-3895	137	7	in	in	ADP
dpc-3895	137	8	a	a	DET
dpc-3895	137	9	real	real	ADJ
dpc-3895	137	10	-	-	PUNCT
dpc-3895	137	11	world	world	NOUN
dpc-3895	137	12	setting	setting	NOUN
dpc-3895	137	13	,	,	PUNCT
dpc-3895	137	14	where	where	SCONJ
dpc-3895	137	15	patients	patient	NOUN
dpc-3895	137	16	differ	differ	VERB
dpc-3895	137	17	at	at	ADV
dpc-3895	137	18	least	least	ADJ
dpc-3895	137	19	in	in	ADP
dpc-3895	137	20	disease	disease	NOUN
dpc-3895	137	21	severity	severity	NOUN
dpc-3895	137	22	and	and	CCONJ
dpc-3895	137	23	comorbidities	comorbiditie	NOUN
dpc-3895	137	24	,	,	PUNCT
dpc-3895	137	25	treatment	treatment	NOUN
dpc-3895	137	26	efficacy	efficacy	NOUN
dpc-3895	137	27	can	can	AUX
dpc-3895	137	28	vary	vary	VERB
dpc-3895	137	29	vastly	vastly	ADV
dpc-3895	137	30	.	.	PUNCT
dpc-3895	138	1	augustin	augustin	PROPN
dpc-3895	138	2	et	et	PROPN
dpc-3895	138	3	al	al	PROPN
dpc-3895	138	4	designed	design	VERB
dpc-3895	138	5	a	a	DET
dpc-3895	138	6	review	review	NOUN
dpc-3895	138	7	of	of	ADP
dpc-3895	138	8	all	all	DET
dpc-3895	138	9	available	available	ADJ
dpc-3895	138	10	published	publish	VERB
dpc-3895	138	11	studies	study	NOUN
dpc-3895	138	12	of	of	ADP
dpc-3895	138	13	real	real	ADJ
dpc-3895	138	14	-	-	PUNCT
dpc-3895	138	15	world	world	NOUN
dpc-3895	138	16	evidence	evidence	NOUN
dpc-3895	138	17	using	use	VERB
dpc-3895	138	18	secukinumab	secukinumab	NOUN
dpc-3895	138	19	in	in	ADP
dpc-3895	138	20	treating	treat	VERB
dpc-3895	138	21	plaque	plaque	NOUN
dpc-3895	138	22	psoriasis	psoriasis	NOUN
dpc-3895	138	23	from	from	ADP
dpc-3895	138	24	1	1	NUM
dpc-3895	138	25	january	january	NOUN
dpc-3895	138	26	2015	2015	NUM
dpc-3895	138	27	to	to	ADP
dpc-3895	138	28	31	31	NUM
dpc-3895	138	29	may	may	PROPN
dpc-3895	138	30	2019	2019	NUM
dpc-3895	138	31	.	.	PUNCT
dpc-3895	139	1	this	this	DET
dpc-3895	139	2	meta	meta	ADJ
dpc-3895	139	3	-	-	PUNCT
dpc-3895	139	4	analysis	analysis	NOUN
dpc-3895	139	5	included	include	VERB
dpc-3895	139	6	43	43	NUM
dpc-3895	139	7	studies	study	NOUN
dpc-3895	139	8	and	and	CCONJ
dpc-3895	139	9	the	the	DET
dpc-3895	139	10	effectiveness	effectiveness	NOUN
dpc-3895	139	11	results	result	VERB
dpc-3895	139	12	for	for	ADP
dpc-3895	139	13	pasi75	pasi75	NOUN
dpc-3895	139	14	/	/	SYM
dpc-3895	139	15	pasi90/	pasi90/	ADP
dpc-3895	139	16	pasi100	pasi100	PROPN
dpc-3895	139	17	at	at	ADP
dpc-3895	139	18	12	12	NUM
dpc-3895	139	19	weeks	week	NOUN
dpc-3895	139	20	were	be	AUX
dpc-3895	139	21	72%/50%/36	72%/50%/36	NUM
dpc-3895	139	22	%	%	NOUN
dpc-3895	139	23	respectively	respectively	ADV
dpc-3895	139	24	.	.	PUNCT
dpc-3895	140	1	the	the	DET
dpc-3895	140	2	endpoint	endpoint	NOUN
dpc-3895	140	3	of	of	ADP
dpc-3895	140	4	clinical	clinical	ADJ
dpc-3895	140	5	improvement	improvement	NOUN
dpc-3895	140	6	of	of	ADP
dpc-3895	140	7	psoriasis	psoriasis	NOUN
dpc-3895	140	8	in	in	ADP
dpc-3895	140	9	our	our	PRON
dpc-3895	140	10	real	real	ADJ
dpc-3895	140	11	-	-	PUNCT
dpc-3895	140	12	life	life	NOUN
dpc-3895	140	13	population	population	NOUN
dpc-3895	140	14	complies	comply	VERB
dpc-3895	140	15	with	with	ADP
dpc-3895	140	16	this	this	DET
dpc-3895	140	17	data	data	NOUN
dpc-3895	140	18	,	,	PUNCT
dpc-3895	140	19	supporting	support	VERB
dpc-3895	140	20	additionally	additionally	ADV
dpc-3895	140	21	the	the	DET
dpc-3895	140	22	consistency	consistency	NOUN
dpc-3895	140	23	secukinumab	secukinumab	NOUN
dpc-3895	140	24	offers	offer	VERB
dpc-3895	140	25	in	in	ADP
dpc-3895	140	26	fast	fast	ADJ
dpc-3895	140	27	treatment	treatment	NOUN
dpc-3895	140	28	efficacy	efficacy	NOUN
dpc-3895	140	29	.	.	PUNCT
dpc-3895	141	1	with	with	ADP
dpc-3895	141	2	regard	regard	NOUN
dpc-3895	141	3	to	to	ADP
dpc-3895	141	4	the	the	DET
dpc-3895	141	5	durability	durability	NOUN
dpc-3895	141	6	of	of	ADP
dpc-3895	141	7	response	response	NOUN
dpc-3895	141	8	,	,	PUNCT
dpc-3895	141	9	secukinumab	secukinumab	NOUN
dpc-3895	141	10	presented	present	VERB
dpc-3895	141	11	long	long	ADV
dpc-3895	141	12	-	-	PUNCT
dpc-3895	141	13	lasting	last	VERB
dpc-3895	141	14	and	and	CCONJ
dpc-3895	141	15	went	go	VERB
dpc-3895	141	16	as	as	ADV
dpc-3895	141	17	far	far	ADV
dpc-3895	141	18	as	as	SCONJ
dpc-3895	141	19	to	to	PART
dpc-3895	141	20	improve	improve	VERB
dpc-3895	141	21	the	the	DET
dpc-3895	141	22	efficacy	efficacy	NOUN
dpc-3895	141	23	at	at	ADP
dpc-3895	141	24	subsequent	subsequent	ADJ
dpc-3895	141	25	timepoints	timepoint	NOUN
dpc-3895	141	26	in	in	ADP
dpc-3895	141	27	this	this	DET
dpc-3895	141	28	study	study	NOUN
dpc-3895	141	29	,	,	PUNCT
dpc-3895	141	30	with	with	ADP
dpc-3895	141	31	almost	almost	ADV
dpc-3895	141	32	100	100	NUM
dpc-3895	141	33	%	%	NOUN
dpc-3895	141	34	of	of	ADP
dpc-3895	141	35	patients	patient	NOUN
dpc-3895	141	36	maintaining	maintain	VERB
dpc-3895	141	37	pasi	pasi	NOUN
dpc-3895	141	38	75	75	NUM
dpc-3895	141	39	response	response	NOUN
dpc-3895	141	40	,	,	PUNCT
dpc-3895	141	41	78.2	78.2	NUM
dpc-3895	141	42	%	%	NOUN
dpc-3895	141	43	achieving	achieve	VERB
dpc-3895	141	44	pasi	pasi	NOUN
dpc-3895	141	45	90	90	NUM
dpc-3895	141	46	response	response	NOUN
dpc-3895	141	47	and	and	CCONJ
dpc-3895	141	48	47.3	47.3	NUM
dpc-3895	141	49	%	%	NOUN
dpc-3895	141	50	achieving	achieve	VERB
dpc-3895	141	51	pasi	pasi	NOUN
dpc-3895	141	52	100	100	NUM
dpc-3895	141	53	response	response	NOUN
dpc-3895	141	54	at	at	ADP
dpc-3895	141	55	week	week	NOUN
dpc-3895	141	56	104	104	NUM
dpc-3895	141	57	,	,	PUNCT
dpc-3895	141	58	whilst	whilst	SCONJ
dpc-3895	141	59	these	these	DET
dpc-3895	141	60	efficacy	efficacy	NOUN
dpc-3895	141	61	rates	rate	NOUN
dpc-3895	141	62	were	be	AUX
dpc-3895	141	63	further	further	ADJ
dpc-3895	141	64	table	table	NOUN
dpc-3895	141	65	3	3	NUM
dpc-3895	141	66	.	.	PUNCT
dpc-3895	141	67	previous	previous	ADJ
dpc-3895	141	68	treatment	treatment	NOUN
dpc-3895	141	69	,	,	PUNCT
dpc-3895	141	70	adjuvant	adjuvant	ADJ
dpc-3895	141	71	therapy	therapy	NOUN
dpc-3895	141	72	,	,	PUNCT
dpc-3895	141	73	reason	reason	NOUN
dpc-3895	141	74	for	for	ADP
dpc-3895	141	75	discontinuation	discontinuation	NOUN
dpc-3895	141	76	.	.	PUNCT
dpc-3895	142	1	patient	patient	NOUN
dpc-3895	142	2	(	(	PUNCT
dpc-3895	142	3	gender	gender	NOUN
dpc-3895	142	4	,	,	PUNCT
dpc-3895	142	5	age	age	NOUN
dpc-3895	142	6	)	)	PUNCT
dpc-3895	142	7	previous	previous	ADJ
dpc-3895	142	8	treatment	treatment	NOUN
dpc-3895	142	9	adjuvant	adjuvant	NOUN
dpc-3895	142	10	therapy	therapy	NOUN
dpc-3895	142	11	week	week	NOUN
dpc-3895	142	12	of	of	ADP
dpc-3895	142	13	treatment	treatment	NOUN
dpc-3895	142	14	reason	reason	NOUN
dpc-3895	142	15	for	for	ADP
dpc-3895	142	16	discontinuation	discontinuation	NOUN
dpc-3895	142	17	discontinuation	discontinuation	NOUN
dpc-3895	142	18	time	time	NOUN
dpc-3895	142	19	female	female	NOUN
dpc-3895	142	20	,	,	PUNCT
dpc-3895	142	21	76y	76y	NUM
dpc-3895	142	22	acitretin	acitretin	PROPN
dpc-3895	142	23	week	week	NOUN
dpc-3895	142	24	52	52	NUM
dpc-3895	142	25	loss	loss	NOUN
dpc-3895	142	26	of	of	ADP
dpc-3895	142	27	effectiveness	effectiveness	NOUN
dpc-3895	142	28	week	week	NOUN
dpc-3895	142	29	80	80	NUM
dpc-3895	142	30	male	male	NOUN
dpc-3895	142	31	,	,	PUNCT
dpc-3895	142	32	49y	49y	X
dpc-3895	142	33	ustekinumab	ustekinumab	NOUN
dpc-3895	142	34	topical	topical	ADJ
dpc-3895	142	35	steroids	steroid	NOUN
dpc-3895	142	36	week	week	NOUN
dpc-3895	142	37	24	24	NUM
dpc-3895	142	38	loss	loss	NOUN
dpc-3895	142	39	of	of	ADP
dpc-3895	142	40	effectiveness	effectiveness	NOUN
dpc-3895	142	41	week	week	NOUN
dpc-3895	142	42	52	52	NUM
dpc-3895	142	43	male	male	NOUN
dpc-3895	142	44	,	,	PUNCT
dpc-3895	142	45	55y	55y	NUM
dpc-3895	142	46	infliximab	infliximab	NOUN
dpc-3895	142	47	,	,	PUNCT
dpc-3895	142	48	ustekinumab	ustekinumab	ADJ
dpc-3895	142	49	topical	topical	ADJ
dpc-3895	142	50	steroids	steroid	NOUN
dpc-3895	142	51	week	week	NOUN
dpc-3895	142	52	48	48	NUM
dpc-3895	142	53	loss	loss	NOUN
dpc-3895	142	54	of	of	ADP
dpc-3895	142	55	effectiveness	effectiveness	NOUN
dpc-3895	142	56	week	week	NOUN
dpc-3895	142	57	112	112	NUM
dpc-3895	142	58	male	male	NOUN
dpc-3895	142	59	,	,	PUNCT
dpc-3895	142	60	52y	52y	X
dpc-3895	142	61	topical	topical	ADJ
dpc-3895	142	62	steroids	steroid	NOUN
dpc-3895	142	63	week	week	NOUN
dpc-3895	142	64	108	108	NUM
dpc-3895	142	65	loss	loss	NOUN
dpc-3895	142	66	of	of	ADP
dpc-3895	142	67	effectiveness	effectiveness	NOUN
dpc-3895	142	68	week	week	NOUN
dpc-3895	142	69	160	160	NUM
dpc-3895	142	70	male	male	NOUN
dpc-3895	142	71	,	,	PUNCT
dpc-3895	142	72	31y	31y	NOUN
dpc-3895	142	73	cyclosporine	cyclosporine	VERB
dpc-3895	142	74	topical	topical	ADJ
dpc-3895	142	75	steroids	steroid	NOUN
dpc-3895	142	76	week	week	NOUN
dpc-3895	142	77	52	52	NUM
dpc-3895	142	78	loss	loss	NOUN
dpc-3895	142	79	of	of	ADP
dpc-3895	142	80	effectiveness	effectiveness	NOUN
dpc-3895	142	81	week	week	NOUN
dpc-3895	142	82	108	108	NUM
dpc-3895	142	83	female	female	NOUN
dpc-3895	142	84	,	,	PUNCT
dpc-3895	142	85	59y	59y	NUM
dpc-3895	142	86	cyclosporine	cyclosporine	NOUN
dpc-3895	142	87	,	,	PUNCT
dpc-3895	142	88	infliximab	infliximab	PROPN
dpc-3895	142	89	methotrexate	methotrexate	PROPN
dpc-3895	142	90	,	,	PUNCT
dpc-3895	142	91	apremilast	apremilast	ADJ
dpc-3895	142	92	loss	loss	NOUN
dpc-3895	142	93	of	of	ADP
dpc-3895	142	94	effectiveness	effectiveness	NOUN
dpc-3895	142	95	week	week	NOUN
dpc-3895	142	96	70	70	NUM
dpc-3895	142	97	female	female	NOUN
dpc-3895	142	98	,	,	PUNCT
dpc-3895	142	99	53y	53y	NUM
dpc-3895	142	100	cyclosporine	cyclosporine	NOUN
dpc-3895	142	101	,	,	PUNCT
dpc-3895	142	102	acitretin	acitretin	ADJ
dpc-3895	142	103	topical	topical	ADJ
dpc-3895	142	104	steroids	steroid	NOUN
dpc-3895	142	105	week	week	NOUN
dpc-3895	142	106	52	52	NUM
dpc-3895	142	107	loss	loss	NOUN
dpc-3895	142	108	of	of	ADP
dpc-3895	142	109	effectiveness	effectiveness	NOUN
dpc-3895	142	110	week	week	NOUN
dpc-3895	142	111	120	120	NUM
dpc-3895	142	112	male	male	NOUN
dpc-3895	142	113	,	,	PUNCT
dpc-3895	142	114	55y	55y	X
dpc-3895	142	115	no	no	DET
dpc-3895	142	116	response	response	NOUN
dpc-3895	142	117	week	week	NOUN
dpc-3895	142	118	16	16	NUM
dpc-3895	142	119	female	female	NOUN
dpc-3895	142	120	,	,	PUNCT
dpc-3895	142	121	47	47	NUM
dpc-3895	142	122	ustekinumab	ustekinumab	NOUN
dpc-3895	142	123	,	,	PUNCT
dpc-3895	142	124	adalimumab	adalimumab	VERB
dpc-3895	142	125	no	no	DET
dpc-3895	142	126	response	response	NOUN
dpc-3895	142	127	week	week	NOUN
dpc-3895	142	128	16	16	NUM
dpc-3895	142	129	male	male	NOUN
dpc-3895	142	130	,	,	PUNCT
dpc-3895	142	131	52y	52y	NUM
dpc-3895	142	132	cyclosporine	cyclosporine	NOUN
dpc-3895	142	133	,	,	PUNCT
dpc-3895	142	134	infliximab	infliximab	PROPN
dpc-3895	142	135	,	,	PUNCT
dpc-3895	142	136	adalimumab	adalimumab	NOUN
dpc-3895	142	137	,	,	PUNCT
dpc-3895	142	138	methotrexate	methotrexate	NOUN
dpc-3895	143	1	methotrexate	methotrexate	NOUN
dpc-3895	143	2	week	week	NOUN
dpc-3895	143	3	0	0	PUNCT
dpc-3895	144	1	no	no	DET
dpc-3895	144	2	response	response	NOUN
dpc-3895	144	3	week	week	NOUN
dpc-3895	144	4	20	20	NUM
dpc-3895	144	5	male	male	NOUN
dpc-3895	144	6	,	,	PUNCT
dpc-3895	144	7	42y	42y	NOUN
dpc-3895	144	8	ulcerative	ulcerative	ADJ
dpc-3895	144	9	colitis	colitis	NOUN
dpc-3895	144	10	week	week	NOUN
dpc-3895	144	11	152	152	NUM
dpc-3895	144	12	original	original	ADJ
dpc-3895	144	13	article	article	NOUN
dpc-3895	144	14	|	|	ADV
dpc-3895	144	15	dermatol	dermatol	ADJ
dpc-3895	144	16	pract	pract	NOUN
dpc-3895	144	17	concept	concept	NOUN
dpc-3895	144	18	.	.	PUNCT
dpc-3895	145	1	2024;14(2):e2024119	2024;14(2):e2024119	NUM
dpc-3895	145	2	7	7	NUM
dpc-3895	145	3	according	accord	VERB
dpc-3895	145	4	to	to	ADP
dpc-3895	145	5	our	our	PRON
dpc-3895	145	6	outcomes	outcome	NOUN
dpc-3895	145	7	,	,	PUNCT
dpc-3895	145	8	secukinumab	secukinumab	NOUN
dpc-3895	145	9	is	be	AUX
dpc-3895	145	10	an	an	DET
dpc-3895	145	11	effective	effective	ADJ
dpc-3895	145	12	treatment	treatment	NOUN
dpc-3895	145	13	choice	choice	NOUN
dpc-3895	145	14	for	for	ADP
dpc-3895	145	15	treating	treat	VERB
dpc-3895	145	16	chronic	chronic	ADJ
dpc-3895	145	17	plaque	plaque	NOUN
dpc-3895	145	18	psoriasis	psoriasis	NOUN
dpc-3895	145	19	,	,	PUNCT
dpc-3895	145	20	but	but	CCONJ
dpc-3895	145	21	,	,	PUNCT
dpc-3895	145	22	additionally	additionally	ADV
dpc-3895	145	23	,	,	PUNCT
dpc-3895	145	24	it	it	PRON
dpc-3895	145	25	can	can	AUX
dpc-3895	145	26	be	be	AUX
dpc-3895	145	27	efficacious	efficacious	ADJ
dpc-3895	145	28	in	in	ADP
dpc-3895	145	29	the	the	DET
dpc-3895	145	30	subgroups	subgroup	NOUN
dpc-3895	145	31	of	of	ADP
dpc-3895	145	32	patients	patient	NOUN
dpc-3895	145	33	with	with	ADP
dpc-3895	145	34	difficult	difficult	ADJ
dpc-3895	145	35	-	-	PUNCT
dpc-3895	145	36	to	to	ADP
dpc-3895	145	37	-	-	PUNCT
dpc-3895	145	38	treat	treat	NOUN
dpc-3895	145	39	manifestations	manifestation	NOUN
dpc-3895	145	40	.	.	PUNCT
dpc-3895	146	1	especially	especially	ADV
dpc-3895	146	2	,	,	PUNCT
dpc-3895	146	3	regarding	regard	VERB
dpc-3895	146	4	lesions	lesion	NOUN
dpc-3895	146	5	at	at	ADP
dpc-3895	146	6	the	the	DET
dpc-3895	146	7	genital	genital	ADJ
dpc-3895	146	8	area	area	NOUN
dpc-3895	146	9	,	,	PUNCT
dpc-3895	146	10	as	as	ADV
dpc-3895	146	11	well	well	ADV
dpc-3895	146	12	as	as	ADP
dpc-3895	146	13	psoriasis	psoriasis	NOUN
dpc-3895	146	14	inversa	inversa	NOUN
dpc-3895	146	15	,	,	PUNCT
dpc-3895	146	16	patients	patient	NOUN
dpc-3895	146	17	in	in	ADP
dpc-3895	146	18	our	our	PRON
dpc-3895	146	19	study	study	NOUN
dpc-3895	146	20	experienced	experience	VERB
dpc-3895	146	21	a	a	DET
dpc-3895	146	22	great	great	ADJ
dpc-3895	146	23	improvement	improvement	NOUN
dpc-3895	146	24	and	and	CCONJ
dpc-3895	146	25	this	this	PRON
dpc-3895	146	26	occurred	occur	VERB
dpc-3895	146	27	rapidly	rapidly	ADV
dpc-3895	146	28	at	at	ADP
dpc-3895	146	29	a	a	DET
dpc-3895	146	30	mean	mean	ADJ
dpc-3895	146	31	time	time	NOUN
dpc-3895	146	32	of	of	ADP
dpc-3895	146	33	5	5	NUM
dpc-3895	146	34	weeks	week	NOUN
dpc-3895	146	35	after	after	ADP
dpc-3895	146	36	therapy	therapy	NOUN
dpc-3895	146	37	initiation	initiation	NOUN
dpc-3895	146	38	.	.	PUNCT
dpc-3895	147	1	in	in	ADP
dpc-3895	147	2	addition	addition	NOUN
dpc-3895	147	3	,	,	PUNCT
dpc-3895	147	4	the	the	DET
dpc-3895	147	5	already	already	ADV
dpc-3895	147	6	well	well	ADV
dpc-3895	147	7	described	describe	VERB
dpc-3895	147	8	advantageous	advantageous	ADJ
dpc-3895	147	9	safety	safety	NOUN
dpc-3895	147	10	profile	profile	NOUN
dpc-3895	147	11	of	of	ADP
dpc-3895	147	12	secukinumab	secukinumab	NOUN
dpc-3895	147	13	is	be	AUX
dpc-3895	147	14	confirmed	confirm	VERB
dpc-3895	147	15	by	by	ADP
dpc-3895	147	16	the	the	DET
dpc-3895	147	17	results	result	NOUN
dpc-3895	147	18	of	of	ADP
dpc-3895	147	19	this	this	DET
dpc-3895	147	20	study	study	NOUN
dpc-3895	147	21	,	,	PUNCT
dpc-3895	147	22	since	since	SCONJ
dpc-3895	147	23	we	we	PRON
dpc-3895	147	24	did	do	AUX
dpc-3895	147	25	not	not	PART
dpc-3895	147	26	report	report	VERB
dpc-3895	147	27	any	any	DET
dpc-3895	147	28	serious	serious	ADJ
dpc-3895	147	29	adverse	adverse	ADJ
dpc-3895	147	30	events	event	NOUN
dpc-3895	147	31	during	during	ADP
dpc-3895	147	32	the	the	DET
dpc-3895	147	33	208	208	NUM
dpc-3895	147	34	weeks	week	NOUN
dpc-3895	147	35	observational	observational	ADJ
dpc-3895	147	36	period	period	NOUN
dpc-3895	147	37	.	.	PUNCT
dpc-3895	148	1	consequently	consequently	ADV
dpc-3895	148	2	,	,	PUNCT
dpc-3895	148	3	this	this	DET
dpc-3895	148	4	real	real	ADJ
dpc-3895	148	5	-	-	PUNCT
dpc-3895	148	6	life	life	NOUN
dpc-3895	148	7	study	study	NOUN
dpc-3895	148	8	offers	offer	VERB
dpc-3895	148	9	information	information	NOUN
dpc-3895	148	10	about	about	ADP
dpc-3895	148	11	clinical	clinical	ADJ
dpc-3895	148	12	efficacy	efficacy	NOUN
dpc-3895	148	13	,	,	PUNCT
dpc-3895	148	14	retention	retention	NOUN
dpc-3895	148	15	and	and	CCONJ
dpc-3895	148	16	safety	safety	NOUN
dpc-3895	148	17	profile	profile	NOUN
dpc-3895	148	18	of	of	ADP
dpc-3895	148	19	secukinumab	secukinumab	NOUN
dpc-3895	148	20	in	in	ADP
dpc-3895	148	21	patients	patient	NOUN
dpc-3895	148	22	from	from	ADP
dpc-3895	148	23	everyday	everyday	ADJ
dpc-3895	148	24	clinical	clinical	ADJ
dpc-3895	148	25	practice	practice	NOUN
dpc-3895	148	26	over	over	ADP
dpc-3895	148	27	a	a	DET
dpc-3895	148	28	long	long	ADJ
dpc-3895	148	29	-	-	PUNCT
dpc-3895	148	30	term	term	NOUN
dpc-3895	148	31	,	,	PUNCT
dpc-3895	148	32	4	4	NUM
dpc-3895	148	33	-	-	PUNCT
dpc-3895	148	34	year	year	NOUN
dpc-3895	148	35	,	,	PUNCT
dpc-3895	148	36	follow	follow	VERB
dpc-3895	148	37	-	-	PUNCT
dpc-3895	148	38	up	up	NOUN
dpc-3895	148	39	period	period	NOUN
dpc-3895	148	40	in	in	ADP
dpc-3895	148	41	greece	greece	PROPN
dpc-3895	148	42	.	.	PUNCT
dpc-3895	149	1	acknowledgement	acknowledgement	NOUN
dpc-3895	149	2	:	:	PUNCT
dpc-3895	149	3	this	this	DET
dpc-3895	149	4	study	study	NOUN
dpc-3895	149	5	was	be	AUX
dpc-3895	149	6	conducted	conduct	VERB
dpc-3895	149	7	in	in	ADP
dpc-3895	149	8	collaboration	collaboration	NOUN
dpc-3895	149	9	with	with	ADP
dpc-3895	149	10	novartis	novartis	PROPN
dpc-3895	149	11	,	,	PUNCT
dpc-3895	149	12	greece	greece	PROPN
dpc-3895	149	13	.	.	PUNCT
dpc-3895	150	1	references	reference	NOUN
dpc-3895	150	2	1	1	NUM
dpc-3895	150	3	.	.	PUNCT
dpc-3895	150	4	rachakonda	rachakonda	ADJ
dpc-3895	150	5	td	td	PROPN
dpc-3895	150	6	,	,	PUNCT
dpc-3895	150	7	schupp	schupp	PROPN
dpc-3895	150	8	cw	cw	PROPN
dpc-3895	150	9	,	,	PUNCT
dpc-3895	150	10	armstrong	armstrong	PROPN
dpc-3895	150	11	aw	aw	INTJ
dpc-3895	150	12	.	.	PUNCT
dpc-3895	150	13	psoriasis	psoriasis	NOUN
dpc-3895	150	14	prevalence	prevalence	NOUN
dpc-3895	150	15	among	among	ADP
dpc-3895	150	16	adults	adult	NOUN
dpc-3895	150	17	in	in	ADP
dpc-3895	150	18	the	the	DET
dpc-3895	150	19	united	united	PROPN
dpc-3895	150	20	states	states	PROPN
dpc-3895	150	21	.	.	PUNCT
dpc-3895	151	1	j	j	PROPN
dpc-3895	151	2	am	be	AUX
dpc-3895	151	3	acad	acad	ADJ
dpc-3895	151	4	dermatol	dermatol	NOUN
dpc-3895	151	5	.	.	PUNCT
dpc-3895	152	1	2014;70(3):512	2014;70(3):512	NUM
dpc-3895	152	2	-	-	SYM
dpc-3895	152	3	516	516	NUM
dpc-3895	152	4	.	.	PUNCT
dpc-3895	153	1	doi	doi	NOUN
dpc-3895	153	2	:	:	PUNCT
dpc-3895	153	3	10.1016	10.1016	NUM
dpc-3895	153	4	/	/	SYM
dpc-3895	153	5	j.jaad.2013.11.013	j.jaad.2013.11.013	PROPN
dpc-3895	153	6	.	.	PUNCT
dpc-3895	154	1	pmid	pmid	NOUN
dpc-3895	154	2	:	:	PUNCT
dpc-3895	154	3	24388724	24388724	NUM
dpc-3895	154	4	.	.	PUNCT
dpc-3895	155	1	2	2	X
dpc-3895	155	2	.	.	X
dpc-3895	155	3	dopytalska	dopytalska	PROPN
dpc-3895	155	4	k	k	PROPN
dpc-3895	155	5	,	,	PUNCT
dpc-3895	155	6	sobolewski	sobolewski	ADJ
dpc-3895	155	7	p	p	NOUN
dpc-3895	155	8	,	,	PUNCT
dpc-3895	155	9	błaszczak	błaszczak	NOUN
dpc-3895	155	10	a	a	NOUN
dpc-3895	155	11	,	,	PUNCT
dpc-3895	155	12	szymańska	szymańska	ADJ
dpc-3895	155	13	e	e	NOUN
dpc-3895	155	14	,	,	PUNCT
dpc-3895	155	15	walecka	walecka	NOUN
dpc-3895	155	16	i.	i.	NOUN
dpc-3895	155	17	psoriasis	psoriasis	NOUN
dpc-3895	155	18	in	in	ADP
dpc-3895	155	19	special	special	ADJ
dpc-3895	155	20	localizations	localization	NOUN
dpc-3895	155	21	.	.	PUNCT
dpc-3895	156	1	reumatologia	reumatologia	NOUN
dpc-3895	156	2	.	.	PUNCT
dpc-3895	157	1	2018;56(6):392	2018;56(6):392	NUM
dpc-3895	157	2	-	-	SYM
dpc-3895	157	3	398	398	NUM
dpc-3895	157	4	.	.	PUNCT
dpc-3895	158	1	doi	doi	NOUN
dpc-3895	158	2	:	:	PUNCT
dpc-3895	158	3	10.5114	10.5114	NUM
dpc-3895	158	4	/	/	SYM
dpc-3895	158	5	reum.2018.80718	reum.2018.80718	NOUN
dpc-3895	158	6	.	.	PUNCT
dpc-3895	159	1	pmid	pmid	NOUN
dpc-3895	159	2	:	:	PUNCT
dpc-3895	159	3	30647487	30647487	NUM
dpc-3895	159	4	.	.	PUNCT
dpc-3895	160	1	pmcid	pmcid	NOUN
dpc-3895	160	2	:	:	PUNCT
dpc-3895	160	3	pmc6330687	pmc6330687	NOUN
dpc-3895	160	4	.	.	PUNCT
dpc-3895	161	1	3	3	X
dpc-3895	161	2	.	.	X
dpc-3895	161	3	hong	hong	PROPN
dpc-3895	161	4	jj	jj	PROPN
dpc-3895	161	5	,	,	PUNCT
dpc-3895	161	6	mosca	mosca	PROPN
dpc-3895	161	7	ml	ml	PROPN
dpc-3895	161	8	,	,	PUNCT
dpc-3895	161	9	hadeler	hadeler	PROPN
dpc-3895	161	10	ek	ek	PROPN
dpc-3895	161	11	,	,	PUNCT
dpc-3895	161	12	brownstone	brownstone	NOUN
dpc-3895	161	13	nd	nd	PRON
dpc-3895	161	14	,	,	PUNCT
dpc-3895	161	15	bhutani	bhutani	PROPN
dpc-3895	161	16	t	t	PROPN
dpc-3895	161	17	,	,	PUNCT
dpc-3895	161	18	liao	liao	PROPN
dpc-3895	161	19	wj	wj	PROPN
dpc-3895	161	20	.	.	PUNCT
dpc-3895	162	1	genital	genital	ADJ
dpc-3895	162	2	and	and	CCONJ
dpc-3895	162	3	inverse	inverse	ADJ
dpc-3895	162	4	/	/	SYM
dpc-3895	162	5	intertriginous	intertriginous	ADJ
dpc-3895	162	6	psoriasis	psoriasis	NOUN
dpc-3895	162	7	:	:	PUNCT
dpc-3895	162	8	an	an	DET
dpc-3895	162	9	updated	update	VERB
dpc-3895	162	10	review	review	NOUN
dpc-3895	162	11	of	of	ADP
dpc-3895	162	12	therapies	therapy	NOUN
dpc-3895	162	13	and	and	CCONJ
dpc-3895	162	14	recommendations	recommendation	NOUN
dpc-3895	162	15	for	for	ADP
dpc-3895	162	16	practical	practical	ADJ
dpc-3895	162	17	management	management	NOUN
dpc-3895	162	18	.	.	PUNCT
dpc-3895	163	1	dermatol	dermatol	NOUN
dpc-3895	163	2	ther	ther	ADV
dpc-3895	163	3	(	(	PUNCT
dpc-3895	163	4	heidelb	heidelb	NOUN
dpc-3895	163	5	)	)	PUNCT
dpc-3895	163	6	.	.	PUNCT
dpc-3895	164	1	2021;11(3):833	2021;11(3):833	NUM
dpc-3895	164	2	-	-	SYM
dpc-3895	164	3	844	844	NUM
dpc-3895	164	4	.	.	PUNCT
dpc-3895	165	1	doi	doi	NOUN
dpc-3895	165	2	:	:	PUNCT
dpc-3895	165	3	10.1007	10.1007	NUM
dpc-3895	165	4	/	/	SYM
dpc-3895	165	5	s13555	s13555	PROPN
dpc-3895	165	6	-	-	PUNCT
dpc-3895	165	7	021	021	NUM
dpc-3895	165	8	-	-	PUNCT
dpc-3895	165	9	00536	00536	NUM
dpc-3895	165	10	-	-	PUNCT
dpc-3895	165	11	6	6	NUM
dpc-3895	165	12	.	.	PUNCT
dpc-3895	166	1	pmid	pmid	NOUN
dpc-3895	166	2	:	:	PUNCT
dpc-3895	166	3	33914293	33914293	NUM
dpc-3895	166	4	.	.	PUNCT
dpc-3895	167	1	pmcid	pmcid	ADJ
dpc-3895	167	2	:	:	PUNCT
dpc-3895	167	3	pmc8163914	pmc8163914	NOUN
dpc-3895	167	4	.	.	PUNCT
dpc-3895	168	1	4	4	X
dpc-3895	168	2	.	.	X
dpc-3895	168	3	blauvelt	blauvelt	VERB
dpc-3895	168	4	a	a	PRON
dpc-3895	168	5	,	,	PUNCT
dpc-3895	168	6	prinz	prinz	PROPN
dpc-3895	168	7	jc	jc	PROPN
dpc-3895	168	8	,	,	PUNCT
dpc-3895	168	9	gottlieb	gottlieb	PROPN
dpc-3895	168	10	ab	ab	PROPN
dpc-3895	168	11	,	,	PUNCT
dpc-3895	168	12	et	et	PROPN
dpc-3895	168	13	al	al	PROPN
dpc-3895	168	14	.	.	PROPN
dpc-3895	168	15	secukinumab	secukinumab	PROPN
dpc-3895	168	16	administration	administration	PROPN
dpc-3895	168	17	by	by	ADP
dpc-3895	168	18	pre	pre	ADJ
dpc-3895	168	19	-	-	ADJ
dpc-3895	168	20	filled	filled	ADJ
dpc-3895	168	21	syringe	syringe	NOUN
dpc-3895	168	22	:	:	PUNCT
dpc-3895	168	23	efficacy	efficacy	NOUN
dpc-3895	168	24	,	,	PUNCT
dpc-3895	168	25	safety	safety	NOUN
dpc-3895	168	26	and	and	CCONJ
dpc-3895	168	27	usability	usability	NOUN
dpc-3895	168	28	results	result	NOUN
dpc-3895	168	29	from	from	ADP
dpc-3895	168	30	a	a	DET
dpc-3895	168	31	randomized	randomized	ADJ
dpc-3895	168	32	controlled	control	VERB
dpc-3895	168	33	trial	trial	NOUN
dpc-3895	168	34	in	in	ADP
dpc-3895	168	35	psoriasis	psoriasis	NOUN
dpc-3895	168	36	(	(	PUNCT
dpc-3895	168	37	feature	feature	NOUN
dpc-3895	168	38	)	)	PUNCT
dpc-3895	168	39	.	.	PUNCT
dpc-3895	169	1	br	br	PROPN
dpc-3895	169	2	j	j	PROPN
dpc-3895	169	3	dermatol	dermatol	NOUN
dpc-3895	169	4	.	.	PUNCT
dpc-3895	170	1	2015;172(2):484	2015;172(2):484	NOUN
dpc-3895	170	2	-	-	SYM
dpc-3895	170	3	493	493	NUM
dpc-3895	170	4	.	.	PUNCT
dpc-3895	171	1	doi	doi	NOUN
dpc-3895	171	2	:	:	PUNCT
dpc-3895	171	3	10.1111	10.1111	NUM
dpc-3895	171	4	/	/	SYM
dpc-3895	171	5	bjd.13348	bjd.13348	NOUN
dpc-3895	171	6	.	.	PUNCT
dpc-3895	172	1	pmid	pmid	NOUN
dpc-3895	172	2	:	:	PUNCT
dpc-3895	172	3	25132411	25132411	NUM
dpc-3895	172	4	.	.	PUNCT
dpc-3895	173	1	5	5	X
dpc-3895	173	2	.	.	X
dpc-3895	173	3	lee	lee	PROPN
dpc-3895	173	4	jh	jh	PROPN
dpc-3895	173	5	,	,	PUNCT
dpc-3895	173	6	morita	morita	PROPN
dpc-3895	173	7	a	a	PROPN
dpc-3895	173	8	,	,	PUNCT
dpc-3895	173	9	tsai	tsai	PROPN
dpc-3895	173	10	tf	tf	X
dpc-3895	173	11	,	,	PUNCT
dpc-3895	173	12	et	et	PROPN
dpc-3895	173	13	al	al	PROPN
dpc-3895	173	14	.	.	PROPN
dpc-3895	173	15	secukinumab	secukinumab	PROPN
dpc-3895	173	16	efficacy	efficacy	PROPN
dpc-3895	173	17	and	and	CCONJ
dpc-3895	173	18	safety	safety	NOUN
dpc-3895	173	19	in	in	ADP
dpc-3895	173	20	asian	asian	ADJ
dpc-3895	173	21	subjects	subject	NOUN
dpc-3895	173	22	with	with	ADP
dpc-3895	173	23	moderate	moderate	ADJ
dpc-3895	173	24	to	to	ADP
dpc-3895	173	25	severe	severe	ADJ
dpc-3895	173	26	plaque	plaque	NOUN
dpc-3895	173	27	psoriasis	psoriasis	NOUN
dpc-3895	173	28	:	:	PUNCT
dpc-3895	173	29	pooled	pool	VERB
dpc-3895	173	30	analysis	analysis	NOUN
dpc-3895	173	31	from	from	ADP
dpc-3895	173	32	the	the	DET
dpc-3895	173	33	fixture	fixture	NOUN
dpc-3895	173	34	and	and	CCONJ
dpc-3895	173	35	erasure	erasure	VERB
dpc-3895	173	36	phase	phase	NOUN
dpc-3895	173	37	iii	iii	NUM
dpc-3895	173	38	clinical	clinical	ADJ
dpc-3895	173	39	studies	study	NOUN
dpc-3895	173	40	.	.	PUNCT
dpc-3895	174	1	journal	journal	PROPN
dpc-3895	174	2	of	of	ADP
dpc-3895	174	3	the	the	DET
dpc-3895	174	4	american	american	PROPN
dpc-3895	174	5	academy	academy	PROPN
dpc-3895	174	6	of	of	ADP
dpc-3895	174	7	dermatology	dermatology	NOUN
dpc-3895	174	8	.	.	PUNCT
dpc-3895	175	1	psoriasis	psoriasis	NOUN
dpc-3895	175	2	and	and	CCONJ
dpc-3895	175	3	other	other	ADJ
dpc-3895	175	4	papulosquamous	papulosquamous	ADJ
dpc-3895	175	5	disorders	disorder	NOUN
dpc-3895	175	6	;	;	PUNCT
dpc-3895	175	7	2015;72(5	2015;72(5	NUM
dpc-3895	175	8	):	):	PUNCT
dpc-3895	175	9	supplement	supplement	NOUN
dpc-3895	175	10	1	1	NUM
dpc-3895	175	11	,	,	PUNCT
dpc-3895	175	12	ab249	ab249	PROPN
dpc-3895	175	13	.	.	PUNCT
dpc-3895	176	1	doi	doi	PROPN
dpc-3895	176	2	:	:	PUNCT
dpc-3895	176	3	10.1016	10.1016	NUM
dpc-3895	176	4	/j.jaad.2015.02.994	/j.jaad.2015.02.994	X
dpc-3895	176	5	.	.	PUNCT
dpc-3895	177	1	6	6	NUM
dpc-3895	177	2	.	.	X
dpc-3895	177	3	rrompoti	rrompoti	PROPN
dpc-3895	177	4	n	n	PRON
dpc-3895	177	5	,	,	PUNCT
dpc-3895	177	6	katsimbri	katsimbri	PROPN
dpc-3895	177	7	p	p	PROPN
dpc-3895	177	8	,	,	PUNCT
dpc-3895	177	9	kokkalis	kokkalis	PROPN
dpc-3895	177	10	g	g	PROPN
dpc-3895	177	11	,	,	PUNCT
dpc-3895	177	12	et	et	PROPN
dpc-3895	177	13	al	al	PROPN
dpc-3895	177	14	.	.	PUNCT
dpc-3895	178	1	real	real	ADJ
dpc-3895	178	2	world	world	NOUN
dpc-3895	178	3	data	datum	NOUN
dpc-3895	178	4	from	from	ADP
dpc-3895	178	5	the	the	DET
dpc-3895	178	6	use	use	NOUN
dpc-3895	178	7	of	of	ADP
dpc-3895	178	8	secukinumab	secukinumab	NOUN
dpc-3895	178	9	in	in	ADP
dpc-3895	178	10	the	the	DET
dpc-3895	178	11	treatment	treatment	NOUN
dpc-3895	178	12	of	of	ADP
dpc-3895	178	13	moderate	moderate	ADJ
dpc-3895	178	14	-	-	PUNCT
dpc-3895	178	15	to	to	ADP
dpc-3895	178	16	severe	severe	ADJ
dpc-3895	178	17	psoriasis	psoriasis	NOUN
dpc-3895	178	18	,	,	PUNCT
dpc-3895	178	19	including	include	VERB
dpc-3895	178	20	scalp	scalp	NOUN
dpc-3895	178	21	and	and	CCONJ
dpc-3895	178	22	palmoplantar	palmoplantar	NOUN
dpc-3895	178	23	psoriasis	psoriasis	NOUN
dpc-3895	178	24	:	:	PUNCT
dpc-3895	178	25	a	a	DET
dpc-3895	178	26	104	104	NUM
dpc-3895	178	27	-	-	PUNCT
dpc-3895	178	28	week	week	NOUN
dpc-3895	178	29	clinical	clinical	ADJ
dpc-3895	178	30	study	study	NOUN
dpc-3895	178	31	.	.	PUNCT
dpc-3895	179	1	dermatol	dermatol	NOUN
dpc-3895	179	2	ther	ther	ADV
dpc-3895	179	3	.	.	PUNCT
dpc-3895	180	1	2019;32(5):e13006	2019;32(5):e13006	X
dpc-3895	180	2	.	.	PUNCT
dpc-3895	180	3	doi	doi	NOUN
dpc-3895	180	4	:	:	PUNCT
dpc-3895	180	5	10.1111	10.1111	NUM
dpc-3895	180	6	/	/	SYM
dpc-3895	180	7	dth.13006	dth.13006	NOUN
dpc-3895	180	8	.	.	PUNCT
dpc-3895	181	1	pmid	pmid	NOUN
dpc-3895	181	2	:	:	PUNCT
dpc-3895	181	3	31228319	31228319	NUM
dpc-3895	181	4	.	.	PUNCT
dpc-3895	182	1	7	7	NUM
dpc-3895	182	2	.	.	X
dpc-3895	182	3	b	b	X
dpc-3895	182	4	bai	bai	PROPN
dpc-3895	182	5	f	f	PROPN
dpc-3895	182	6	,	,	PUNCT
dpc-3895	182	7	li	li	PROPN
dpc-3895	182	8	gg	gg	PROPN
dpc-3895	182	9	,	,	PUNCT
dpc-3895	182	10	liu	liu	PROPN
dpc-3895	182	11	q	q	PROPN
dpc-3895	182	12	,	,	PUNCT
dpc-3895	182	13	niu	niu	PROPN
dpc-3895	182	14	x	x	PROPN
dpc-3895	182	15	,	,	PUNCT
dpc-3895	182	16	li	li	PROPN
dpc-3895	182	17	r	r	PROPN
dpc-3895	182	18	,	,	PUNCT
dpc-3895	182	19	ma	ma	PROPN
dpc-3895	182	20	h.	h.	PROPN
dpc-3895	182	21	short	short	ADJ
dpc-3895	182	22	-	-	PUNCT
dpc-3895	182	23	term	term	NOUN
dpc-3895	182	24	efficacy	efficacy	NOUN
dpc-3895	182	25	and	and	CCONJ
dpc-3895	182	26	safety	safety	NOUN
dpc-3895	182	27	of	of	ADP
dpc-3895	182	28	il-17	il-17	PRON
dpc-3895	182	29	,	,	PUNCT
dpc-3895	182	30	il-12/23	il-12/23	PROPN
dpc-3895	182	31	,	,	PUNCT
dpc-3895	182	32	and	and	CCONJ
dpc-3895	182	33	il-23	il-23	NOUN
dpc-3895	182	34	inhibitors	inhibitor	NOUN
dpc-3895	182	35	brodalumab	brodalumab	VERB
dpc-3895	182	36	,	,	PUNCT
dpc-3895	182	37	secukinumab	secukinumab	NOUN
dpc-3895	182	38	,	,	PUNCT
dpc-3895	182	39	ixekizumab	ixekizumab	NOUN
dpc-3895	182	40	,	,	PUNCT
dpc-3895	182	41	ustekinumab	ustekinumab	NOUN
dpc-3895	182	42	,	,	PUNCT
dpc-3895	182	43	guselkumab	guselkumab	NOUN
dpc-3895	182	44	,	,	PUNCT
dpc-3895	182	45	tildrakizumab	tildrakizumab	NOUN
dpc-3895	182	46	,	,	PUNCT
dpc-3895	182	47	and	and	CCONJ
dpc-3895	182	48	risankizumab	risankizumab	VERB
dpc-3895	182	49	for	for	ADP
dpc-3895	182	50	the	the	DET
dpc-3895	182	51	treatment	treatment	NOUN
dpc-3895	182	52	of	of	ADP
dpc-3895	182	53	moderate	moderate	ADJ
dpc-3895	182	54	to	to	ADP
dpc-3895	182	55	severe	severe	ADJ
dpc-3895	182	56	plaque	plaque	NOUN
dpc-3895	182	57	psoriasis	psoriasis	NOUN
dpc-3895	182	58	:	:	PUNCT
dpc-3895	182	59	a	a	DET
dpc-3895	182	60	systematic	systematic	ADJ
dpc-3895	182	61	review	review	NOUN
dpc-3895	182	62	and	and	CCONJ
dpc-3895	182	63	network	network	NOUN
dpc-3895	182	64	secondary	secondary	ADJ
dpc-3895	182	65	involvement	involvement	NOUN
dpc-3895	182	66	.	.	PUNCT
dpc-3895	183	1	burlando	burlando	NOUN
dpc-3895	183	2	et	et	PROPN
dpc-3895	183	3	al	al	PROPN
dpc-3895	183	4	recently	recently	ADV
dpc-3895	183	5	presented	present	VERB
dpc-3895	183	6	the	the	DET
dpc-3895	183	7	superiority	superiority	NOUN
dpc-3895	183	8	of	of	ADP
dpc-3895	183	9	anti	anti	ADJ
dpc-3895	183	10	-	-	ADJ
dpc-3895	183	11	il17	il17	ADJ
dpc-3895	183	12	antibodies	antibodie	VERB
dpc-3895	183	13	,	,	PUNCT
dpc-3895	183	14	in	in	ADP
dpc-3895	183	15	comparison	comparison	NOUN
dpc-3895	183	16	to	to	ADP
dpc-3895	183	17	anti	anti	ADJ
dpc-3895	183	18	-	-	NOUN
dpc-3895	183	19	il12/23	il12/23	ADJ
dpc-3895	183	20	and	and	CCONJ
dpc-3895	183	21	anti	anti	ADJ
dpc-3895	183	22	-	-	ADJ
dpc-3895	183	23	tnfα	tnfα	ADJ
dpc-3895	183	24	drugs	drug	NOUN
dpc-3895	183	25	,	,	PUNCT
dpc-3895	183	26	in	in	ADP
dpc-3895	183	27	improving	improve	VERB
dpc-3895	183	28	genital	genital	ADJ
dpc-3895	183	29	psoriasis	psoriasis	NOUN
dpc-3895	183	30	in	in	ADP
dpc-3895	183	31	a	a	DET
dpc-3895	183	32	small	small	ADJ
dpc-3895	183	33	group	group	NOUN
dpc-3895	183	34	of	of	ADP
dpc-3895	183	35	female	female	ADJ
dpc-3895	183	36	patients	patient	NOUN
dpc-3895	183	37	[	[	X
dpc-3895	183	38	16	16	NUM
dpc-3895	183	39	]	]	PUNCT
dpc-3895	183	40	.	.	PUNCT
dpc-3895	184	1	with	with	ADP
dpc-3895	184	2	regard	regard	NOUN
dpc-3895	184	3	to	to	ADP
dpc-3895	184	4	drug	drug	NOUN
dpc-3895	184	5	retention	retention	NOUN
dpc-3895	184	6	,	,	PUNCT
dpc-3895	184	7	we	we	PRON
dpc-3895	184	8	report	report	VERB
dpc-3895	184	9	only	only	ADV
dpc-3895	184	10	11	11	NUM
dpc-3895	184	11	patients	patient	NOUN
dpc-3895	184	12	that	that	PRON
dpc-3895	184	13	had	have	VERB
dpc-3895	184	14	to	to	PART
dpc-3895	184	15	discontinue	discontinue	VERB
dpc-3895	184	16	the	the	DET
dpc-3895	184	17	treatment	treatment	NOUN
dpc-3895	184	18	.	.	PUNCT
dpc-3895	185	1	seven	seven	NUM
dpc-3895	185	2	patients	patient	NOUN
dpc-3895	185	3	lost	lose	VERB
dpc-3895	185	4	pasi75	pasi75	NOUN
dpc-3895	185	5	within	within	ADP
dpc-3895	185	6	more	more	ADJ
dpc-3895	185	7	than	than	ADP
dpc-3895	185	8	2	2	NUM
dpc-3895	185	9	years	year	NOUN
dpc-3895	185	10	of	of	ADP
dpc-3895	185	11	treatment	treatment	NOUN
dpc-3895	185	12	and	and	CCONJ
dpc-3895	185	13	lost	lose	VERB
dpc-3895	185	14	its	its	PRON
dpc-3895	185	15	effectiveness	effectiveness	NOUN
dpc-3895	185	16	.	.	PUNCT
dpc-3895	186	1	three	three	NUM
dpc-3895	186	2	patients	patient	NOUN
dpc-3895	186	3	had	have	VERB
dpc-3895	186	4	to	to	PART
dpc-3895	186	5	switch	switch	VERB
dpc-3895	186	6	to	to	ADP
dpc-3895	186	7	other	other	ADJ
dpc-3895	186	8	therapies	therapy	NOUN
dpc-3895	186	9	because	because	SCONJ
dpc-3895	186	10	they	they	PRON
dpc-3895	186	11	did	do	AUX
dpc-3895	186	12	not	not	PART
dpc-3895	186	13	respond	respond	VERB
dpc-3895	186	14	to	to	ADP
dpc-3895	186	15	the	the	DET
dpc-3895	186	16	drug	drug	NOUN
dpc-3895	186	17	by	by	ADP
dpc-3895	186	18	week	week	NOUN
dpc-3895	186	19	16	16	NUM
dpc-3895	186	20	(	(	PUNCT
dpc-3895	186	21	table	table	NOUN
dpc-3895	186	22	 	 	SPACE
dpc-3895	186	23	3	3	NUM
dpc-3895	186	24	)	)	PUNCT
dpc-3895	186	25	.	.	PUNCT
dpc-3895	187	1	these	these	DET
dpc-3895	187	2	results	result	NOUN
dpc-3895	187	3	adhere	adhere	VERB
dpc-3895	187	4	to	to	ADP
dpc-3895	187	5	what	what	PRON
dpc-3895	187	6	has	have	AUX
dpc-3895	187	7	been	be	AUX
dpc-3895	187	8	presented	present	VERB
dpc-3895	187	9	in	in	ADP
dpc-3895	187	10	other	other	ADJ
dpc-3895	187	11	real	real	ADJ
dpc-3895	187	12	-	-	PUNCT
dpc-3895	187	13	world	world	NOUN
dpc-3895	187	14	studies	study	NOUN
dpc-3895	187	15	assessing	assess	VERB
dpc-3895	187	16	psoriasis	psoriasis	NOUN
dpc-3895	187	17	patients	patient	NOUN
dpc-3895	187	18	treated	treat	VERB
dpc-3895	187	19	with	with	ADP
dpc-3895	187	20	secukinumab	secukinumab	NOUN
dpc-3895	187	21	[	[	X
dpc-3895	187	22	6,10,17].additionally	6,10,17].additionally	ADV
dpc-3895	187	23	,	,	PUNCT
dpc-3895	187	24	it	it	PRON
dpc-3895	187	25	needs	need	VERB
dpc-3895	187	26	to	to	PART
dpc-3895	187	27	be	be	AUX
dpc-3895	187	28	mentioned	mention	VERB
dpc-3895	187	29	that	that	SCONJ
dpc-3895	187	30	,	,	PUNCT
dpc-3895	187	31	in	in	ADP
dpc-3895	187	32	our	our	PRON
dpc-3895	187	33	study	study	NOUN
dpc-3895	187	34	,	,	PUNCT
dpc-3895	187	35	almost	almost	ADV
dpc-3895	187	36	half	half	NOUN
dpc-3895	187	37	of	of	ADP
dpc-3895	187	38	the	the	DET
dpc-3895	187	39	patients	patient	NOUN
dpc-3895	187	40	who	who	PRON
dpc-3895	187	41	discontinued	discontinue	VERB
dpc-3895	187	42	secukinumab	secukinumab	NOUN
dpc-3895	187	43	(	(	PUNCT
dpc-3895	187	44	5/11	5/11	NUM
dpc-3895	187	45	,	,	PUNCT
dpc-3895	187	46	45	45	NUM
dpc-3895	187	47	%	%	NOUN
dpc-3895	187	48	)	)	PUNCT
dpc-3895	187	49	were	be	AUX
dpc-3895	187	50	bioexperienced	bioexperience	VERB
dpc-3895	187	51	with	with	ADP
dpc-3895	187	52	at	at	ADV
dpc-3895	187	53	least	least	ADV
dpc-3895	187	54	one	one	NUM
dpc-3895	187	55	biologic	biologic	NOUN
dpc-3895	187	56	drug	drug	NOUN
dpc-3895	187	57	that	that	PRON
dpc-3895	187	58	failed	fail	VERB
dpc-3895	187	59	in	in	ADP
dpc-3895	187	60	the	the	DET
dpc-3895	187	61	management	management	NOUN
dpc-3895	187	62	of	of	ADP
dpc-3895	187	63	the	the	DET
dpc-3895	187	64	disease	disease	NOUN
dpc-3895	187	65	.	.	PUNCT
dpc-3895	188	1	previous	previous	ADJ
dpc-3895	188	2	biologic	biologic	NOUN
dpc-3895	188	3	experience	experience	NOUN
dpc-3895	188	4	has	have	AUX
dpc-3895	188	5	been	be	AUX
dpc-3895	188	6	already	already	ADV
dpc-3895	188	7	identified	identify	VERB
dpc-3895	188	8	as	as	ADP
dpc-3895	188	9	a	a	DET
dpc-3895	188	10	factor	factor	NOUN
dpc-3895	188	11	influencing	influence	VERB
dpc-3895	188	12	drug	drug	NOUN
dpc-3895	188	13	survival	survival	NOUN
dpc-3895	188	14	[	[	X
dpc-3895	188	15	18	18	NUM
dpc-3895	188	16	]	]	PUNCT
dpc-3895	188	17	.	.	PUNCT
dpc-3895	189	1	another	another	DET
dpc-3895	189	2	key	key	ADJ
dpc-3895	189	3	point	point	NOUN
dpc-3895	189	4	to	to	PART
dpc-3895	189	5	be	be	AUX
dpc-3895	189	6	mentioned	mention	VERB
dpc-3895	189	7	is	be	AUX
dpc-3895	189	8	the	the	DET
dpc-3895	189	9	fact	fact	NOUN
dpc-3895	189	10	that	that	SCONJ
dpc-3895	189	11	in	in	ADP
dpc-3895	189	12	january	january	PROPN
dpc-3895	189	13	2022	2022	NUM
dpc-3895	189	14	,	,	PUNCT
dpc-3895	189	15	the	the	DET
dpc-3895	189	16	local	local	ADJ
dpc-3895	189	17	label	label	NOUN
dpc-3895	189	18	of	of	ADP
dpc-3895	189	19	secukinumab	secukinumab	NOUN
dpc-3895	189	20	was	be	AUX
dpc-3895	189	21	updated	update	VERB
dpc-3895	189	22	to	to	PART
dpc-3895	189	23	include	include	VERB
dpc-3895	189	24	an	an	DET
dpc-3895	189	25	intensified	intensify	VERB
dpc-3895	189	26	dosing	dose	VERB
dpc-3895	189	27	scheme	scheme	NOUN
dpc-3895	189	28	(	(	PUNCT
dpc-3895	189	29	300	300	NUM
dpc-3895	189	30	mg	mg	NOUN
dpc-3895	189	31	every	every	DET
dpc-3895	189	32	2	2	NUM
dpc-3895	189	33	weeks	week	NOUN
dpc-3895	189	34	,	,	PUNCT
dpc-3895	189	35	as	as	ADP
dpc-3895	189	36	maintenance	maintenance	NOUN
dpc-3895	189	37	dose	dose	NOUN
dpc-3895	189	38	)	)	PUNCT
dpc-3895	189	39	for	for	ADP
dpc-3895	189	40	adult	adult	NOUN
dpc-3895	189	41	patients	patient	NOUN
dpc-3895	189	42	with	with	ADP
dpc-3895	189	43	moderate	moderate	ADJ
dpc-3895	189	44	to	to	ADP
dpc-3895	189	45	severe	severe	ADJ
dpc-3895	189	46	plaque	plaque	NOUN
dpc-3895	189	47	psoriasis	psoriasis	NOUN
dpc-3895	189	48	and	and	CCONJ
dpc-3895	189	49	body	body	NOUN
dpc-3895	189	50	weight	weight	NOUN
dpc-3895	189	51	90	90	NUM
dpc-3895	189	52	kg	kg	NOUN
dpc-3895	189	53	or	or	CCONJ
dpc-3895	189	54	higher	high	ADJ
dpc-3895	189	55	,	,	PUNCT
dpc-3895	189	56	based	base	VERB
dpc-3895	189	57	on	on	ADP
dpc-3895	189	58	clinical	clinical	ADJ
dpc-3895	189	59	response	response	NOUN
dpc-3895	189	60	.	.	PUNCT
dpc-3895	190	1	since	since	SCONJ
dpc-3895	190	2	the	the	DET
dpc-3895	190	3	observation	observation	NOUN
dpc-3895	190	4	period	period	NOUN
dpc-3895	190	5	of	of	ADP
dpc-3895	190	6	this	this	DET
dpc-3895	190	7	study	study	NOUN
dpc-3895	190	8	started	start	VERB
dpc-3895	190	9	before	before	ADP
dpc-3895	190	10	this	this	DET
dpc-3895	190	11	update	update	NOUN
dpc-3895	190	12	,	,	PUNCT
dpc-3895	190	13	it	it	PRON
dpc-3895	190	14	is	be	AUX
dpc-3895	190	15	not	not	PART
dpc-3895	190	16	known	know	VERB
dpc-3895	190	17	,	,	PUNCT
dpc-3895	190	18	whether	whether	SCONJ
dpc-3895	190	19	the	the	DET
dpc-3895	190	20	efficacy	efficacy	NOUN
dpc-3895	190	21	outcomes	outcome	NOUN
dpc-3895	190	22	in	in	ADP
dpc-3895	190	23	patients	patient	NOUN
dpc-3895	190	24	who	who	PRON
dpc-3895	190	25	belong	belong	VERB
dpc-3895	190	26	to	to	ADP
dpc-3895	190	27	this	this	DET
dpc-3895	190	28	subpopulation	subpopulation	NOUN
dpc-3895	190	29	and	and	CCONJ
dpc-3895	190	30	show	show	VERB
dpc-3895	190	31	a	a	DET
dpc-3895	190	32	sub	sub	ADJ
dpc-3895	190	33	-	-	ADJ
dpc-3895	190	34	optimal	optimal	ADJ
dpc-3895	190	35	response	response	NOUN
dpc-3895	190	36	could	could	AUX
dpc-3895	190	37	have	have	AUX
dpc-3895	190	38	responded	respond	VERB
dpc-3895	190	39	better	well	ADV
dpc-3895	190	40	,	,	PUNCT
dpc-3895	190	41	had	have	VERB
dpc-3895	190	42	this	this	DET
dpc-3895	190	43	option	option	NOUN
dpc-3895	190	44	been	be	AUX
dpc-3895	190	45	available	available	ADJ
dpc-3895	190	46	at	at	ADP
dpc-3895	190	47	the	the	DET
dpc-3895	190	48	time	time	NOUN
dpc-3895	190	49	[	[	X
dpc-3895	190	50	19	19	NUM
dpc-3895	190	51	]	]	PUNCT
dpc-3895	190	52	.	.	PUNCT
dpc-3895	191	1	treatment	treatment	NOUN
dpc-3895	191	2	with	with	ADP
dpc-3895	191	3	secukinumab	secukinumab	NOUN
dpc-3895	191	4	during	during	ADP
dpc-3895	191	5	the	the	DET
dpc-3895	191	6	208	208	NUM
dpc-3895	191	7	weeks	week	NOUN
dpc-3895	191	8	of	of	ADP
dpc-3895	191	9	observation	observation	NOUN
dpc-3895	191	10	did	do	AUX
dpc-3895	191	11	not	not	PART
dpc-3895	191	12	reveal	reveal	VERB
dpc-3895	191	13	any	any	DET
dpc-3895	191	14	major	major	ADJ
dpc-3895	191	15	adverse	adverse	ADJ
dpc-3895	191	16	events	event	NOUN
dpc-3895	191	17	or	or	CCONJ
dpc-3895	191	18	systemic	systemic	ADJ
dpc-3895	191	19	infections	infection	NOUN
dpc-3895	191	20	and	and	CCONJ
dpc-3895	191	21	it	it	PRON
dpc-3895	191	22	was	be	AUX
dpc-3895	191	23	generally	generally	ADV
dpc-3895	191	24	well	well	ADV
dpc-3895	191	25	-	-	PUNCT
dpc-3895	191	26	tolerated	tolerate	VERB
dpc-3895	191	27	.	.	PUNCT
dpc-3895	192	1	only	only	ADV
dpc-3895	192	2	three	three	NUM
dpc-3895	192	3	patients	patient	NOUN
dpc-3895	192	4	reported	report	VERB
dpc-3895	192	5	aes	aes	PROPN
dpc-3895	192	6	of	of	ADP
dpc-3895	192	7	low	low	ADJ
dpc-3895	192	8	grade	grade	NOUN
dpc-3895	192	9	,	,	PUNCT
dpc-3895	192	10	which	which	PRON
dpc-3895	192	11	at	at	ADP
dpc-3895	192	12	no	no	DET
dpc-3895	192	13	point	point	NOUN
dpc-3895	192	14	was	be	AUX
dpc-3895	192	15	an	an	DET
dpc-3895	192	16	adequate	adequate	ADJ
dpc-3895	192	17	enough	enough	ADJ
dpc-3895	192	18	reason	reason	NOUN
dpc-3895	192	19	to	to	PART
dpc-3895	192	20	discontinue	discontinue	VERB
dpc-3895	192	21	secukinumab	secukinumab	NOUN
dpc-3895	192	22	.	.	PUNCT
dpc-3895	193	1	these	these	PRON
dpc-3895	193	2	were	be	AUX
dpc-3895	193	3	characterized	characterize	VERB
dpc-3895	193	4	as	as	ADP
dpc-3895	193	5	self	self	NOUN
dpc-3895	193	6	-	-	PUNCT
dpc-3895	193	7	limited	limited	ADJ
dpc-3895	193	8	without	without	ADP
dpc-3895	193	9	requiring	require	VERB
dpc-3895	193	10	any	any	DET
dpc-3895	193	11	additional	additional	ADJ
dpc-3895	193	12	treatment	treatment	NOUN
dpc-3895	193	13	.	.	PUNCT
dpc-3895	194	1	one	one	NUM
dpc-3895	194	2	42	42	NUM
dpc-3895	194	3	-	-	PUNCT
dpc-3895	194	4	year	year	NOUN
dpc-3895	194	5	-	-	PUNCT
dpc-3895	194	6	old	old	ADJ
dpc-3895	194	7	male	male	ADJ
dpc-3895	194	8	patient	patient	NOUN
dpc-3895	194	9	was	be	AUX
dpc-3895	194	10	diagnosed	diagnose	VERB
dpc-3895	194	11	with	with	ADP
dpc-3895	194	12	ulcerative	ulcerative	ADJ
dpc-3895	194	13	colitis	colitis	NOUN
dpc-3895	194	14	at	at	ADP
dpc-3895	194	15	week	week	NOUN
dpc-3895	194	16	152	152	NUM
dpc-3895	194	17	of	of	ADP
dpc-3895	194	18	treatment	treatment	NOUN
dpc-3895	194	19	.	.	PUNCT
dpc-3895	195	1	personal	personal	ADJ
dpc-3895	195	2	and	and	CCONJ
dpc-3895	195	3	family	family	NOUN
dpc-3895	195	4	history	history	NOUN
dpc-3895	195	5	were	be	AUX
dpc-3895	195	6	negative	negative	ADJ
dpc-3895	195	7	of	of	ADP
dpc-3895	195	8	any	any	DET
dpc-3895	195	9	inflammatory	inflammatory	ADJ
dpc-3895	195	10	bowel	bowel	NOUN
dpc-3895	195	11	disease	disease	NOUN
dpc-3895	195	12	,	,	PUNCT
dpc-3895	195	13	and	and	CCONJ
dpc-3895	195	14	he	he	PRON
dpc-3895	195	15	was	be	AUX
dpc-3895	195	16	a	a	DET
dpc-3895	195	17	smoker	smoker	NOUN
dpc-3895	195	18	.	.	PUNCT
dpc-3895	196	1	this	this	PRON
dpc-3895	196	2	is	be	AUX
dpc-3895	196	3	characterized	characterize	VERB
dpc-3895	196	4	as	as	ADP
dpc-3895	196	5	a	a	DET
dpc-3895	196	6	paradoxical	paradoxical	ADJ
dpc-3895	196	7	gastrointestinal	gastrointestinal	ADJ
dpc-3895	196	8	effect	effect	NOUN
dpc-3895	196	9	of	of	ADP
dpc-3895	196	10	il-17	il-17	NOUN
dpc-3895	196	11	inhibitors	inhibitor	NOUN
dpc-3895	196	12	with	with	ADP
dpc-3895	196	13	a	a	DET
dpc-3895	196	14	still	still	ADV
dpc-3895	196	15	unclear	unclear	ADJ
dpc-3895	196	16	pathogenetic	pathogenetic	ADJ
dpc-3895	196	17	mechanism	mechanism	NOUN
dpc-3895	196	18	.	.	PUNCT
dpc-3895	197	1	it	it	PRON
dpc-3895	197	2	is	be	AUX
dpc-3895	197	3	believed	believe	VERB
dpc-3895	197	4	that	that	DET
dpc-3895	197	5	type	type	NOUN
dpc-3895	197	6	i	i	PRON
dpc-3895	197	7	interferon	interferon	ADJ
dpc-3895	197	8	might	might	AUX
dpc-3895	197	9	be	be	AUX
dpc-3895	197	10	involved	involve	VERB
dpc-3895	197	11	and	and	CCONJ
dpc-3895	197	12	may	may	AUX
dpc-3895	197	13	be	be	AUX
dpc-3895	197	14	the	the	DET
dpc-3895	197	15	reason	reason	NOUN
dpc-3895	197	16	for	for	ADP
dpc-3895	197	17	a	a	DET
dpc-3895	197	18	hyperactive	hyperactive	ADJ
dpc-3895	197	19	innate	innate	ADJ
dpc-3895	197	20	inflammatory	inflammatory	ADJ
dpc-3895	197	21	pathway	pathway	NOUN
dpc-3895	197	22	[	[	X
dpc-3895	197	23	20	20	NUM
dpc-3895	197	24	]	]	PUNCT
dpc-3895	197	25	.	.	PUNCT
dpc-3895	198	1	furthermore	furthermore	ADV
dpc-3895	198	2	,	,	PUNCT
dpc-3895	198	3	three	three	NUM
dpc-3895	198	4	of	of	ADP
dpc-3895	198	5	our	our	PRON
dpc-3895	198	6	patients	patient	NOUN
dpc-3895	198	7	had	have	VERB
dpc-3895	198	8	a	a	DET
dpc-3895	198	9	quantiferon	quantiferon	PROPN
dpc-3895	198	10	tuberculosis	tuberculosis	NOUN
dpc-3895	198	11	conversion	conversion	NOUN
dpc-3895	198	12	and	and	CCONJ
dpc-3895	198	13	as	as	ADP
dpc-3895	198	14	per	per	ADP
dpc-3895	198	15	the	the	DET
dpc-3895	198	16	guidelines	guideline	NOUN
dpc-3895	198	17	they	they	PRON
dpc-3895	198	18	underwent	undergo	VERB
dpc-3895	198	19	prophylactic	prophylactic	ADJ
dpc-3895	198	20	antibiotic	antibiotic	ADJ
dpc-3895	198	21	therapy	therapy	NOUN
dpc-3895	198	22	without	without	ADP
dpc-3895	198	23	clinical	clinical	ADJ
dpc-3895	198	24	or	or	CCONJ
dpc-3895	198	25	radiographic	radiographic	ADJ
dpc-3895	198	26	evidence	evidence	NOUN
dpc-3895	198	27	of	of	ADP
dpc-3895	198	28	tb	tb	ADP
dpc-3895	198	29	infection	infection	NOUN
dpc-3895	198	30	.	.	PUNCT
dpc-3895	199	1	we	we	PRON
dpc-3895	199	2	acknowledge	acknowledge	VERB
dpc-3895	199	3	the	the	DET
dpc-3895	199	4	fact	fact	NOUN
dpc-3895	199	5	that	that	SCONJ
dpc-3895	199	6	this	this	PRON
dpc-3895	199	7	is	be	AUX
dpc-3895	199	8	a	a	DET
dpc-3895	199	9	retrospective	retrospective	ADJ
dpc-3895	199	10	monocentric	monocentric	ADJ
dpc-3895	199	11	observational	observational	ADJ
dpc-3895	199	12	study	study	NOUN
dpc-3895	199	13	and	and	CCONJ
dpc-3895	199	14	the	the	DET
dpc-3895	199	15	data	datum	NOUN
dpc-3895	199	16	extracted	extract	VERB
dpc-3895	199	17	were	be	AUX
dpc-3895	199	18	obtained	obtain	VERB
dpc-3895	199	19	from	from	ADP
dpc-3895	199	20	a	a	DET
dpc-3895	199	21	small	small	ADJ
dpc-3895	199	22	number	number	NOUN
dpc-3895	199	23	of	of	ADP
dpc-3895	199	24	patients	patient	NOUN
dpc-3895	199	25	.	.	PUNCT
dpc-3895	200	1	this	this	DET
dpc-3895	200	2	retrospective	retrospective	ADJ
dpc-3895	200	3	nature	nature	NOUN
dpc-3895	200	4	of	of	ADP
dpc-3895	200	5	this	this	DET
dpc-3895	200	6	study	study	NOUN
dpc-3895	200	7	could	could	AUX
dpc-3895	200	8	also	also	ADV
dpc-3895	200	9	explain	explain	VERB
dpc-3895	200	10	the	the	DET
dpc-3895	200	11	small	small	ADJ
dpc-3895	200	12	number	number	NOUN
dpc-3895	200	13	of	of	ADP
dpc-3895	200	14	reported	report	VERB
dpc-3895	200	15	aes	aes	PROPN
dpc-3895	200	16	extracted	extract	VERB
dpc-3895	200	17	from	from	ADP
dpc-3895	200	18	patient	patient	ADJ
dpc-3895	200	19	records	record	NOUN
dpc-3895	200	20	that	that	PRON
dpc-3895	200	21	were	be	AUX
dpc-3895	200	22	used	use	VERB
dpc-3895	200	23	for	for	ADP
dpc-3895	200	24	this	this	DET
dpc-3895	200	25	analysis	analysis	NOUN
dpc-3895	200	26	.	.	PUNCT
dpc-3895	201	1	8	8	NUM
dpc-3895	201	2	original	original	ADJ
dpc-3895	201	3	article	article	NOUN
dpc-3895	201	4	|	|	ADV
dpc-3895	201	5	dermatol	dermatol	ADJ
dpc-3895	201	6	pract	pract	NOUN
dpc-3895	201	7	concept	concept	NOUN
dpc-3895	201	8	.	.	PUNCT
dpc-3895	202	1	2024;14(2):e2024119	2024;14(2):e2024119	NUM
dpc-3895	202	2	cosmet	cosmet	NOUN
dpc-3895	202	3	investig	investig	NOUN
dpc-3895	202	4	dermatol	dermatol	NOUN
dpc-3895	202	5	.	.	PUNCT
dpc-3895	203	1	2019;12:249	2019;12:249	NUM
dpc-3895	203	2	-	-	SYM
dpc-3895	203	3	253	253	NUM
dpc-3895	204	1	.	.	PUNCT
dpc-3895	204	2	doi	doi	NOUN
dpc-3895	204	3	:	:	PUNCT
dpc-3895	204	4	10.2147/	10.2147/	NUM
dpc-3895	204	5	ccid.s165040	ccid.s165040	NOUN
dpc-3895	204	6	.	.	PUNCT
dpc-3895	205	1	pmid	pmid	NOUN
dpc-3895	205	2	:	:	PUNCT
dpc-3895	205	3	31118728	31118728	NUM
dpc-3895	205	4	.	.	PUNCT
dpc-3895	206	1	pmcid	pmcid	ADJ
dpc-3895	206	2	:	:	PUNCT
dpc-3895	206	3	pmc6498391	pmc6498391	NOUN
dpc-3895	206	4	.	.	PUNCT
dpc-3895	207	1	14	14	NUM
dpc-3895	207	2	.	.	PUNCT
dpc-3895	208	1	reich	reich	PROPN
dpc-3895	208	2	k	k	PROPN
dpc-3895	208	3	,	,	PUNCT
dpc-3895	208	4	sullivan	sullivan	PROPN
dpc-3895	208	5	j	j	PROPN
dpc-3895	208	6	,	,	PUNCT
dpc-3895	208	7	arenberger	arenberger	ADV
dpc-3895	208	8	p	p	NOUN
dpc-3895	208	9	,	,	PUNCT
dpc-3895	208	10	et	et	PROPN
dpc-3895	208	11	al	al	PROPN
dpc-3895	208	12	.	.	PROPN
dpc-3895	208	13	secukinumab	secukinumab	PROPN
dpc-3895	208	14	shows	show	VERB
dpc-3895	208	15	high	high	ADJ
dpc-3895	208	16	and	and	CCONJ
dpc-3895	208	17	sustained	sustain	VERB
dpc-3895	208	18	efficacy	efficacy	NOUN
dpc-3895	208	19	in	in	ADP
dpc-3895	208	20	nail	nail	NOUN
dpc-3895	208	21	psoriasis	psoriasis	NOUN
dpc-3895	208	22	:	:	PUNCT
dpc-3895	208	23	2.5	2.5	NUM
dpc-3895	208	24	-	-	PUNCT
dpc-3895	208	25	year	year	NOUN
dpc-3895	208	26	results	result	NOUN
dpc-3895	208	27	from	from	ADP
dpc-3895	208	28	the	the	DET
dpc-3895	208	29	randomized	randomized	ADJ
dpc-3895	208	30	placebo	placebo	NOUN
dpc-3895	208	31	-	-	PUNCT
dpc-3895	208	32	controlled	control	VERB
dpc-3895	208	33	transfigure	transfigure	NOUN
dpc-3895	208	34	study	study	NOUN
dpc-3895	208	35	.	.	PUNCT
dpc-3895	209	1	br	br	PROPN
dpc-3895	209	2	j	j	PROPN
dpc-3895	209	3	dermatol	dermatol	NOUN
dpc-3895	209	4	.	.	PUNCT
dpc-3895	210	1	2021;184(3):425	2021;184(3):425	VERB
dpc-3895	210	2	-	-	SYM
dpc-3895	210	3	436	436	NUM
dpc-3895	210	4	.	.	PUNCT
dpc-3895	211	1	doi	doi	NOUN
dpc-3895	211	2	:	:	PUNCT
dpc-3895	211	3	10.1111	10.1111	NUM
dpc-3895	211	4	/	/	SYM
dpc-3895	211	5	bjd.19262	bjd.19262	PROPN
dpc-3895	211	6	.	.	PUNCT
dpc-3895	212	1	pmid	pmid	NOUN
dpc-3895	212	2	:	:	PUNCT
dpc-3895	212	3	32479641	32479641	NUM
dpc-3895	212	4	.	.	PUNCT
dpc-3895	213	1	15	15	NUM
dpc-3895	213	2	.	.	PUNCT
dpc-3895	214	1	gottlieb	gottlieb	PROPN
dpc-3895	214	2	ab	ab	PROPN
dpc-3895	214	3	,	,	PUNCT
dpc-3895	214	4	kubanov	kubanov	PROPN
dpc-3895	214	5	a	a	PRON
dpc-3895	214	6	,	,	PUNCT
dpc-3895	214	7	van	van	PROPN
dpc-3895	214	8	doorn	doorn	PROPN
dpc-3895	214	9	m	m	PROPN
dpc-3895	214	10	,	,	PUNCT
dpc-3895	214	11	et	et	PROPN
dpc-3895	214	12	al	al	PROPN
dpc-3895	214	13	.	.	PROPN
dpc-3895	214	14	sustained	sustain	VERB
dpc-3895	214	15	efficacy	efficacy	NOUN
dpc-3895	214	16	of	of	ADP
dpc-3895	214	17	secukinumab	secukinumab	NOUN
dpc-3895	214	18	in	in	ADP
dpc-3895	214	19	patients	patient	NOUN
dpc-3895	214	20	with	with	ADP
dpc-3895	214	21	moderate	moderate	ADJ
dpc-3895	214	22	-	-	PUNCT
dpc-3895	214	23	to	to	ADP
dpc-3895	214	24	-	-	PUNCT
dpc-3895	214	25	severe	severe	ADJ
dpc-3895	214	26	palmoplantar	palmoplantar	NOUN
dpc-3895	214	27	psoriasis	psoriasis	NOUN
dpc-3895	214	28	:	:	PUNCT
dpc-3895	214	29	2·5	2·5	NUM
dpc-3895	214	30	-	-	PUNCT
dpc-3895	214	31	year	year	NOUN
dpc-3895	214	32	results	result	NOUN
dpc-3895	214	33	from	from	ADP
dpc-3895	214	34	gesture	gesture	NOUN
dpc-3895	214	35	,	,	PUNCT
dpc-3895	214	36	a	a	DET
dpc-3895	214	37	randomized	randomized	ADJ
dpc-3895	214	38	,	,	PUNCT
dpc-3895	214	39	double	double	ADV
dpc-3895	214	40	blind	blind	ADJ
dpc-3895	214	41	,	,	PUNCT
dpc-3895	214	42	placebo	placebo	NOUN
dpc-3895	214	43	-	-	PUNCT
dpc-3895	214	44	controlled	control	VERB
dpc-3895	214	45	trial	trial	NOUN
dpc-3895	214	46	.	.	PUNCT
dpc-3895	215	1	br	br	PROPN
dpc-3895	215	2	j	j	PROPN
dpc-3895	215	3	dermatol	dermatol	NOUN
dpc-3895	215	4	.	.	PUNCT
dpc-3895	216	1	2020;182(4	2020;182(4	NUM
dpc-3895	216	2	):	):	PUNCT
dpc-3895	216	3	889	889	NUM
dpc-3895	216	4	-	-	SYM
dpc-3895	216	5	899	899	NUM
dpc-3895	216	6	.	.	PUNCT
dpc-3895	216	7	doi	doi	NOUN
dpc-3895	216	8	:	:	PUNCT
dpc-3895	216	9	10.1111	10.1111	NUM
dpc-3895	216	10	/	/	SYM
dpc-3895	216	11	bjd.18331	bjd.18331	PROPN
dpc-3895	216	12	.	.	PUNCT
dpc-3895	217	1	pmid	pmid	NOUN
dpc-3895	217	2	:	:	PUNCT
dpc-3895	217	3	31286480	31286480	NUM
dpc-3895	217	4	.	.	PUNCT
dpc-3895	218	1	16	16	NUM
dpc-3895	218	2	.	.	PUNCT
dpc-3895	219	1	burlando	burlando	PROPN
dpc-3895	219	2	m	m	PROPN
dpc-3895	219	3	,	,	PUNCT
dpc-3895	219	4	herzum	herzum	PROPN
dpc-3895	219	5	a	a	PROPN
dpc-3895	219	6	,	,	PUNCT
dpc-3895	219	7	carmisciano	carmisciano	PROPN
dpc-3895	219	8	l	l	PROPN
dpc-3895	219	9	,	,	PUNCT
dpc-3895	219	10	cozzani	cozzani	ADJ
dpc-3895	219	11	e	e	NOUN
dpc-3895	219	12	,	,	PUNCT
dpc-3895	219	13	parodi	parodi	ADJ
dpc-3895	219	14	a.	a.	NOUN
dpc-3895	219	15	biological	biological	NOUN
dpc-3895	219	16	therapy	therapy	NOUN
dpc-3895	219	17	in	in	ADP
dpc-3895	219	18	genital	genital	ADJ
dpc-3895	219	19	psoriasis	psoriasis	NOUN
dpc-3895	219	20	in	in	ADP
dpc-3895	219	21	women	woman	NOUN
dpc-3895	219	22	.	.	PUNCT
dpc-3895	220	1	dermatol	dermatol	NOUN
dpc-3895	220	2	ther	ther	ADV
dpc-3895	220	3	.	.	PUNCT
dpc-3895	221	1	2020;33(1):e13110	2020;33(1):e13110	X
dpc-3895	221	2	.	.	PUNCT
dpc-3895	222	1	doi	doi	NOUN
dpc-3895	222	2	:	:	PUNCT
dpc-3895	222	3	10.1111	10.1111	NUM
dpc-3895	222	4	/	/	SYM
dpc-3895	222	5	dth.13110	dth.13110	PROPN
dpc-3895	222	6	.	.	PUNCT
dpc-3895	223	1	pmid	pmid	NOUN
dpc-3895	223	2	:	:	PUNCT
dpc-3895	223	3	31595647	31595647	NUM
dpc-3895	223	4	.	.	PUNCT
dpc-3895	224	1	17	17	NUM
dpc-3895	224	2	.	.	PUNCT
dpc-3895	225	1	mendes	mende	NOUN
dpc-3895	225	2	-	-	PUNCT
dpc-3895	225	3	bastos	bastos	PROPN
dpc-3895	225	4	p	p	X
dpc-3895	225	5	,	,	PUNCT
dpc-3895	225	6	morais	morais	PROPN
dpc-3895	225	7	p	p	PROPN
dpc-3895	225	8	,	,	PUNCT
dpc-3895	225	9	ferreira	ferreira	PROPN
dpc-3895	225	10	p	p	PROPN
dpc-3895	225	11	,	,	PUNCT
dpc-3895	225	12	et	et	PROPN
dpc-3895	225	13	al	al	PROPN
dpc-3895	225	14	.	.	PROPN
dpc-3895	225	15	persistence	persistence	NOUN
dpc-3895	225	16	,	,	PUNCT
dpc-3895	225	17	effectiveness	effectiveness	NOUN
dpc-3895	225	18	,	,	PUNCT
dpc-3895	225	19	and	and	CCONJ
dpc-3895	225	20	real	real	ADJ
dpc-3895	225	21	-	-	PUNCT
dpc-3895	225	22	world	world	NOUN
dpc-3895	225	23	outcomes	outcome	NOUN
dpc-3895	225	24	in	in	ADP
dpc-3895	225	25	psoriasis	psoriasis	NOUN
dpc-3895	225	26	patients	patient	NOUN
dpc-3895	225	27	treated	treat	VERB
dpc-3895	225	28	with	with	ADP
dpc-3895	225	29	secukinumab	secukinumab	NOUN
dpc-3895	225	30	in	in	ADP
dpc-3895	225	31	portugal	portugal	PROPN
dpc-3895	225	32	.	.	PUNCT
dpc-3895	226	1	dermatol	dermatol	NOUN
dpc-3895	226	2	ther	ther	ADV
dpc-3895	226	3	.	.	PUNCT
dpc-3895	227	1	2022;35(7):e15510	2022;35(7):e15510	X
dpc-3895	227	2	.	.	PUNCT
dpc-3895	227	3	doi	doi	NOUN
dpc-3895	227	4	:	:	PUNCT
dpc-3895	227	5	10.1111	10.1111	NUM
dpc-3895	227	6	/	/	SYM
dpc-3895	227	7	dth.15510	dth.15510	PROPN
dpc-3895	227	8	.	.	PUNCT
dpc-3895	228	1	pmid	pmid	NOUN
dpc-3895	228	2	:	:	PUNCT
dpc-3895	228	3	35419886	35419886	NUM
dpc-3895	228	4	.	.	PUNCT
dpc-3895	229	1	18	18	NUM
dpc-3895	229	2	.	.	X
dpc-3895	229	3	yiu	yiu	PROPN
dpc-3895	229	4	zzn	zzn	PROPN
dpc-3895	229	5	,	,	PUNCT
dpc-3895	229	6	mason	mason	PROPN
dpc-3895	229	7	kj	kj	PROPN
dpc-3895	229	8	,	,	PUNCT
dpc-3895	229	9	hampton	hampton	PROPN
dpc-3895	229	10	pj	pj	PROPN
dpc-3895	229	11	,	,	PUNCT
dpc-3895	229	12	et	et	PROPN
dpc-3895	229	13	al	al	PROPN
dpc-3895	229	14	.	.	PROPN
dpc-3895	229	15	drug	drug	PROPN
dpc-3895	229	16	survival	survival	NOUN
dpc-3895	229	17	of	of	ADP
dpc-3895	229	18	adalimumab	adalimumab	PROPN
dpc-3895	229	19	,	,	PUNCT
dpc-3895	229	20	ustekinumab	ustekinumab	NOUN
dpc-3895	229	21	and	and	CCONJ
dpc-3895	229	22	secukinumab	secukinumab	NOUN
dpc-3895	229	23	in	in	ADP
dpc-3895	229	24	patients	patient	NOUN
dpc-3895	229	25	with	with	ADP
dpc-3895	229	26	psoriasis	psoriasis	NOUN
dpc-3895	229	27	:	:	PUNCT
dpc-3895	229	28	a	a	DET
dpc-3895	229	29	prospective	prospective	ADJ
dpc-3895	229	30	cohort	cohort	NOUN
dpc-3895	229	31	study	study	NOUN
dpc-3895	229	32	from	from	ADP
dpc-3895	229	33	the	the	DET
dpc-3895	229	34	british	british	PROPN
dpc-3895	229	35	association	association	PROPN
dpc-3895	229	36	of	of	ADP
dpc-3895	229	37	dermatologists	dermatologists	PROPN
dpc-3895	229	38	biologics	biologic	NOUN
dpc-3895	229	39	and	and	CCONJ
dpc-3895	229	40	immunomodulators	immunomodulator	NOUN
dpc-3895	229	41	register	register	VERB
dpc-3895	229	42	(	(	PUNCT
dpc-3895	229	43	badbir	badbir	NOUN
dpc-3895	229	44	)	)	PUNCT
dpc-3895	229	45	.	.	PUNCT
dpc-3895	230	1	br	br	PROPN
dpc-3895	230	2	j	j	PROPN
dpc-3895	230	3	dermatol	dermatol	NOUN
dpc-3895	230	4	.	.	PUNCT
dpc-3895	231	1	2020;183(2):294	2020;183(2):294	NUM
dpc-3895	231	2	-	-	SYM
dpc-3895	231	3	302	302	NUM
dpc-3895	231	4	.	.	PUNCT
dpc-3895	232	1	doi	doi	NOUN
dpc-3895	232	2	:	:	PUNCT
dpc-3895	232	3	10.1111	10.1111	NUM
dpc-3895	232	4	/bjd.18981	/bjd.18981	NOUN
dpc-3895	232	5	.	.	PUNCT
dpc-3895	233	1	pmid	pmid	NOUN
dpc-3895	233	2	:	:	PUNCT
dpc-3895	233	3	32124442	32124442	NUM
dpc-3895	233	4	.	.	PUNCT
dpc-3895	234	1	19	19	NUM
dpc-3895	234	2	.	.	X
dpc-3895	234	3	secukinumab	secukinumab	NOUN
dpc-3895	234	4	,	,	PUNCT
dpc-3895	234	5	summary	summary	NOUN
dpc-3895	234	6	of	of	ADP
dpc-3895	234	7	product	product	NOUN
dpc-3895	234	8	characteristics	characteristic	NOUN
dpc-3895	234	9	,	,	PUNCT
dpc-3895	234	10	date	date	NOUN
dpc-3895	234	11	of	of	ADP
dpc-3895	234	12	last	last	ADJ
dpc-3895	234	13	revision	revision	NOUN
dpc-3895	234	14	:	:	PUNCT
dpc-3895	234	15	10	10	NUM
dpc-3895	234	16	july	july	PROPN
dpc-3895	234	17	2023	2023	NUM
dpc-3895	234	18	.	.	PUNCT
dpc-3895	235	1	20	20	NUM
dpc-3895	235	2	.	.	PUNCT
dpc-3895	236	1	mehta	mehta	PROPN
dpc-3895	236	2	p	p	PROPN
dpc-3895	236	3	,	,	PUNCT
dpc-3895	236	4	lawrence	lawrence	PROPN
dpc-3895	236	5	a	a	PRON
dpc-3895	236	6	,	,	PUNCT
dpc-3895	236	7	aggarwal	aggarwal	NOUN
dpc-3895	236	8	a.	a.	NOUN
dpc-3895	236	9	paradoxical	paradoxical	ADJ
dpc-3895	236	10	gastrointestinal	gastrointestinal	ADJ
dpc-3895	236	11	effects	effect	NOUN
dpc-3895	236	12	of	of	ADP
dpc-3895	236	13	interleukin-17	interleukin-17	NOUN
dpc-3895	236	14	blockers	blocker	NOUN
dpc-3895	236	15	.	.	PUNCT
dpc-3895	237	1	ann	ann	PROPN
dpc-3895	237	2	rheum	rheum	PROPN
dpc-3895	237	3	dis	dis	PROPN
dpc-3895	237	4	.	.	PUNCT
dpc-3895	238	1	2023;82(6):e152	2023;82(6):e152	PROPN
dpc-3895	238	2	.	.	PUNCT
dpc-3895	239	1	doi	doi	NOUN
dpc-3895	239	2	:	:	PUNCT
dpc-3895	239	3	10.1136	10.1136	NUM
dpc-3895	239	4	/	/	SYM
dpc-3895	239	5	annrheumdis-2020	annrheumdis-2020	NOUN
dpc-3895	239	6	-	-	PUNCT
dpc-3895	239	7	218719	218719	NUM
dpc-3895	239	8	.	.	PUNCT
dpc-3895	240	1	pmid	pmid	NOUN
dpc-3895	240	2	:	:	PUNCT
dpc-3895	240	3	32988844	32988844	NUM
dpc-3895	240	4	.	.	PUNCT
dpc-3895	241	1	meta	meta	VERB
dpc-3895	241	2	-	-	PUNCT
dpc-3895	241	3	analysis	analysis	NOUN
dpc-3895	241	4	of	of	ADP
dpc-3895	241	5	randomized	randomized	ADJ
dpc-3895	241	6	controlled	control	VERB
dpc-3895	241	7	trials	trial	NOUN
dpc-3895	241	8	.	.	PUNCT
dpc-3895	242	1	j	j	PROPN
dpc-3895	242	2	immunol	immunol	NOUN
dpc-3895	242	3	res	re	NOUN
dpc-3895	242	4	.	.	PUNCT
dpc-3895	243	1	2019;2019:2546161	2019;2019:2546161	NUM
dpc-3895	243	2	.	.	PUNCT
dpc-3895	244	1	doi	doi	NOUN
dpc-3895	244	2	:	:	PUNCT
dpc-3895	244	3	10.1155/2019/2546161	10.1155/2019/2546161	NUM
dpc-3895	244	4	.	.	PUNCT
dpc-3895	245	1	pmid	pmid	NOUN
dpc-3895	245	2	:	:	PUNCT
dpc-3895	245	3	31583255	31583255	NUM
dpc-3895	245	4	.	.	PUNCT
dpc-3895	246	1	pmcid	pmcid	NOUN
dpc-3895	246	2	:	:	PUNCT
dpc-3895	246	3	pmc6754904	pmc6754904	ADJ
dpc-3895	246	4	.	.	PUNCT
dpc-3895	247	1	8	8	X
dpc-3895	247	2	.	.	X
dpc-3895	247	3	bissonnette	bissonnette	NOUN
dpc-3895	247	4	r	r	PROPN
dpc-3895	247	5	,	,	PUNCT
dpc-3895	247	6	luger	luger	PROPN
dpc-3895	247	7	t	t	PROPN
dpc-3895	247	8	,	,	PUNCT
dpc-3895	247	9	thaçi	thaçi	NOUN
dpc-3895	247	10	d	d	PROPN
dpc-3895	247	11	,	,	PUNCT
dpc-3895	247	12	et	et	PROPN
dpc-3895	247	13	al	al	PROPN
dpc-3895	247	14	.	.	PROPN
dpc-3895	247	15	secukinumab	secukinumab	PROPN
dpc-3895	247	16	demonstrates	demonstrate	VERB
dpc-3895	247	17	high	high	ADJ
dpc-3895	247	18	sustained	sustain	VERB
dpc-3895	247	19	efficacy	efficacy	NOUN
dpc-3895	247	20	and	and	CCONJ
dpc-3895	247	21	a	a	DET
dpc-3895	247	22	favourable	favourable	ADJ
dpc-3895	247	23	safety	safety	NOUN
dpc-3895	247	24	profile	profile	NOUN
dpc-3895	247	25	in	in	ADP
dpc-3895	247	26	patients	patient	NOUN
dpc-3895	247	27	with	with	ADP
dpc-3895	247	28	moderate	moderate	ADJ
dpc-3895	247	29	-	-	PUNCT
dpc-3895	247	30	to	to	ADP
dpc-3895	247	31	-	-	PUNCT
dpc-3895	247	32	severe	severe	ADJ
dpc-3895	247	33	psoriasis	psoriasis	NOUN
dpc-3895	247	34	through	through	ADP
dpc-3895	247	35	5	5	NUM
dpc-3895	247	36	 	 	SPACE
dpc-3895	247	37	years	year	NOUN
dpc-3895	247	38	of	of	ADP
dpc-3895	247	39	treatment	treatment	NOUN
dpc-3895	247	40	(	(	PUNCT
dpc-3895	247	41	sculpture	sculpture	NOUN
dpc-3895	247	42	extension	extension	NOUN
dpc-3895	247	43	study	study	NOUN
dpc-3895	247	44	)	)	PUNCT
dpc-3895	247	45	.	.	PUNCT
dpc-3895	248	1	j	j	PROPN
dpc-3895	248	2	eur	eur	PROPN
dpc-3895	248	3	acad	acad	PROPN
dpc-3895	248	4	dermatol	dermatol	NOUN
dpc-3895	248	5	venereol	venereol	NOUN
dpc-3895	248	6	.	.	PUNCT
dpc-3895	249	1	2018;32(9):1507	2018;32(9):1507	NUM
dpc-3895	249	2	-	-	SYM
dpc-3895	249	3	1514	1514	NUM
dpc-3895	249	4	.	.	PUNCT
dpc-3895	250	1	doi	doi	NOUN
dpc-3895	250	2	:	:	PUNCT
dpc-3895	250	3	10.1111	10.1111	NUM
dpc-3895	250	4	/	/	SYM
dpc-3895	250	5	jdv.14878	jdv.14878	PROPN
dpc-3895	250	6	.	.	PUNCT
dpc-3895	251	1	pmid	pmid	NOUN
dpc-3895	251	2	:	:	PUNCT
dpc-3895	251	3	29444376	29444376	NUM
dpc-3895	251	4	.	.	PUNCT
dpc-3895	252	1	pmcid	pmcid	NOUN
dpc-3895	252	2	:	:	PUNCT
dpc-3895	252	3	pmc6175198	pmc6175198	NOUN
dpc-3895	252	4	.	.	PUNCT
dpc-3895	253	1	9	9	X
dpc-3895	253	2	.	.	X
dpc-3895	253	3	langley	langley	PROPN
dpc-3895	253	4	rg	rg	PROPN
dpc-3895	253	5	,	,	PUNCT
dpc-3895	253	6	sofen	sofen	PROPN
dpc-3895	253	7	h	h	PROPN
dpc-3895	253	8	,	,	PUNCT
dpc-3895	253	9	dei	dei	NOUN
dpc-3895	253	10	-	-	PUNCT
dpc-3895	253	11	cas	cas	NOUN
dpc-3895	253	12	i	i	PROPN
dpc-3895	253	13	,	,	PUNCT
dpc-3895	253	14	et	et	PROPN
dpc-3895	253	15	al	al	PROPN
dpc-3895	253	16	.	.	PROPN
dpc-3895	253	17	secukinumab	secukinumab	PROPN
dpc-3895	253	18	long	long	ADJ
dpc-3895	253	19	-	-	PUNCT
dpc-3895	253	20	term	term	NOUN
dpc-3895	253	21	efficacy	efficacy	NOUN
dpc-3895	253	22	and	and	CCONJ
dpc-3895	253	23	safety	safety	NOUN
dpc-3895	253	24	in	in	ADP
dpc-3895	253	25	psoriasis	psoriasis	NOUN
dpc-3895	253	26	through	through	ADP
dpc-3895	253	27	to	to	ADP
dpc-3895	253	28	year	year	NOUN
dpc-3895	253	29	5	5	NUM
dpc-3895	253	30	of	of	ADP
dpc-3895	253	31	treatment	treatment	NOUN
dpc-3895	253	32	:	:	PUNCT
dpc-3895	253	33	results	result	NOUN
dpc-3895	253	34	of	of	ADP
dpc-3895	253	35	a	a	DET
dpc-3895	253	36	randomized	randomized	ADJ
dpc-3895	253	37	extension	extension	NOUN
dpc-3895	253	38	of	of	ADP
dpc-3895	253	39	the	the	DET
dpc-3895	253	40	phase	phase	NOUN
dpc-3895	253	41	iii	iii	NOUN
dpc-3895	253	42	erasure	erasure	NOUN
dpc-3895	253	43	and	and	CCONJ
dpc-3895	253	44	fixture	fixture	NOUN
dpc-3895	253	45	trials	trial	NOUN
dpc-3895	253	46	.	.	PUNCT
dpc-3895	254	1	br	br	PROPN
dpc-3895	254	2	j	j	PROPN
dpc-3895	254	3	dermatol	dermatol	NOUN
dpc-3895	254	4	.	.	PUNCT
dpc-3895	255	1	2023;188(2):198	2023;188(2):198	NUM
dpc-3895	255	2	-	-	SYM
dpc-3895	255	3	207	207	NUM
dpc-3895	255	4	.	.	PUNCT
dpc-3895	256	1	doi	doi	NOUN
dpc-3895	256	2	:	:	PUNCT
dpc-3895	256	3	10.1093	10.1093	NUM
dpc-3895	256	4	/	/	SYM
dpc-3895	256	5	bjd	bjd	PROPN
dpc-3895	256	6	/	/	SYM
dpc-3895	256	7	ljac040	ljac040	PROPN
dpc-3895	256	8	.	.	PUNCT
dpc-3895	257	1	pmid	pmid	NOUN
dpc-3895	257	2	:	:	PUNCT
dpc-3895	257	3	36763857	36763857	NUM
dpc-3895	257	4	.	.	PUNCT
dpc-3895	258	1	10	10	NUM
dpc-3895	258	2	.	.	X
dpc-3895	258	3	augustin	augustin	PROPN
dpc-3895	258	4	m	m	PROPN
dpc-3895	258	5	,	,	PUNCT
dpc-3895	258	6	sator	sator	PROPN
dpc-3895	258	7	pg	pg	PROPN
dpc-3895	258	8	,	,	PUNCT
dpc-3895	258	9	von	von	PROPN
dpc-3895	258	10	kiedrowski	kiedrowski	PROPN
dpc-3895	258	11	r	r	PROPN
dpc-3895	258	12	,	,	PUNCT
dpc-3895	258	13	et	et	PROPN
dpc-3895	258	14	al	al	PROPN
dpc-3895	258	15	.	.	PROPN
dpc-3895	258	16	secukinumab	secukinumab	PROPN
dpc-3895	258	17	demonstrated	demonstrate	VERB
dpc-3895	258	18	sustained	sustained	ADJ
dpc-3895	258	19	retention	retention	NOUN
dpc-3895	258	20	,	,	PUNCT
dpc-3895	258	21	effectiveness	effectiveness	NOUN
dpc-3895	258	22	and	and	CCONJ
dpc-3895	258	23	safety	safety	NOUN
dpc-3895	258	24	in	in	ADP
dpc-3895	258	25	a	a	DET
dpc-3895	258	26	real	real	ADJ
dpc-3895	258	27	-	-	PUNCT
dpc-3895	258	28	world	world	NOUN
dpc-3895	258	29	setting	setting	NOUN
dpc-3895	258	30	in	in	ADP
dpc-3895	258	31	patients	patient	NOUN
dpc-3895	258	32	with	with	ADP
dpc-3895	258	33	moderate	moderate	ADJ
dpc-3895	258	34	-	-	PUNCT
dpc-3895	258	35	to	to	ADP
dpc-3895	258	36	-	-	PUNCT
dpc-3895	258	37	severe	severe	ADJ
dpc-3895	258	38	plaque	plaque	NOUN
dpc-3895	258	39	psoriasis	psoriasis	NOUN
dpc-3895	258	40	:	:	PUNCT
dpc-3895	258	41	long	long	ADJ
dpc-3895	258	42	-	-	PUNCT
dpc-3895	258	43	term	term	NOUN
dpc-3895	258	44	results	result	NOUN
dpc-3895	258	45	from	from	ADP
dpc-3895	258	46	an	an	DET
dpc-3895	258	47	interim	interim	ADJ
dpc-3895	258	48	analysis	analysis	NOUN
dpc-3895	258	49	of	of	ADP
dpc-3895	258	50	the	the	DET
dpc-3895	258	51	serena	serena	PROPN
dpc-3895	258	52	study	study	NOUN
dpc-3895	258	53	.	.	PUNCT
dpc-3895	259	1	j	j	PROPN
dpc-3895	259	2	eur	eur	PROPN
dpc-3895	259	3	acad	acad	PROPN
dpc-3895	259	4	dermatol	dermatol	NOUN
dpc-3895	259	5	venereol	venereol	NOUN
dpc-3895	259	6	.	.	PUNCT
dpc-3895	260	1	2022;36(10	2022;36(10	NUM
dpc-3895	260	2	):	):	PUNCT
dpc-3895	260	3	1796	1796	NUM
dpc-3895	260	4	-	-	SYM
dpc-3895	260	5	1804	1804	NUM
dpc-3895	260	6	.	.	PUNCT
dpc-3895	261	1	doi	doi	NOUN
dpc-3895	261	2	:	:	PUNCT
dpc-3895	261	3	10.1111	10.1111	NUM
dpc-3895	261	4	/	/	SYM
dpc-3895	261	5	jdv.18329	jdv.18329	PROPN
dpc-3895	261	6	.	.	PUNCT
dpc-3895	262	1	pmid	pmid	NOUN
dpc-3895	262	2	:	:	PUNCT
dpc-3895	262	3	35696305	35696305	NUM
dpc-3895	262	4	.	.	PUNCT
dpc-3895	263	1	11	11	NUM
dpc-3895	263	2	.	.	PUNCT
dpc-3895	263	3	bagel	bagel	PROPN
dpc-3895	263	4	j	j	PROPN
dpc-3895	263	5	,	,	PUNCT
dpc-3895	263	6	duffin	duffin	PROPN
dpc-3895	263	7	kc	kc	PROPN
dpc-3895	263	8	,	,	PUNCT
dpc-3895	263	9	moore	moore	PROPN
dpc-3895	263	10	a	a	PROPN
dpc-3895	263	11	,	,	PUNCT
dpc-3895	263	12	et	et	PROPN
dpc-3895	263	13	al	al	PROPN
dpc-3895	263	14	.	.	PUNCT
dpc-3895	264	1	the	the	DET
dpc-3895	264	2	effect	effect	NOUN
dpc-3895	264	3	of	of	ADP
dpc-3895	264	4	secukinumab	secukinumab	NOUN
dpc-3895	264	5	on	on	ADP
dpc-3895	264	6	moderate	moderate	ADJ
dpc-3895	264	7	-	-	PUNCT
dpc-3895	264	8	to	to	ADP
dpc-3895	264	9	-	-	PUNCT
dpc-3895	264	10	severe	severe	ADJ
dpc-3895	264	11	scalp	scalp	NOUN
dpc-3895	264	12	psoriasis	psoriasis	NOUN
dpc-3895	264	13	:	:	PUNCT
dpc-3895	264	14	results	result	NOUN
dpc-3895	264	15	of	of	ADP
dpc-3895	264	16	a	a	DET
dpc-3895	264	17	24	24	NUM
dpc-3895	264	18	-	-	PUNCT
dpc-3895	264	19	week	week	NOUN
dpc-3895	264	20	,	,	PUNCT
dpc-3895	264	21	randomized	randomize	VERB
dpc-3895	264	22	,	,	PUNCT
dpc-3895	264	23	double	double	ADJ
dpc-3895	264	24	-	-	PUNCT
dpc-3895	264	25	blind	blind	ADJ
dpc-3895	264	26	,	,	PUNCT
dpc-3895	264	27	placebo	placebo	NOUN
dpc-3895	264	28	-	-	PUNCT
dpc-3895	264	29	controlled	control	VERB
dpc-3895	264	30	phase	phase	NOUN
dpc-3895	264	31	3b	3b	NUM
dpc-3895	264	32	study	study	NOUN
dpc-3895	264	33	.	.	PUNCT
dpc-3895	265	1	j	j	PROPN
dpc-3895	265	2	am	be	AUX
dpc-3895	265	3	acad	acad	ADJ
dpc-3895	265	4	dermatol	dermatol	NOUN
dpc-3895	265	5	.	.	PUNCT
dpc-3895	266	1	2017;77(4):667	2017;77(4):667	NUM
dpc-3895	266	2	-	-	PUNCT
dpc-3895	266	3	674	674	NUM
dpc-3895	266	4	.	.	PUNCT
dpc-3895	267	1	doi	doi	NOUN
dpc-3895	267	2	:	:	PUNCT
dpc-3895	267	3	10.1016	10.1016	NUM
dpc-3895	267	4	/j.jaad.2017.05.033	/j.jaad.2017.05.033	PUNCT
dpc-3895	267	5	.	.	PUNCT
dpc-3895	268	1	pmid	pmid	NOUN
dpc-3895	268	2	:	:	PUNCT
dpc-3895	268	3	28780364	28780364	NUM
dpc-3895	268	4	.	.	PUNCT
dpc-3895	269	1	12	12	NUM
dpc-3895	269	2	.	.	PUNCT
dpc-3895	270	1	kircik	kircik	PROPN
dpc-3895	270	2	l	l	PROPN
dpc-3895	270	3	,	,	PUNCT
dpc-3895	270	4	fowler	fowler	PROPN
dpc-3895	270	5	j	j	PROPN
dpc-3895	270	6	,	,	PUNCT
dpc-3895	270	7	weiss	weiss	PROPN
dpc-3895	270	8	j	j	PROPN
dpc-3895	270	9	,	,	PUNCT
dpc-3895	270	10	meng	meng	PROPN
dpc-3895	270	11	x	x	PROPN
dpc-3895	270	12	,	,	PUNCT
dpc-3895	270	13	guana	guana	PROPN
dpc-3895	270	14	a	a	PRON
dpc-3895	270	15	,	,	PUNCT
dpc-3895	270	16	nyirady	nyirady	PROPN
dpc-3895	270	17	j.	j.	PROPN
dpc-3895	270	18	efficacy	efficacy	PROPN
dpc-3895	270	19	of	of	ADP
dpc-3895	270	20	secukinumab	secukinumab	NOUN
dpc-3895	270	21	for	for	ADP
dpc-3895	270	22	moderate	moderate	ADJ
dpc-3895	270	23	-	-	PUNCT
dpc-3895	270	24	to	to	ADP
dpc-3895	270	25	-	-	PUNCT
dpc-3895	270	26	severe	severe	ADJ
dpc-3895	270	27	head	head	NOUN
dpc-3895	270	28	and	and	CCONJ
dpc-3895	270	29	neck	neck	NOUN
dpc-3895	270	30	psoriasis	psoriasis	NOUN
dpc-3895	270	31	over	over	ADP
dpc-3895	270	32	52	52	NUM
dpc-3895	270	33	weeks	week	NOUN
dpc-3895	270	34	:	:	PUNCT
dpc-3895	270	35	pooled	pool	VERB
dpc-3895	270	36	analysis	analysis	NOUN
dpc-3895	270	37	of	of	ADP
dpc-3895	270	38	four	four	NUM
dpc-3895	270	39	phase	phase	NOUN
dpc-3895	270	40	3	3	NUM
dpc-3895	270	41	studies	study	NOUN
dpc-3895	270	42	.	.	PUNCT
dpc-3895	271	1	dermatol	dermatol	NOUN
dpc-3895	271	2	ther	ther	ADV
dpc-3895	271	3	(	(	PUNCT
dpc-3895	271	4	heidelb	heidelb	NOUN
dpc-3895	271	5	)	)	PUNCT
dpc-3895	271	6	.	.	PUNCT
dpc-3895	272	1	2016;6(4):627	2016;6(4):627	NUM
dpc-3895	272	2	-	-	NOUN
dpc-3895	272	3	638	638	NUM
dpc-3895	272	4	.	.	PUNCT
dpc-3895	273	1	doi	doi	NOUN
dpc-3895	273	2	:	:	PUNCT
dpc-3895	273	3	10.1007/	10.1007/	NUM
dpc-3895	273	4	s13555	s13555	PROPN
dpc-3895	273	5	-	-	PUNCT
dpc-3895	273	6	016	016	NUM
dpc-3895	273	7	-	-	PUNCT
dpc-3895	273	8	0139	0139	NUM
dpc-3895	273	9	-	-	PUNCT
dpc-3895	273	10	0	0	NUM
dpc-3895	273	11	.	.	PUNCT
dpc-3895	274	1	pmid	pmid	NOUN
dpc-3895	274	2	:	:	PUNCT
dpc-3895	274	3	27573260	27573260	NUM
dpc-3895	274	4	.	.	PUNCT
dpc-3895	275	1	pmcid	pmcid	NOUN
dpc-3895	275	2	:	:	PUNCT
dpc-3895	275	3	pmc5120628	pmc5120628	PROPN
dpc-3895	275	4	.	.	PUNCT
dpc-3895	276	1	13	13	NUM
dpc-3895	276	2	.	.	X
dpc-3895	276	3	kivelevitch	kivelevitch	PROPN
dpc-3895	276	4	d	d	PROPN
dpc-3895	276	5	,	,	PUNCT
dpc-3895	276	6	amin	amin	NOUN
dpc-3895	276	7	s	s	PROPN
dpc-3895	276	8	,	,	PUNCT
dpc-3895	276	9	menter	menter	ADJ
dpc-3895	276	10	a.	a.	NOUN
dpc-3895	276	11	clinical	clinical	ADJ
dpc-3895	276	12	utility	utility	NOUN
dpc-3895	276	13	of	of	ADP
dpc-3895	276	14	secukinumab	secukinumab	NOUN
dpc-3895	276	15	in	in	ADP
dpc-3895	276	16	moderate	moderate	ADJ
dpc-3895	276	17	-	-	PUNCT
dpc-3895	276	18	to	to	ADP
dpc-3895	276	19	-	-	PUNCT
dpc-3895	276	20	severe	severe	ADJ
dpc-3895	276	21	scalp	scalp	NOUN
dpc-3895	276	22	psoriasis	psoriasis	NOUN
dpc-3895	276	23	:	:	PUNCT
dpc-3895	276	24	evidence	evidence	NOUN
dpc-3895	276	25	to	to	ADP
dpc-3895	276	26	date	date	NOUN
dpc-3895	276	27	.	.	PUNCT
dpc-3895	277	1	clin	clin	PROPN